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ABSTRACT
Concussions resulting from blast exposures represent a significant source of
injury among military service members and the civilian population. Overall, traumatic
brain injuries (TBIs) are a significant cause of hospitalization, disability, long-term care,
and mortality across all age groups in the United States. Blast induced traumatic brain
injury (biTBI) is an increasingly recognized subtype of brain injury, especially among
military personnel. Blast exposure may influence a number of neurological processes,
such as the inflammatory response, representing a unique biological profile. Outcomes
from a TBI vary, even in similar injuries, and biomarkers including proteins and gene
expression are increasingly studied to determine potential underlying mechanisms of
injury and recovery processes. Biomarkers may yield insight into differential biological
pathways in the various severities and subtypes of brain injury. This novel study proposes
the examination of clinical and demographic characteristics and the identification of
possible biological mechanisms through gene expression and protein analysis following
brain injury. This study will be the first to examine gene expression related to
inflammatory activation using sequencing and other unique methods to gain insight into
immune pathways following blast exposure in clinical populations during the acute and
subacute stages of injury. A deeper understanding of the role of inflammatory activation
profiles will help direct future research in blast exposure and improve outcomes for
individuals affected by this injury.
Keywords: concussion, cytokines, inflammation, biomarkers, RNA sequencing
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CHAPTER ONE
INTRODUCTION
Dissertation Manuscript Outline
This dissertation manuscript is prepared in accordance with the guidelines set
forth by the Clemson University Graduate School and the School of Nursing Healthcare
Genetics Program’s Article-Style Format for Dissertation. The manuscript is comprised
of five chapters. Chapter One outlines the problem and significance of the research as
well as provides an overview of the research methodologies as they relate to each article.
Chapter Two provides context for the research in an in-depth literature review of
cytokine and gene expression studies in human TBI populations. Chapter Three explores
the bench research findings for gene expression inflammatory pathways altered following
blast exposure. Chapter Four examines laboratory findings of changes in inflammatory
cytokines following concussion and blast exposure. Finally, Chapter Five provides an
overview of the research findings and implications for healthcare genetics, considers
strengths and limitations of the work, and offers future directions for research. Chapters
Two and Three are the articles submitted for consideration of publication, and chapter
Four is to be submitted for publication.
Statement of the Problem
Protein and gene expression biomarkers are well-acknowledged in the literature
for potential clinical utility among traumatic brain injury (TBI) patient populations (Di
Battista et al., 2015). However, the biological role of these biomarkers in mild TBI
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pathologies has remained elusive, specifically in concussions occurring with blast
exposures in military personnel. This information is needed to improve the health of
military personnel who experience concussion, as there are few ways to determine the
impact on health. Further research would also help to inform decisions regarding return to
duty or training in order to prevent potential negative consequences of additional
exposures on neuronal health (DePalma, 2015; Ruff, Riechers, Wang, Piero, & Ruff,
2012). Table 1-1 defines key terms used throughout this manuscript.
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Table 1-1.
Key terms in this manuscript.
Term
Blast

Blast injury

Blunt force head injury / Closed head
injury
Concussion

Cytokine

Pro-inflammatory
Anti-inflammatory

Dendritic spine

Definition
A shock (i.e. overpressure) wave formed
by an explosion to cause a solid or liquid
quickly converted to a gas form resulting in
a release of energy. The shock wave travels
at supersonic speeds of 3,000-8,000 m/sec
(Ritenour & Baskin, 2008; Wightman &
Gladish, 2001)
Within the central nervous system, injury
from a shock wave can cause damage
including the neurons, blood brain barrier,
and cerebrovascular system (Ritenour &
Baskin, 2008). Also referred to as blast
induced TBI, or biTBI, in the literature.
A blow to the head results in brain injury.
The skull remains intact.
Defined by one of the following: 1) an
alteration in mental state, loss of memory;
2) loss of consciousness for less than 30
minutes; or, 3) another focal neurological
deficit. Also called a mild traumatic brain
injury (mTBI) in the literature (Menon,
Schwab, Wright, & Maas, 2010).
Small proteins released by leukocytes
(white blood cells) and glial cells (i.e.
microglia) that function in mediating
inflammatory response (Woodcock &
Morganti-Kossmann, 2013).
Cytokines that activate the immune
response.
Cytokines that induce activity mitigating
the immune response, such as clearing
debris.
Part of a neuron that receives, stores, and
sends neurotransmitters.
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Gene expression

*Gene network
Hub

Glial cells

Interleukin-6 (IL-6)

Interleukin-10 (IL-10)
Microglia

Moderate blast exposure

Neddylation

Nuclear factor kappa light-chain enhancer
of activated B cells (NF-κB)
Operation Iraqi Freedom (OIF) and

The information from a gene is transcribed
into a functional product. The primary
control for this process occurs when the
messenger RNA (mRNA) is transcribed,
which was studied in Chapter 3.
Connected molecular pathway that
regulates gene expression.
A connection, such as a gene, that has
multiple interactions within the network.
For example, the gene AKT1 in Chapter 3.
The most numerous cells in the central
nervous system; function in maintenance
and support for neural cells. Microglia are
one type of glial cell.
Traditionally classified as a proinflammatory cytokine, though may also
have anti-inflammatory properties.
Traditionally defined as an antiinflammatory cytokine.
The primary immune cell type in central
nervous system and the first to respond to
injury or pathogens. Direct the
inflammatory response through release of
cytokines and other inflammatory-related
products (Hendriksen, van Bergeijk,
Oosting, & Redegeld, 2017).
The force of the blast experienced by
military personnel described in Chapter 3
( 5psi). This definition has been specified
by the military collaborators involved in
this work.
A type of ubiquitination; also regulates
dendritic spine development (Vogl et al.,
2015).
Among its many functions, is a master
regulator of cytokines, such as IL-6 and
TNF .
OEF, also known as the Global War on
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Operation Enduring Freedom (OEF)

Terrorism, began in 2001 with targeting al
Qaeda and the Taliban in Afghanistan. OIF
began in 2003 with the United States
invasion of Iraq. Samples for Chapter 4 of
this study are from Afghanistan.
Penetrating head injury
The skull is perforated, such as by a high
speed projectile, object, or bone fragment.
Traumatic brain injury (TBI)
A biomechanical force to the head, with or
without direct impact, resulting in
pathological changes in the brain.
Traditionally classified as a proTumor necrosis factor (TNF )
inflammatory cytokine
Ubiquitination
The process of removing of oxidized and
misfolded proteins following injury, which
can protect neurons from reactive oxidative
species (ROS)
Note. See also Chapter 3 for a legend to interpret gene networks.
Significance of Concussion and Blast Exposure in the Military
In Chapters Three and Four, the results of studies in military personnel
experiencing concussion and blast exposure are discussed. Briefly, concussion, also
known as mild TBI (mTBI) in the literature, is considered one of the most prevalent
injuries among military personnel serving in recent combat and training environments
(Hayward, 2008; Mac Donald et al., 2014). Approximately 80% of concussions occurring
among military personnel are caused by blast exposures (Defense and Veterans Brain
Injury Center, 2017; Rigg & Mooney, 2011). However, due to co-occurrence of multiple
injuries common at the time of a blast exposure, blast injury to the brain is often difficult
to study alone (Champion, Holcomb, & Young, 2009). Evidence of long-term
neurological effects shown in the literature highlight the need for deeper understanding of
the pathophysiology of underlying chronic symptoms and the need to produce data to
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inform the development of novel treatments for mTBIs (Carr et al., 2015; Echemendia &
Julian, 2001; Giza & Hovda, 2001; Reid et al., 2014; Schatz & Moser, 2011). Although
medical care of TBI patients has advanced, at this time there are no FDA-approved
pharmaceuticals specifically addressing TBI pathology (Hinson, Rowell, & Schreiber,
2015; Maas, Stocchetti, & Bullock, 2008). Biomarkers, including gene expression and
proteins, introduced in Chapter One and detailed in the Chapter Two literature review,
may ultimately identify therapeutic targets to improve the care of patients and foster
recovery from TBIs (Di Battista et al., 2015; Hinson et al., 2015). Thus, this line of
research is vital, as biomarkers will ultimately improve diagnosis, prognosis, and care for
patients with concussion.
Significance of the Inflammatory Response in Concussion and Blast Exposure
Recent studies report that serum biomarkers may objectively detect blast
exposures, as compared to trauma controls, even in the absence of physical symptoms
(Papa et al., 2016; Papa et al., 2012). Taken together with literature indicating the
harmful effects of neurological insults over time, further evaluation of potential
biomarkers to inform diagnosis and prognosis of concussion and blast exposure is needed
(Echemendia & Julian, 2001; Giza & Hovda, 2001; Schatz & Moser, 2011).
Introduction to gene expression.
The Chapter Two literature review highlights the importance of gene expression
to TBI research, in addition to cytokine activity. Importantly, considered a master
regulator of cytokines, nuclear factor kappa light-chain enhancer of activated B cells
(NF-κB) is a transcriptional activator of target genes involved in numerous biological
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functions including the development of immune cells such as leukocytes and regulation
of the expression of cytokines and chemokines (Barichello, Generoso, Simoes, Elias, &
Quevedo, 2013; Kawai & Akira, 2007). Though the NF-κB pathway regulates cytokines
and has been implicated in clinical TBI gene expression studies (see review in Chapter
Two), the dynamics of the NF-κB pathway together with inflammatory cytokine
alterations within the context of clinical blast exposure has not yet been fully explored.
Chapter Three describes the details of the gene expression study for this dissertation.
Introduction to cytokines.
In addition to gene expression, the Chapter Two literature review underscores the
importance of inflammatory cytokines for understanding neurological recovery processes
in persons with TBI. Clinical studies show that inflammatory biomarkers, including
immune cell counts and cytokine concentrations, are associated with sustaining a TBI
when measured during the acute period, in coordinating recovery during the acute and
sub-acute periods, and have been proposed as a possible therapeutic target after TBI
(McKee & Lukens, 2016; Schwarzmaier & Plesnila, 2014). Cytokines are especially
interesting to the study of concussion as they may serve as practical clinical measures at
the bedside as well as reveal underlying inflammatory processes (Hinson et al., 2015;
Woodcock & Morganti-Kossmann, 2013). Chapter Four describes the results of the
cytokine study for this dissertation.
Summary
In Chapter One, a brief overview was included to underline the significance of
this research. Considering the limited amount of current research in inflammatory and
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immune pathways related specifically to clinical blast exposure and concussion, literature
related to inflammatory markers clinical TBI populations will be reviewed in greater
detail in Chapter Two. Chapter Three describes results of the gene expression study for
this dissertation, while Chapter Four describes the results of the cytokine study. Research
questions as they relate to the studies in Chapters Three and Four are introduced below
for guidance through the dissertation manuscript.
Research Questions
The research questions are addressed together in the introduction to better explain
the collective goals for this dissertation. Specific Aims are addressed separately in
Chapters 3 and 4 as noted below in order to allow details for each study.
Background: Concussions, including those caused by blast exposures, are associated
with poor outcomes among the military population. Blast exposures result in altered
neurological processes such as inflammatory pathways. Alterations in the NF- B
network, a known regulator of cytokines produced during inflammation, have been
identified in clinical TBI. However, the NF- B gene pathway has not been fully explored
following injury specific to blast exposures.
Purpose: The purpose of this study is to examine gene expression related to
inflammatory activation using sequencing and protein analyses to gain insight into
inflammatory pathways following blast exposure in military personnel.
Aim One (Chapter 3): In a military training environment, determine gene activity
changes related to NF- B through RNA sequencing following blast exposure.
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Hypothesis 1a: Blast exposure will result in alterations in NF- B inflammatory-related
gene expression pathways during the sub-acute period.
Aim Two (Chapter 4): In a combat environment, determine changes in NF-kb activity
detected through cytokine activity immediately following concussions (blast exposures
and blunt force injuries).
Hypothesis 2a: Compared to healthy controls, there will be increased levels of
inflammatory cytokines including IL-6, IL-10, and TNF in the concussed group within
8 hours following injury.
Hypothesis 2b: Compared to healthy controls, levels of inflammatory cytokines
including IL-6, IL-10, and TNF will return to baseline levels within 24 hours of injury
in the concussed group.
Hypothesis 2c: Mean change over time for each cytokine (IL-6, IL-10, and TNF ) will
be significantly different in the concussed group as compared to the healthy control
group.
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ABSTRACT
Traumatic brain injuries (TBIs) are a significant cause of hospitalization,
disability, long-term medical care cost, and mortality across all age groups in the United
States and across the world. Outcomes from a TBI vary, even in patients with similar
severity and type of injuries, yet, identifying those patients at highest risk for non-optimal
recovery remains difficult. Biomarkers including proteins and gene expression are an
increasingly studied area, as they provide a platform to identify underlying mechanisms
of injury, patients at risk for poor recovery and recovery processes to inform therapeutics.
Initiation of the inflammatory system is fundamental to recovery from TBIs; however, if
it is over-activated or prolonged it may compromise recovery and lead to more chronic
symptoms. The purpose of this literature review is to examine recent clinical studies of
gene expression in traumatic brain injury and related proteomic pathways, with a focus
on characterizing the role of inflammation in recovery from TBIs, as well as how it may
shape more chronic symptoms. This review identified 5 papers that report altered
inflammatory gene regulation and 17 papers that report altered cytokines as related to
recovery from TBIs. This paper will link these gene-expression studies to inflammatory
activation studies and provide an indication of how these acute changes in gene-activity
may shape immune response to TBIs and recovery. A deeper understanding of the role of
immune activity following a TBI will ultimately direct future research for the
improvement of outcomes for individuals affected by this injury.
Keywords: traumatic brain injury, cytokines, biomarkers, gene expression
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CHAPTER TWO
A REVIEW OF GENE EXPRESSION AND INFLAMMATORY RESPONSE IN
CLINICAL POPULATIONS OF TRAUMATIC BRAIN INJURY
Introduction
The dissertation research topic is inflammation, as characterized by gene
expression and cytokine changes, in military personnel with acute blast exposures and
concussions. In undertaking a literature review of this topic, very little information is
available to date in clinical populations. Considering the recent reviews of blast exposure
in preclinical models, and the limited amount of research in inflammatory pathways
related specifically to clinical blast exposure or concussion, a review of gene expression
and cytokine changes as it relates to the broader population of clinical TBI was
undertaken (Xiong, Mahmood, & Chopp, 2013). This decision to expand to the broader
TBI category was made with the knowledge that not all of this information may translate
to the specific population represented in this dissertation research. However, the goal was
that the knowledge gained from review of studies of human TBI populations would be
used establish the current state of the science in order to inform the design and
methodologies of the dissertation research. Additionally, rather than relying on one
methodology, the integration of -omics data, such as gene expression and protein
analysis, in the design of research studies has been postulated to strengthen the
understanding of the complex relationships between genotype and phenotype (Ritchie,
Holzinger, Li, Pendergrass, & Kim, 2015). Any knowledge thus gained from the
subsequent research studies, detailed in Chapters 3 and 4, would then add to the growing
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field of gene express and cytokine research in persons with blast exposure and
concussion.
Significance of concussion and blast exposure in the military.
Concussion, also known as mild TBI (mTBI) in the literature, is considered the
signature injury among military personnel serving in recent combat and training
environments (Hayward, 2008; Mac Donald et al., 2014). The vast majority (80%) of
concussions occurring among military personnel are caused by blast exposures (Defense
and Veterans Brain Injury Center, 2017; Rigg & Mooney, 2011). Over 360,000
individuals serving in Operation Iraqi Freedom and Operation Enduring Freedom since
the year 2000 have experienced at least one blast injury, with most exposures due to
improvised explosive devices (IEDs) (Champion, Holcomb, & Young, 2009; Defense
and Veterans Brain Injury Center, 2017; Elder, Stone, & Ahlers, 2014; Hayward, 2008).
Significance of traumatic brain injury.
Traumatic brain injury (TBI) is a significant healthcare issue, effecting 2.5 million
Americans each year and leading to 30% of all injury-related deaths (Taylor, 2017).
Sources of injury may include falls, motor vehicle accidents, assaults, and blunt trauma.
TBIs occur across all populations, regardless of age, ethnicity, socioeconomic status, or
sex. TBIs can result in long-lasting disabilities for the injured person, effecting quality of
life for both the person and his or her family members (Taylor, 2017). TBI care is
estimated to cost up to $76.5 billion each year in the US from medical care costs and loss
of work (Coronado et al., 2011; Ma, Chan, & Carruthers, 2014). Significant savings of
$2.2 million (p<0.05) in projected life care cost for individuals who undergo
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rehabilitation therapies in the post-acute TBI stage have been reported (Griesbach,
Kreber, Harrington, & Ashley, 2015). A review of the societal economic burden of TBI
concluded that successful rehabilitation treatments could result in substantial annual
savings for society—up to $302 million (Humphreys, Wood, Phillips, & Macey, 2013).
Decreasing the substantial economic burden to society and individuals is an important
motivator to improve the clinical care of TBI patients, thereby reducing the symptoms
and deficits that can result. Though medical care of TBI patients has advanced, at this
time there are no FDA-approved pharmaceuticals or non-pharmacological interventions
to reduce the risk of developing symptoms acutely, or to treat symptoms and deficits if
they become chronic (Maas, Stocchetti, & Bullock, 2008).
Definition of TBI.
A TBI is defined as a biomechanical force to the head, with or without direct
impact, resulting in pathological changes in the brain, and include both blunt force and
blast related injuries (McCrory et al., 2013; Menon, Schwab, Wright, & Maas, 2010).
TBIs are categorized into mild, moderate, and severe, most often using the Glasgow
Coma Scale (GCS), a tool developed by Teasdale and Jennett (1974) classifying subjects
based on initial clinical exam. The mTBIs account for approximately 80% of traumatic
brain injuries (Ruff, Iverson, Barth, Bush, & Broshek, 2009). As defined by the American
Congress of Rehabilitation Medicine, a mTBI is characterized by one of the following:
loss of memory, loss of consciousness (<30 minutes), alteration in mental state, or any
focal neurological deficit. Exclusion criteria for this category of TBI include: GCS of <13
after 30 minutes, loss of consciousness for >30 minutes, and posttraumatic amnesia
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lasting >24 hours (Menon, Schwab, Wright, Maas, et al., 2010). Traditionally mTBIs
have been believed to do little or no long-term harm, even though approximately 10% of
patients experience ongoing complications (Carroll et al., 2004; Cassidy et al., 2014).
Accumulating recent research demonstrates long-term detrimental effects of mTBIs, with
the greatest risk in those individuals who sustain multiple events of TBIs (Echemendia &
Julian, 2001; Giza & Hovda, 2001; Schatz & Moser, 2011). These long-term effects
highlight the need for additional study in the pathophysiology and treatments for mTBIs.
Biomarkers obtained in peripheral blood and cerebral spinal fluid (CSF), including gene
expression and proteins described in the literature review below, are a current
advancement that may aid in the care of individuals with TBIs in order to help improve
outcomes. Summarized in this paper are the potential clinical utility of biomarkers for the
improved diagnosis, prognosis, and individual treatment plans for patients increasingly
supported by the literature, as well as future directions (Di Battista et al., 2015).
TBI from blast exposure.
Brain injury from primary blast injury occurs due to a shock (i.e. blast or
overpressure) wave formed by an explosion (Ritenour & Baskin, 2008; Wightman &
Gladish, 2001). Resulting tissue damage depends upon factors such as the magnitude of
the peak pressure and the duration of the force, as well as enclosures which cause the
shock waves to bounce thereby intensifying the risk of injury (Rezaei, Salimi Jazi, &
Karami, 2014; Wightman & Gladish, 2001). The energy from a blast enters the body as
stress waves and shear waves. Stress waves are longitudinal waves affecting the spaces
between tissues and gases, resulting in tissue and microvascular damage; while shear
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waves are transverse waves causing disruption in attachments between tissues (Champion
et al., 2009; Ritenour & Baskin, 2008; Yeh & Schecter, 2012). Thus, tissues likely to be
damaged are those in contact with gaseous regions, such as the middle ear, lungs, and
bowel, as well as the central nervous system (Bochicchio et al., 2008; Kirkman & Watts,
2011; Mac Donald et al., 2011; Ropper, 2011; Wightman & Gladish, 2001). Brain injury
results when shearing forces from the explosion result in diffuse or axonal injury to the
brain, and may also induce cerebrovascular damage and blood brain barrier disruption
(Cernak, Wang, Jiang, Bian, & Savic, 2001; Ritenour & Baskin, 2008; Yeoh, Bell, &
Monson, 2013). Whether the clinical presentation and pathophysiology of concussion
caused by blast is distinct from a penetrating or closed head TBI remains to be
determined (Courtney & Courtney, 2015; Mac Donald et al., 2014). However, due to cooccurrence of multiple injuries common at the time of a blast exposure, blast injury to the
brain is often difficult to study alone (Champion et al., 2009).
The need for research in mTBI and blast exposure.
One in ten patients with mTBI will continue to experience long-term
complications (Carroll et al., 2004; Cassidy et al., 2014). Specifically, evidence of
chronic neurological effects has been shown in repeated concussions and post-concussive
syndrome as well as chronic low-level blast exposure (Carr et al., 2015; Echemendia &
Julian, 2001; Giza & Hovda, 2001; Reid et al., 2014; Schatz & Moser, 2011). These longterm effects underscore the need for deeper understanding of the pathophysiology of
underlying chronic symptoms and the need to produce data to inform the development of
novel treatments for mTBIs. Although medical care of TBI patients has advanced, at this
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time there are no FDA-approved pharmaceuticals specifically addressing TBI pathology
(Hinson, Rowell, & Schreiber, 2015; Maas et al., 2008). Recent evidence suggests that
serum biomarkers may objectively detect blast exposures as compared with trauma
controls (Papa et al., 2016; Papa et al., 2012). Gene expression and protein biomarker
research is essential, as biomarkers may ultimately identify therapeutic targets to improve
care and foster recovery for persons with TBIs (Di Battista et al., 2015; Hinson et al.,
2015; Prieto, Ye, & Veenstra, 2008).
Statement of the Problem.
Although the potential clinical utility of biomarkers such as proteins and gene
expression in patient care is well recognized, the role in various TBI pathologies has yet
to be fully realized. Inflammation is a key pathway required for recovery from TBIs, but
much remains unknown about the characteristics of activation and regulation that likely
contribute to acute and long-term recovery. The purpose of this literature review is to
examine the current state of clinical TBI research in gene expression and inflammatory
biomarkers.
Literature Review
Method.
Considering the limited current research in cytokines and gene expression
pathways related specifically to clinical blast exposure or concussion, literature related to
inflammatory markers in acute TBI clinical populations was reviewed. The electronic
database PubMed was systematically searched from November 1, 2016 to January 30,
2017. The searches were updated September 2017. Search terms for gene expression
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studies included: brain injury and gene expression. Search terms for inflammatory protein
marker studies included: brain injury, cytokines, IL-6, IL-10, and TNF . Published, fulltext, original research articles in English appearing in peer-reviewed journals over the
past 10 years were included. The search was limited to human populations. Articles
meeting these criteria were screened for eligibility based on original studies in human
populations. Articles for the gene expression review included adults who sustained a mild
or moderate TBI. Articles for the inflammatory protein markers review included
adolescents and adults who sustained a mild, moderate, or severe TBI, due to the limited
number of mild and moderate TBI articles. Articles meeting the eligibility criteria were
screened for inclusion. The following criteria caused articles to be excluded: studies of
animals and cell lines, pediatric populations, diagnoses other than TBI, research older
than 10 years, reviews, case studies, and those that did not include gene expression or
inflammatory protein markers.
Results for gene expression. After applying the inclusion and exclusion criteria to
6,596 titles and abstracts, 952 full-text articles were assessed for eligibility, with only 5
of these articles evaluating gene expression in adults with mild to moderate traumatic
brain injury.
Results for inflammatory protein markers. Following application of the inclusion
and exclusion criteria to 6,452 titles and abstracts, 1,265 full-text articles were eligible for
screening, with 17 articles that evaluated inflammatory protein markers in the adult
population with mild, moderate, or severe brain injury.
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Gene Expression Studies
Background.
Several clinical studies show that gene expression varies after TBI. Gene
expression is the process by which a sequence of nucleic acids in a gene (i.e. genotype)
are transcribed into ribonucleic acid (RNA) and translated into protein, which ultimately
gives rise to the phenotype, or expressed traits, of an organism (Raser & O'Shea, 2005).
Thus, methods of measuring gene expression can be accomplished at the RNA level by
examining the activity of genes. Often, gene expression methods in the literature are
referring to measurement of the messenger RNA (mRNA), the RNA molecules which are
translated into proteins (Wickramasinghe & Laskey, 2015). mRNA is measured through a
variety of technologies, notably DNA microarray, Northern Blot, real time PCR, and,
most recently, high-throughput RNA sequencing methods (RNA-seq) (Bolón-Canedo,
Sánchez-Maroño, Alonso-Betanzos, Benítez, & Herrera, 2014; Mortazavi, Williams,
McCue, Schaeffer, & Wold, 2008; Wang, Gerstein, & Snyder, 2009).
Clinical Studies.
The literature review returned five clinical studies of gene expression in TBI.
Results from the studies are summarized in Table 2-1 and Table 2-2.

31

Table 2-1.
Summary of gene expression literature review results

Reference

Platform

Specimen
Source

Population

Blood Draw
Timepoints

Cho et al.
(2016)

Affymetrix

Peripheral
whole blood

mTBI (total n=66)

Acute
<48 hours
after injury

qPCR

Gill et al.
(2016)

Affymetrix

Young (19-35
years old, n=33)
Old (60-89 years
old, n=33)
Athletes

Peripheral
blood
mononuclear
cells

Sports-related
concussion (n=15)
Non-concussed
controls (n=16)

MerchantBorna et al.
(2016)

Affymetrix

Peripheral
blood
mononuclear
cells

Athletes
Sports-related
concussion (n=15)
Non-concussed
controls (n=16)

Livingston et
al. (2016)

Affymetrix

Peripheral
whole blood

mTBI (total n=40)
TMI+ (n=17)

Total Number of
Differentially Expressed
Genes
Young: 42
Old: 5

Subacute
1 week after
injury
Baseline
(before
injury)

Young: 28
Old: 1

Acute
<6 hours after
injury

71

Subacute
1 week after
injury
Baseline
(before
injury)

65

Acute
<6 hours after
injury

71

Subacute
1 week after
injury
Acute
<48 hours
after injury

65

Chronic
symptoms
</=18 months
after injury

29

76

TMI- (n=23)
Heinzelmann
et al. (2014)

Affymetrix

Peripheral
whole blood

Military, mild to
moderate TBI
blast-TBI (n=19)
Controls without
TBI (n=17)
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Table 2-2
Summary of differentially expressed gene pathways from literature
Reference

Gene Pathways

Cho et al. (2016)

Cell signaling,
development, growth, and
proliferation
Intracellular regulation of
calcium

Gill et al. (2016)

Nuclear factor kappa lightchain enhancer of activated
B cells (NF-κB)

Representative
Genes
BACH2

Gene name

Fold
change
1.616

P value

S100P

S100 calcium binding
protein P

1.954

*

S100A8

S100 calcium binding
protein A8

1.515

*

LRRN3

Leucine-rich repeat
neuronal 3

2.849

*

LEF1

Lymphoid enhancer
binding factor 1

1.539

*

NOG
IL8

Noggin
Interleukin 8

1.852
acute
-6.94
subacute
-13.80

*

CXCL2

NR4A2

Merchant-Borna et al.
(2016)

Inflammatory Response,
Infectious Disease, Renal
and Urological Disease

Hubs:
IL-6
IL-12
TRL4
NF-κB

Glucocorticoid Receptor
Signaling

Livingston et al. (2016)

Neurological Disease, Cell
Death and Survival, Cell
Cycle
Inflammatory pathways
related to cellular
development
Organismal Injury and
Abnormalities

Basic leucine zipper
transcription factor 2

Chemokine (C-X-C
motif) ligand 2

Nuclear receptor
subfamily 4, group A,
member 2

acute
-4.47
subacute
-7.11
acute
-7.12
subacute
-6.63

*

1.18E-04
2.08E-07
1.38E-04
3.77E-07
5.87E-07
5.39E-08

**

**

interleukin 6
interleukin 12
toll-like receptor 4
Nuclear factor kappa
light-chain enhancer
of activated B cells

LOC100134822

Uncharacterized
LOC100134822

1.62

5.05E-05

FcαR (aka CD89)

Fc fragment of IgA,
receptor for

1.58

4.81E-08
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Heinzelmann et al. (2014)

Cellular Organization

MCTP2

Multiple C2 domains,
transmembrane 2

1.54

1.85E-05

Nuclear factor kappa lightchain enhancer of activated
B cells (NF-κB) pathway

GPR27

G-protein-coupled
receptor 27

1.52

5.88E-05

Ubiquitin pathway

TNS1

Tensin-1

-2.3682

0.00062

MARCH8

Membrane-associated
ring finger (C3HC4)
8, E3 ubiquitin
protein ligase

-1.6123

0.00065

TRIM58

Tripartite motif
containing 58

-1.9188

0.00012

Note. For the Cho et al. (2016) study, values are reported at the 48-hour time period; fold
changes were also significant for all reported genes at one week. Positive numbers
indicate upregulation; negative numbers indicate downregulation. *p < 0.05; **denotes
differently expressed gene network.
One study aimed to compare gene expression in older (60-89 years old) and
younger (19-35 years old) cohorts of mTBI patients within 24 hours of injury (Cho et al.,
2016). Notably, being “older,” has consistently been linked to a greater risk of poor
recovery in clinical TBI studies (Hukkelhoven et al., 2003; McIntyre, Mehta, Janzen,
Aubut, & Teasell, 2013). Cho et al. (2016) found that, compared to younger patients, the
older patients experienced overall worse recovery from injury as determined by magnetic
resonance imaging (MRI) one-week following the TBI. The MRI findings were linked to
differential gene activation, including several genes involved in the inflammatory
response [measured using GeneChip 3’ IVT Plus Expression kit (Affymetrix, Santa
Clara, CA, USA)]. First, LRRN3 and LEF1, genes implicated in regulation of
inflammation, were highly upregulated in the younger cohort as compared to the older
cohort. Lesser upregulation of these inflammatory genes suggests a decreased ability of
the older population to modulate inflammatory responses. Second, there was a decreased
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expression of BACH2 gene that transcribes basic leucine zipper transcription factor 2
(BACH2) in older as compared to younger adults at 48 hours following injury. BACH2 is
expressed in B cells, and it modulates the proinflammatory response in preclinical models
(Muto et al., 2004; Roychoudhuri et al., 2013; Vahedi et al., 2015). Decreased BACH2
gene expression may therefore lead to suppression of the neuroprotective humoral
immune response in TBI. Third, in older individuals, neuronal recovery may be impaired
through upregulation of the genes S100 calcium binding protein P (S100P) and S100
calcium binding protein A8 (S100A8). Both genes are part of the S100 gene family
involved in the regulation of intracellular calcium levels (Zimmer, Eubanks,
Ramakrishnan, & Criscitiello, 2013), and previously associated with neuronal recovery
following injury (Di Battista et al., 2015). S100P also activates signaling pathways such
as NF-κB. Considered a master regulator of cytokines, NF-κB is a transcriptional
activator of target genes involved in numerous biological functions including the
development of immune cells such as leukocytes and regulation of the expression of
cytokines and chemokines (Barichello, Generoso, Simoes, Elias, & Quevedo, 2013;
Kawai & Akira, 2007). For example, one preclinical TBI study found that regulatory T
cells decreased the expression of proinflammatory cytokines through suppression of the
NF-κB pathway (Yu, Cao, Ran, & Sun, 2016). These gene expression results from Cho et
al. (2016) suggest that regulation of immune and inflammatory responses as well as
neuronal repair following TBI may vary across age groups, with maladaptive responses
in older adults associated with worse outcomes. Further comparison of gene expression
profiles, including inflammatory-related pathways such as NF-κB, across young and old
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age groups may yield insight into the biological mechanisms which lead to better versus
worse outcomes following TBI. Comparing these types of gene expression studies to
neuroimaging findings may also yield further insight into neuronal changes occurring
following injury.
A second study of acutely concussed collegiate athletes also implicated changes
in inflammatory gene expression following injury (Gill et al., 2016). Biomarkers in whole
blood collected following concussion was compared to baseline levels collected preseason. Following head injury, 28 differentially expressed genes [Affymetrix HG U133
Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA)] were associated with the
inflammatory response, including the NF-κB pathway, as seen in Figure 2-1 (Gill et al.,
2016). In the third gene expression study, further gene network analysis of this athlete
population revealed interleukin 6 (IL-6), interleukin 12 (IL-12), and toll-like receptor 4
(TRL4) as hubs (see Table 1-1 for definitions) at 6 hours post-injury, in addition to NF-κB
at both 6 hours and 7 days post-injury (Merchant-Borna et al., 2016) (see Figure 2-2).
Together, these four hubs modulate both the innate immune response and the transition to
the adaptive immune response, suggesting alterations in immune system functioning may
influence neuronal recovery during the acute period (Merchant-Borna et al., 2016).
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Figure 2-1.
Differential Gene Expression Following Concussion in Athletes

Note. Used with permission by:
Gill, J., Merchant-Borna, K., Lee, H., Livingston, W. S., Olivera, A., Cashion, A., . . . Bazarian, J.
J. (2016). Sports-Related Concussion Results in Differential Expression of Nuclear
Factor-kappaB Pathway Genes in Peripheral Blood During the Acute and Subacute
Periods. J Head Trauma Rehabil, 31(4), 269-276. doi:10.1097/htr.0000000000000191
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Figure 2-2.
Altered Gene Expression in the NF- B Pathway Following Concussion in Athletes

Note. Used with permission by:
Merchant-Borna, K., Lee, H., Wang, D., Bogner, V., van Griensven, M., Gill, J., & Bazarian, J. J.
(2016). Genome-Wide Changes in Peripheral Gene Expression following Sports-Related
Concussion. J Neurotrauma, 33(17), 1576-1585. doi:10.1089/neu.2015.4191

Altered gene expression has also been observed in a fourth study of a
subpopulation of mTBI patients with traumatic meningeal injury (TMI). Livingston et al.
(2016) found 76 differentially expressed genes [Affymetrix HG-U133 Plus 2.0
microarray (Affymetrix, Santa Clara, CA)] in patients positive for TMI (TMI+) (n=17) as
compared to mild TBI patients with no neuroimaging findings (n=23). The altered genes
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were found to be involved in three main gene networks. Four genes with the greatest fold
changes were LOC100134822, FcαR, MCTP2, and GPR27, with FcαR implicated in
inflammatory processes (Ben Mkaddem, Rossato, Heming, & Monteiro, 2013). In
addition, three of these genes (FcαR, MCTP2, and GPR27) mapped to inflammatory
processes in cellular development using Ingenuity Pathway Analysis (IPA). The most
significantly altered gene pathway in TMI+ patients was the nuclear factor kappa lightchain enhancer of activated B cells (NF-κB) pathway. While its role in TMI is yet to be
studied, both findings suggest a potential biological pathway specific to patients with a
meningeal injury; further studies are needed. To date, this is the only study examining
gene expression in patients with a meningeal injury (Livingston et al., 2016).
Finally, in addition to these four acute/subacute studies, a chronic TBI study
found 29 differentially expressed genes [Affymetrix GeneChip Human Gene U133 Plus
2.0 Arrays (Affymetrix, Santa Clara, CA, USA)] in a cohort of military personnel with
medical history of blast-TBI (n=19) as compared to control military personnel with no
TBI (n=17) (Heinzelmann et al., 2014). Genes within the ubiquitin pathway (TNS1,
C3HC4, MARCH8, and TRIM58), which functions in the removal of oxidized and
damaged proteins following neuronal injury, were notably down-regulated in the blastTBI population, suggesting a role for this pathway in chronic symptoms following blastTBI (Heinzelmann et al., 2014). Although this study differs from previously discussed
studies regarding population type (military vs. civilian), outcomes over time (chronic vs.
acute/subacute outcomes), and injury type (blast vs. closed head), the differential gene
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expression results following neuronal insult contributes to the accumulating evidence for
the roles of multiple biological pathways in TBI recoveries.
Summary.
Results from these five studies show that gene expression changes are observed in
individuals following mild TBIs and concussions. Specifically, inflammatory geneactivity is related to response to these brain injuries. It is interesting to note that alteration
of the NF-κB pathway is implicated in all four of the acute/subacute studies. Notably, the
NF- κB pathway has been previously associated with the regulation of proinflammatory
cytokines in meningitis (Barichello et al., 2013) as well as blood-brain barrier
permeability (Merrill & Murphy, 1997). Based on the current state of research found
here, and previous neurological-related work, further examination of the role of this NFκB pathway in acute/subacute mTBI recoveries is warranted. These studies used
variations of the Affymetrix microarray platform to examine gene expression differences.
This platform has limitations, including batch effect, a recognized systematic error of
microarray technology which occurs when many samples are processed in separate
“batches” (Chen et al., 2011). No clinical TBI gene expression studies have yet utilized a
more global RNA sequencing methodology. Therefore, additional studies are needed that
use other methods for analyses, such as RNA-seq, and also include cohorts of patients
with mild TBI and blast exposure.
Cytokines in Traumatic Brain Injury
The inflammatory response after a brain injury results in biological changes that
are interrelated, including those of proteins and gene activity (Jassam, Izzy, Whalen,
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McGavern, & El Khoury, 2017). Therefore, gene activity and proteins have
complementary activities that coordinate the response to brain injury. Current studies
examining gene-activity across the genome have consistently implicated inflammatory
pathways, including NF-κB, a major regulator of cytokines (Kawai & Akira, 2007). For
this reason, this section of the review is focused on inflammatory proteins, to more
comprehensively understand the biological underpinnings that shape onset of symptoms
following and recovery after TBI.
Summary of cytokine review results.
Results of the cytokine literature review are summarized in Table 2-3. To give a
brief overview of the results, 17 studies of cytokines in adult clinical TBI were found.
Notably, there were only two studies in mild TBI, with the remainder of the studies in
moderate to severe TBI. There was one blast study and two military studies. Most studies
(15) focused on measurement of cytokines in the acute time period, although some of
these studies (5) considered chronic outcomes at 6-12 months. Two studies measured
cytokines in the chronic period. Increased levels of IL-6 were found in 14 studies,
increased IL-10 in 10 studies, and increased TNF in 8 studies. Details of these studies
are listed in Table 2-3. Considering the complexity of the biological response following
TBI, the discussion will focus on the understanding of these cytokine findings within the
wider context of TBI inflammatory processes, as well as broader, potential clinical
applications. Thus, the review is organized to address important considerations for
moving the research forward, including: acute and chronic studies, bio-specimen source,
biological pathways, interventions, as well as age and TBI severity.
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Introduction to Inflammatory Cytokines and Concussion
Inflammation is instrumental in the TBI recovery process. Clinical TBI studies
associate inflammatory biomarkers, such as cytokine concentrations and immune cell
counts, with TBI during the acute period, as well as during the acute and sub-acute
recovery periods (McKee & Lukens, 2016). In further support of the critical role of
inflammation in TBI recovery, modulation of the inflammatory response has been
proposed as a possible therapeutic target after TBI (Schwarzmaier & Plesnila, 2014).
Cytokines are especially interesting to the study of concussion as they may serve as
practical clinical measures at the bedside as well as reveal underlying inflammatory
processes. The role of cytokines in the inflammatory response following brain injury is
well-recognized (Hinson et al., 2015; Woodcock & Morganti-Kossmann, 2013). Briefly,
cytokines, small proteins released by leukocytes and glial cells that function in mediating
inflammatory response, are a well-documented research area in preclinical and limited
clinical TBI studies (Lenzlinger, Morganti-Kossmann, Laurer, & McIntosh, 2001;
Woodcock & Morganti-Kossmann, 2013).
Inflammatory response to TBI.
What are Cytokines? Cytokines are a variety of proteins (including interleukins,
interferons, and growth factors) secreted by immune cells that are involved in signaling
between cells during the immune response to injuries, such as a TBI. Cytokines are
generally categorized as having pro-inflammatory (such as IL-1,-12; TNFα, INF-γ) or
anti-inflammatory effects (IL-10; TGF-β) (Hernandez-Ontiveros et al., 2013; McKee &
Lukens, 2016), with some having both pro-and anti-inflammatory effects that assist in
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communication between inflammatory and anti-inflammatory activities (IL-6) (Brandt &
Pedersen, 2010). Both pro- and anti-inflammatory cytokines are produced by microglia
and other glia, such as astrocytes, following insult to the brain, and the two types of
cytokines work in concert to determine the fate of affected neurons. Anti-inflammatory
cytokines shift the balance toward neuroregenerative and neuroprotective biological
pathways and pro-inflammatory cytokines shift the balance toward apoptosis and cell
death. Together these cytokines work to maintain the balance of inflammation
(Hernandez-Ontiveros et al., 2013).
What is the inflammatory response in TBI? Inflammation plays a central role in
the recovery of patients from a TBI; observable through the activities of immune cells
and cytokines. A TBI initiates a cascade of inflammatory events that are closely regulated
(McKee & Lukens, 2016; Plesnila, 2016). Specifically, TBIs cause the release of
substances, damage-associated molecular patterns (DAMPs), also known as alarmins,
from injured cells that then trigger a subsequent immune response (Bianchi, 2007; Tang,
Kang, Coyne, Zeh, & Lotze, 2012). The DAMPs signal pattern recognition receptors on
microglia within the central nervous system (CNS) to produce pro- and antiinflammatory cytokines and chemokines; resulting cytokines and chemokines then
activate and recruit immune cells to the injured tissues (Kigerl, de Rivero Vaccari,
Dietrich, Popovich, & Keane, 2014). Within 24 hours, peripheral immune cells, such as
neutrophils, are recruited first across the blood-brain barrier (Plesnila, 2016) to the site of
injury (Clark, Schiding, Kaczorowski, Marion, & Kochanek, 1994; McKee & Lukens,
2016; Peruzzotti-Jametti et al., 2014). Within the CNS, astrocytes and microglia,
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phagocytic immune cells of the brain (Hernandez-Ontiveros et al., 2013), become
activated 3-5 days post-injury while the number of neutrophils diminishes. T cells, B
cells, and monocytes, normally found in peripheral circulation, are also found at the
injury site at 3-5 days (McKee & Lukens, 2016). Of note, CNS produced cytokines and
activated microglia have been found to remain elevated for months to years following
injury, indicating an unusually lengthened immune response to TBI in human patients
(Gentleman et al., 2004; Johnson et al., 2013; Ramlackhansingh et al., 2011). This is
associated with long-term symptoms (Bombardier et al., 2010; Bryant, 2008) and
cognitive deficits that patients may experience following TBI (Smith, Johnson, &
Stewart, 2013). Current research suggests that injury to the brain results in an
inflammatory response, which is beneficial when regulated appropriately. If
inflammation is prolonged in time, or it is either excessive or insufficient in the degree of
activation, it can indicate poor clinical neurological outcome (McKee & Lukens, 2016;
Santarsieri, Kumar, Kochanek, Berga, & Wagner, 2015).
A note on “immune privilege.” In further support of the importance of cytokines
and inflammation to brain injury recovery, the long-held theory of central nervous system
(CNS) immune privilege has been challenged. Current evidence shows that peripheral
immune cells cross the blood brain barrier (BBB), and immune cells within the brain
reach the periphery (Carson, Doose, Melchior, Schmid, & Ploix, 2006; Louveau, Harris,
& Kipnis, 2015). Microglia activated following brain insult release a cascade of pro- and
anti-inflammatory cytokines, regulating the innate immune response (Hendriksen, van
Bergeijk, Oosting, & Redegeld, 2017; Hernandez-Ontiveros et al., 2013). Potential
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clinical utility of these markers depends on factors such as the specificity to type and
severity of injury as well as ability to be correlated with other protein markers of injury
(Woodcock et al., 2013).
Measurement of cytokines in clinical studies. In clinical TBI studies,
inflammatory and immune responses are monitored through serum, cerebrospinal fluid
(CSF) and blood levels, and include: immune cell counts (neutrophils, B cells, and T
cells), concentrations of cytokines: [interleukin (IL) -1, -6, -8, -10, -18, tumor necrosis
factor α (TNFα), granulocyte colony-stimulating factor (G-CSF)], inflammasomes, type 1
interferon (INF), and transforming growth factor β (TGFβ) (McKee & Lukens, 2016).
Technologies that have been used to measure inflammatory biomarkers in TBI patients
including, but not limited to: flow cytometry (aka cytometry bead-based array) such as
the BD™ Cytometric Bead Array (CBA) Human Inflammatory Cytokine Kit (BD
Biosciences, San Diego, CA) (Ferreira et al., 2014; Schneider Soares et al., 2012);
multiplex bead array assays (Wisniewski et al., 2007) including the Luminex™ bead
array assay (Millipore, Billerica, Massachusetts) (Kumar, Rubin, Berger, Kochanek, &
Wagner, 2016; Santarsieri et al., 2015); the enzyme-linked immunosorbent assay
(ELISA) (Wisniewski et al., 2007), and Simoa, an ultrasensitive paramagnetic bead-based
ELISA (Quanterix Corporation, Cambridge, MA) (Devoto et al., 2016). Important
components of laboratory measures include reliability (the reproducibility of the results)
and validity (measurement of the intended value; includes sensitivity and specificity)
(Kane & Radosevich, 2010).

45

Studies of Inflammatory Markers and TBI Outcomes.
Cytokines are elevated following blast exposure.
A study in a military blast population demonstrates significantly increased
concentrations of pro-inflammatory (TNF , IL-6), and anti-inflammatory (IL-10)
cytokines, with level alterations dependent upon degree of blast exposure, immediately
following that exposure in a military training environment (Figure 2-3) (Gill et al., 2017),
though this finding is yet to be confirmed in additional clinical populations.
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Figure 2-3.
Comparison of TNF and IL-6 in moderate versus no/low blast exposures

Note. Permission obtained from Gill, J., Motamedi, V., Osier, N., Dell, K., Arcurio, L.,
Carr, W., . . . Yarnell, A. (2017). Moderate blast exposure results in increased IL6 and TNFalpha in peripheral blood. Brain Behav Immun.
doi:10.1016/j.bbi.2017.02.015
Considering the limited clinical research in blast exposure, studies in the wider
TBI population are considered.
During the acute phase, serum and plasma cytokines are increased and can
relate to TBI outcomes.
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Cytokines are associated with TBI outcomes when measured in the acute period.
For example, in a study of severe TBI male patients (n=24), significantly higher plasma
levels of IL-10, -8 and -6 measured both at hospital admission and 24 hours post-injury
were found in non-survivors as compared to those patients who survived (Ferreira et al.,
2014). Results from a similar study in patients with a range of TBI severities, including
mild (n=18), moderate (n=16), and severe (n=93), revealed that increased serum IL-10
levels at 10 and 30 hours post-injury were significant predictors of mortality in the severe
TBI cohort (Schneider Soares et al., 2012). Additional evaluations of severe TBI patients
show that elevated plasma IL-10 and TNF are associated with poor 6 month outcomes
(Di Battista et al., 2016); increased serum IL-6 is associated with poor neurological
outcomes (Lustenberger et al., 2016); and increased serum IL-6, IL-10, and TNF is
associated with unfavorable 6-month outcomes (Santarsieri et al., 2015).
Although published previous to the eligibility dates for inclusion in this review, it
is important to note that these studies have built on 15+ years of previous research
associating elevated cytokines with poor outcomes. For example, similar to Ferreira et al.
(2014), a prior study of moderate and severe TBI patients demonstrated that elevated
plasma IL-6 concentrations (>100 pg/mL) on day 1 following a TBI were associated with
death within one week of the injury (Woiciechowsky et al., 2002). Likewise, plasma
elevations of IL-6 and IL-12, and a decrease of malone dialdehyde (MDA) (indicator of
oxidative stress) were reported within 24 hours following injury in patients who did not
survive following a severe isolated TBI (n=15) as compared to survivors (n=7) (Arand,
Melzner, Kinzl, Bruckner, & Gebhard, 2001). These seven studies suggest that elevations
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of both pro-inflammatory and anti-inflammatory cytokines relate to greater mortality and
poor neurological outcomes. Collectively, these studies suggest that elevations of
peripheral IL-10 and/or IL-6 levels may be useful when evaluating severe TBI prognosis,
and specifically in relation to mortality. IL-10 is considered an anti-inflammatory
cytokine, to function as a negative regulator of pro-inflammatory cytokine production,
while IL-6 is considered to have both pro-inflammatory and anti-inflammatory activities
to signal immune cells, including microglia, to the injury site (McKee & Lukens, 2016).
To clarify these complex relationships, the need for additional research in mild to
moderate TBI populations is evident.
Sample Source and heterogeneity are relevant concerns in TBI cytokine
research. Given that cytokine levels have been associated with TBI outcomes in clinical
studies, the implication of clinical utility of these biomarkers has stimulated many
questions including which bio-specimen source is optimal for the measurement of
cytokines. Although many studies evaluate serum or plasma concentrations of cytokines,
circulating concentrations of cytokines may differ from cerebrospinal fluid (CSF) or
brain tissue concentrations as a direct result of the blood brain barrier (BBB) and the
blood meningeal barrier (BMB) though these differences remain poorly understood
(Jensen, Massie, & De Keyser, 2013).
Previous work in severe TBI patients that examined cytokines in serum and CSF,
an increase in levels of anti-inflammatory markers (IL-1ra, s-TNF-r-1, and IL-10) were
found in the serum. This finding was not consistent in the CSF of patients with
extracranial injuries compared to patients with only isolated head injury and no additional
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injuries. Additionally, in CSF alone, concentrations of the pro-inflammatory marker (IL1β) and anti-inflammatory markers (IL-1ra, s-TNF-r-1, and IL-10) were higher in all
patients compared to controls regardless of the presence of additional injuries. Included
in these marker findings were patients with an increased ICP as well as patients with an
unfavorable outcome at 6 months (Shiozaki et al., 2005) which suggests that extracranial
injury may be responsible for observed elevated serum cytokine levels.
Thus, more recent studies in TBI patients have considered comparison of CSF and
plasma or serum sources, with elevated levels observed in CSF as compared to plasma or
serum. Elevated levels of CSF IL-6, and serum IL-10 and TNFα were associated with
poor outcome at 6 and 12 months (Kumar et al., 2015). IL-6, IL-10, and TNFα CSF
concentrations were elevated in TBI patients compared to controls during first 6 days
after injury (Juengst, Kumar, Failla, Goyal, & Wagner, 2015). All biomarkers measured,
including increased CSF IL-6, IL-10, and TNFα associated with poor 6-month outcomes,
with IL-6 remaining elevated at day 5 (Nwachuku et al., 2016). Overall, these studies
seem to give evidence of higher levels of cytokines present in the CSF as compared to
serum or plasma.
Considering well-known heterogeneity among TBI studies, such as age as
observed in some of the studies in this review (Note the delineation of ages in Table 2-3),
it may be interesting to note differences in pediatric vs adult studies. For example, in
contrast to the Shiozaki et al. (2005) study, a population of pediatric patients with isolated
severe TBI (n=14) showed that an increase in plasma or CSF concentrations of IL-1β and
IL-6 occurring between the 2- and 24-hr post injury was associated with greater injury
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severity (GCS<5) and worse outcome at 6 months (GOS≤3) (Chiaretti et al., 2005).
While Shiozaki et al. (2005) did not measure IL-6, the IL-1β concentration was increased
in CSF, but not serum, from adult patient cohorts with and without additional injuries and
worse outcomes. IL-1β was also increased in the plasma of the pediatric population, even
though the pediatric patients were isolated head injuries, while the results in the adult
population imply elevated serum cytokines are likely due to extracranial injuries
(Chiaretti et al., 2005; Shiozaki et al., 2005). These studies confirm the need for
ongoing/continuing research to further understand the role of the BBB in isolated vs.
extracranial head injuries among heterogeneous populations, such adult vs. pediatric, and
clarification of the optimal source for measuring inflammatory biomarkers.
Three other studies measured cytokine levels in the brain tissue of severe patients.
Using intracranial microdialysis to measure IL-6, significantly higher levels (p=0.04)
were observed in the brain parenchyma of severe TBI survivors as compared to nonsurvivors (Winter, Pringle, Clough, & Church, 2004). These results suggest a
neuroprotective role for IL-6 within the injured brain. In a more recent study using
cerebral microdialysis, post-TBI cerebral production of cytokines was also supported
(Helmy, Carpenter, Menon, Pickard, & Hutchinson, 2011). Similar to Winter et al.
(2004), more work in 2011 showed a trend of increased IL-6 (did not reach significance)
in first 24 hours after injury, followed by gradual decline, which also did not associate
with poor outcomes (Perez-Barcena et al., 2011). Contrasting results by Shiozaki et al.
(2005) suggest that extracranial injury contributes to the increased peripheral cytokine
levels. More recent evidence suggests that isolated brain injury may, in fact, contribute
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to the altered circulating (plasma or serum) cytokine levels that are observed post-TBI.
For example, Di Battista et al. (2016) found that poor outcomes and mortality in
moderate and severe TBI patients (n=166) were associated with elevated plasma levels of
IL-1β, IL-10, and TNFα within 24 hours of admission. These cytokine increases are
possibly associated with the activation of the sympathetic nervous system, as evidenced
by the positive association of increased levels of epinephrine and norepinephrine with
elevated levels of cytokines (Di Battista et al., 2016). Overall, evidence from these recent
seven studies, found in Table 2-3, seems to suggest cytokines are altered in serum, CSF,
and brain tissue following TBI in the acute period, and that these altered levels may have
prognostic value in the acute or chronic time periods following TBI. However, additional
studies are needed to confirm associations of specific cytokines with TBI outcomes, and
to elucidate the specific biological functions of various cytokines in the inflammatory and
recovery processes following TBI. Further research is also needed to differentiate the
roles of cytokines in mild and moderate TBI, as most studies have focused on severe TBI
cohorts. Future research studies should take into account the following: 1) recent
development of higher-sensitivity techniques; 2) potential confounding factors within and
between patient cohorts such as the presence of additional injuries, age, gender, how
outcomes are measured, and the timing of sample collection [recognized issues in the
literature (Loane & Faden, 2010)]; and, 3) the potential interrelationship of the
inflammatory response with other biological pathways.
Cytokines may persist in the chronic period post-TBI. In addition to
inflammatory cytokines during the acute period following TBI, three studies described
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evidence that inflammatory cytokines, measured in serum, contributed to TBI outcomes
in the chronic period, greater than three months following injury. The most recent study
was of a military population deployed less than 16 months prior to sample collection,
increased plasma levels of IL-6 and TNF-α were found in military personnel
experiencing high PTSD as compared to low PTSD in those military personnel with TBI
(Devoto et al., 2016). The increased level of IL-6 in the chronic period is interesting
considering similar observations in acute period studies. These similar observations
suggest dysregulation of the immune system resulting from an inflammatory state left
chronically unresolved from the acute response to injury (Gentleman et al., 2004;
Johnson et al., 2013). The work by Devoto et al. (2016) demonstrates the association of
chronic inflammation, indicated by elevated cytokine levels in post-TBI persons with
comorbid conditions, such as PTSD and depression, highlighting the need to detect and
alleviate chronic inflammation after TBI. Another study of patients with severe TBI
(n=19) with measurements taken at admission, 3 months, and 6 months, found
persistently increased plasma levels of TNF-α, IL-6, INF-γ, and IL-1b at 3 and 6 months
(Licastro et al., 2016). Elevated cytokine levels were associated with a slower rate of
cognitive recovery and poorer cognitive functioning neuropsychological tests at 12
months. Increased levels of TNF-α and INF-γ were also associated with poor functional
recovery at 12 months, using measurements from the Functional Independence Measure
and Disability Rating Scale (Licastro et al., 2016). Although limited in quantity, chronic
phase studies are similar to acute phase studies as they seem to point to an important role
of chronic inflammation, as measured by circulating cytokines, in TBI recoveries.
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Inflammation is not independent of other biological pathways. Inflammatory
markers are part of well-regulated systems that coordinate to promote recovery, but also
can become dysregulated, and thus may explain poor recovery even in the chronic period
of TBI. In support of this concept, inflammatory markers may influence other types of
pathways, such as those in the endocrine system. For example, the hypothalamicpituitary-adrenal (HPA) axis regulates cortisol secretion and is known to have a central
role in the body’s response to physical and psychological trauma (Yeager, Pioli, &
Guyre, 2011). Cytokines such as IL-1β, IL-6, and TNFα are known to have bidirectional
interactions with the HPA axis, which provide regulation of inflammation (Black, 1994).
Specifically, immune cells have glucocorticoid receptors that cortisol activates to reduce
inflammation (Walker & Spencer, 2018). These cytokines also feedback on the HPA
axis, to further regulate cortisol activity, as well as inflammation, such that both systems
are regulated sufficiently (Yeager et al., 2011). During states of disease and sickness,
inflammatory cytokines increase along with resistance to glucocorticoid. This likely
occurs through the interference of inflammatory cytokine pathways with glucocorticoid
receptor pathways, contributing to the progression of disease (Pace, Hu, & Miller, 2007;
Yeager et al., 2011). In support of this interaction between cytokines and the HPA axis,
an acute phase study of severe TBI patients (n=91) correlated a greater inflammatory load
score (ILS), calculated by averaging serum concentrations of interleukin (IL)-6, IL-10,
soluble Fas (sFas), soluble intracellular adhesion molecule (sICAM)-1, tumor necrosis
factor alpha (TNF-α), and CSF cortisol levels for days 0-6 post injury, to poor outcomes
at 6 months as measured by the Glasgow Outcome Score-Extended (Santarsieri et al.,
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2015). In this study both a high or low mean cortisol level was found to mediate this
effect on ILS, implicating the neuroendocrine and immune systems together in TBI
outcomes. Thus, both under- and over reactive immune/inflammatory responses may
result in poor outcomes, and cortisol levels may be important in understanding
inflammation during acute recovery from TBIs (Santarsieri et al., 2015). Another possible
influence on the endocrine system post-TBI is brain-derived neurotrophic factor (BDNF),
a neurotrophin expressed in the brain that functions in the plasticity and survival of
neurons (Hempstead, 2015), which has been found to influence the HPA axis (Colzato,
Van der Does, Kouwenhoven, Elzinga, & Hommel, 2011; Gray, Milner, & McEwen,
2013; Shalev et al., 2009). In a follow-up study to Santarsieri et al. (2015), increased
serum cortisol and decreased serum BDNF at days 0-3 post injury were linked to poor
clinical outcomes (Kumar et al., 2016). Elevated CSF BDNF has been previously
associated with greater risk for mortality after a severe TBI (Failla, Conley, & Wagner,
2016). Therefore, regulation of immune function, in part through endocrine function, is
important during the acute period, and relates to a greater likelihood of poor recovery.
Interventions for inflammation.
Finally, interventions, including pharmacological and nonpharmacological
methods may modulate inflammatory responses, thereby altering outcomes following
TBI. For example, a randomized controlled trial of severe TBI patients demonstrated that
patients (n=65) receiving pre-hospital resuscitation with hypertonic saline (n=30)
experienced significantly reduced serum levels of TNF-α and IL-10 as compared to the
group who received normal saline (n=35) (Scarpelini et al., 2010). Hypertonic saline has
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the potential to confer beneficial anti-inflammatory and immune modulation effects in
addition to the fluid shift from intracellular to intravascular and interstitial spaces
(Strandvik, 2009). However, the impact on acute or chronic outcomes was not reported
(Scarpelini et al., 2010). Conversely, a separate study found hypertonic saline did not
alter 6-month outcomes or survival (GOSE, DRS) in severe TBI patients (n=1087).
However, serum inflammatory markers were not measured (Williams et al., 2010). Thus,
the influence of hypertonic saline on TBI patient outcomes as well as inflammatory
cytokines remains to be answered. Results of a randomized controlled study of a
pharmacological agent, ulinastatin, administered every 8 hours revealed TNF-α, IL-2, and
IL-6 levels as well as incidence of multiple organ dysfunction syndrome (MODS) and
systemic inflammatory response syndrome (SIRS) were decreased in the treatment
(n=32)versus control group (n=28), as measured at admission and 10 days post-injury
outcomes (Tu, Diao, Yang, Sun, & Zhang, 2012).
Summary and Relevance to Nursing
TBIs are a significant cause of hospitalization, disability, long-term care, and
mortality across all age groups in the United States (Taylor, 2017). Factors including
genetic predisposition, the timing and relative concentrations of immune and
inflammatory markers, and environmental influences, can modulate neurological
recovery processes following TBI, and these complicated relationships among the
aforementioned factors remain largely uncharacterized (McKee & Lukens, 2016;
Santarsieri et al., 2015). Results of this literature review show that pro- and antiinflammatory cytokines (IL-6, IL-10, and TNF- α) are elevated in the acute period
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following injury, may remain chronically unresolved, and are associated with poorer
outcomes. Interventions for inflammation are currently in development. Taking note of
how these interventions influence the balance of inflammatory cytokines in a variety of
tissues will be critical in future studies to optimize patient outcomes. At this time, studies
of gene expression following TBI in clinical populations are few, yet promising,
warranting further exploration into the biological pathways including, but not limited to
inflammation, altered following TBI. These studies will yield insight into pathways that
can then be studied at a proteomic biomarker level, such as cytokines, which will allow
for the development of diagnostics and therapeutics to directly help the patient. As
demonstrated in this review, biomarkers, including but not limited to cytokines, are an
increasingly studied area to determine potential underlying mechanisms of injury and
recovery processes after TBI. Additionally, biomarkers may yield insight into differential
biological pathways in the various severity and subtypes of brain injury (Di Battista et al.,
2015). Although the potential clinical utility of biomarkers in patient care is well
recognized, the roles in TBI pathologies has yet to be fully realized. A deeper
understanding of biological profiles will help direct future research to aid health care
providers, nurses, and other medical personnel in improved diagnosis, monitoring and
treatment for individuals with TBI.
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Table 2-3.
Recent literature examining cytokines in clinical TBI
Reference

Population

(Devoto et al., 2016)

Mild and
moderate TBI

Inflammation Relates to Chronic
Behavioral and Neurological
Symptoms in Military with
Traumatic Brain Injuries.

N=83
Cases = 63
Controls = 20

Biomarkers

IL-6;
IL-10;
TNFα

Specimen
Source and
Collection
Times
Plasma
Chronic: <16
months following
deployment

Inflammatory cytokine and
chemokine profiles are associated
with patient outcome and the
hyperadrenergic state following
acute brain injury.

Moderate and
Severe TBI
N = 187
Cases = 166
Controls = 21
74.7% male; age
16-67 yrs.

IL-6 and TNF-α levels higher in TBI vs.
control:
IL-6, p = 0.007
TNFα, p = 0.003
PTSD following TBI associated with higher
levels of IL-6 and TNF-α:

All male, military
personnel; cases
mean age 33.2 yrs;
controls mean age
31.6 yrs
(Di Battista et al., 2016)

Significant IL-6, IL-10, and TNF Results

IL-6, p = 0.001
TNFα, p = 0.013
IL-1β;
IL-2;
IL-4;
IL-5;
IL-8
IL-10;
IL-12p70;
IL-13;
TNFα;
IFN-γ;
IP-10;
MCP-1;
MCP-4;
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Plasma
Acute: hospital
admission, 6, 12,
and 24-hours
post-injury

Elevated IL-10 in all injured patients as
compared to controls:
IL-10, p < 0.001
Elevated IL-10 and TNF-α associated with
poor outcome at 6 months (GOS-E):
IL-10, p < 0.05
TNFα, p < 0.05

Reference

Population

Biomarkers

Specimen
Source and
Collection
Times

Significant IL-6, IL-10, and TNF Results

MDC;
MIP-1β;
TARC

(Ferreira et al., 2014)

Severe TBI

Increased levels of interleukin-6, 8 and -10 are associated with fatal
outcome following severe
traumatic brain injury.

N = 37
Cases = 24
Control = 13

IL-1b;
IL-6;
IL-8;
IL-10;
IL-12p70;
TNF-α

Males, 18-74 yrs.

Plasma
Acute: hospital
admission (5.6
hour mean time
from injury), 24
and 72 hours
post-injury

Il-6, IL-10, and TNFα elevated in TBI patients
at admission compared to controls:
IL-6, p < 0.05
IL-10, p < 0.05
TNFα, p < 0.05
Il-6 and IL-10 elevated in TBI patients with
fatal injuries, compared to TBI survivors, at
admission and 24 hours:
IL-10, p < 0.05
TNFα, p < 0.05
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Reference

Population

(Gill et al., 2017)

Blast Exposure

Moderate blast exposure results in
increased IL-6 and TNFalpha in
peripheral blood.

N = 62
Cases = 30
Controls = 32

Biomarkers

IL-6;
IL-10;
TNFα

Specimen
Source and
Collection
Times
Serum
Acute: day of
blast, 24 hours
later

Significant IL-6, IL-10, and TNF Results

Elevated IL-6 and TNFα in cases immediately
following blast as compared to controls:
IL-6, p < 0.01
IL-10, p < 0.01

Military; males,
30.55 yrs. (mean)
(Helmy et al., 2011)

Severe TBI

The cytokine response to human
traumatic brain injury: temporal
profiles and evidence for cerebral
parenchymal production.

N = 12
Males and females,
18-61 yrs.

(Hergenroeder et al., 2010)

Severe TBI

Serum IL-6: a candidate
biomarker for intracranial
pressure elevation following
isolated traumatic brain injury.

N = 42
Cases = 28,
Controls = 14
35 males and 7
females,
14-56 yrs.

42 cytokines,
including:
IL-6;
IL-10;
TNFα

IL-10;
IL-13;
IL-15;
IL-16;
IL-1α;
IL-1β;
Il-1ra;
IL-2;
IL-3;
IL-4;
Il-5;

Plasma;
Microdialysate
Acute: daily for
5 days

Serum
Acute: first 24
hours after
injury, and daily
for 5 days
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Peaks of cytokines (2x higher concentrations
than the median) in brain microdialysate were
noted on the following days:
Day 1: TNFα
Day 2: IL-6
Day 4-5: IL-10
Il-6 and IL-10 were 10x higher in brain
microdialysate than plasma, p < 0.001.
IL-6 levels within 17 hours of injury
associated with elevated ICP after TBI:
IL-6, p = 0.002

Reference

Population

Biomarkers

Specimen
Source and
Collection
Times

Significant IL-6, IL-10, and TNF Results

IL-6;
IL-7

(Juengst et al., 2015)
Acute inflammatory biomarker
profiles predict depression risk
following moderate to severe
traumatic brain injury.

Moderate and
Severe TBI
N= 56
CSF Cases = 41
Serum Cases = 50
Controls = 15
Males and females,
18–70 yrs.

(Kumar et al., 2015)

Severe TBI

Acute CSF interleukin-6
trajectories after TBI:
Associations with
neuroinflammation, polytrauma,
and outcome.

N = 129
Cases = 114
Controls = 15
Males and females,
18-70 yrs.

IL-1 β;
IL-4;
IL-5;
IL-6;
IL-7;
IL-8;
IL-10;
IL-12;
TNFα;
sVCAM-1;
sICAM-1;
sFAS.

CSF;
Serum

IL-1β;
IL-4;
IL-5;
IL-6;
IL-7;
IL-8;
IL-10;
IL-12;

CSF;
Serum

Acute: CSF was
collected twice
daily, serum
collected once
daily; for up to 6
days post injury

Acute: samples
collected every
12 hours, up to 5
days post injury
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IL-6, IL-10, and TNFα CSF concentrations
elevated in cases compared to controls during
first 6 days after injury:
IL-6, p < 0.05
IL-10, p < 0.05
TNFα, p < 0.05

CSF IL-6 levels elevated in cases compared to
controls at each day following injury:
IL-6, p < 0.001
CSF IL-10, and TNFα elevated in TBI subgroup with high IL-6 levels:

Reference

Population

Biomarkers

Specimen
Source and
Collection
Times

TNF-α;
sVCAM-1;
sICAM-1;
sFAS

Significant IL-6, IL-10, and TNF Results

IL-10, p < 0.05
TNFα, p < 0.05
Elevated levels of CSF IL-6, and serum IL-10
and TNFα also associated with poor outcome
at 6 and 12 months (GOS):
IL-6, p < 0.001
IL-10, p < 0.05
TNFα, p < 0.05
Elevated serum IL-6 associated with poor 6month outcome:
IL-6, p = 0.015

(Licastro et al., 2016)

Severe TBI

Peripheral Inflammatory Markers
and Antioxidant Response during
the Post-Acute and Chronic Phase
after Severe Traumatic Brain
Injury.

N = 19

TNFα;
IL-6;
INFγ;
IL-1b

Males and females,
19-61 yrs.

62

Plasma
Chronic: First
sample collected
at 15-66 after
TBI, followed by
3 and 6 months
later

Increased levels of all cytokines measured
associated with poor cognitive outcomes:
IL-6, p = 0.0170
TNFα, p = 0.0033

Reference

(Lustenberger et al., 2016)

Population

Severe TBI
N = 123

The effect of brain injury on the
inflammatory response following
severe trauma.

Biomarkers

IL-6;
CRP;
leukocytes

Isolated TBI = 26

Specimen
Source and
Collection
Times
Serum
Acute: upon
admission, and
days 1-3 post
injury

TBI with
polytrauma = 36

(Nwachuku et al., 2016)
Time course of cerebrospinal fluid
inflammatory biomarkers and
relationship to 6-month
neurologic outcome in adult
severe traumatic brain injury.

N = 32 cases
Biomarkers
compared to
laboratory
standards

IL-6 levels significantly different between the
groups at admission and for 3 days postinjury, with peak at 1 day:
IL-6, p < 0.05
Increased IL-6 levels significantly related to
multiple organ failure, sepsis and neurological
outcomes (GOS) in TBI cohorts:

Polytrauma, no TBI
= 61
Males and females,
16-66 yrs.
Severe TBI

Significant IL-6, IL-10, and TNF Results

IL-6, p < 0.05

IL-1β;
IL-6;
TNF-α;
IFN-γ;
IL-12p70;
L-10;
IL-8

Males and females,
17-80 yrs.

63

CSF
Acute: samples
collected days 15 post-injury

Increased IL-6, IL-10, and TNF-α (and all
biomarkers) associated with poor 6-month
outcome (GOS) (p < 0.05), with IL-6
remaining elevated at day 5.
IL-6, p < 0.05

Reference

(Perez-Barcena et al., 2011)

Population

Biomarkers

Severe TBI

Lack of correlation among
intracerebral cytokines,
intracranial pressure, and brain
tissue oxygenation in patients with
traumatic brain injury and diffuse
lesions.

IL-1;
Il-6;
N = 16
IL-8;
Feasibility study, no IL-10
controls
IL12;
TNFα
Males and females,
15-65 yrs.

(Santarsieri et al., 2015)

Severe TBI

Variable neuroendocrine–immune
dysfunction in individuals with
unfavorable outcome after severe
traumatic brain injury.

N = 115
Cases = 91
Controls = 24

IL-6;
IL-10;
sFas;
ICAM-1;
TNF-α;
Cortisol

Males and females,
16-75 yrs.

Specimen
Source and
Collection
Times
Serum;
Microdialysate

Increased IL-6 (did not reach significance) in
first 24 hours after injury, followed by gradual
decline.

Acute: samples
collected every
24 hours for 7
days

No association between IL-6 and ICP, brain
oxygenation, or edema.

CSF;
Serum

IL-6, IL-10, and TNF-α higher in cases
compared to controls, p < 0.01

Acute: CSF
collected twice
daily, up to 6
post-injury

IL-6, IL-10, and TNF-α significantly
associated with unfavorable 6-month outcome
(GOS) and CSF cortisol:

Serum collected
once daily, up to
6 days
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Significant IL-6, IL-10, and TNF Results

IL-6, p < 0.01
IL-10, p < 0.01
TNFα, p < 0.05

Reference

(Schneider Soares et al., 2012)
Interleukin-10 Is an Independent
Biomarker of Severe Traumatic
Brain
Injury Prognosis.

Population

Mild, Moderate,
and Severe TBI

Biomarkers

IL-10;
TNF-α

Specimen
Source and
Collection
Times
Serum
Acute: hospital
admission, and
two additional
samples up to 4
days later

N = 127
Cases = 93
Controls = 34
Males and females,
18-79 yrs.

(Stein et al., 2011)

Severe TBI

Relationship of Serum and
Cerebrospinal Fluid Biomarkers
with Intracranial Hypertension
and Cerebral Hypoperfusion After
Severe Traumatic Brain Injury.

N = 24
Mostly male
(95.8%), 18-83 yrs.

Significant IL-6, IL-10, and TNF Results

Elevated IL-10, but not TNFα, correlated
significantly with GCS severity:
IL-10, p < 0.0001
Increased IL-10 levels associated with greater
mortality rate in severe TBI:
IL-10, p = 0.01

TNFα;
IL-1 ;
IL-6;
IL-8;
IL-10
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CSF;
Serum
Acute: hospital
admission and
twice daily for 7
days

Increased serum TNFα levels correlate with
increased ICP and decreased CPP:
TNFα, p < 0.001

Reference

Population

(Yan et al., 2014)

Severe TBI

Post-traumatic hypoxia is
associated with prolonged cerebral
cytokine production, higher serum
biomarker levels, and poor
outcome in patients with severe
traumatic brain injury.

N = 62
Cases = 42
Controls = 20

(Yousefzadeh-Chabok et al.,
2015)

Severe TBI

Males and females,
16-74 yrs.

N = 44
The Relationship Between Serum
Levels of Interleukins 6, 8, 10 and
Clinical Outcome in Patients With
Severe Traumatic Brain Injury.

Biomarkers

IL-2;
IL-4;
IL-6;
IL-8;
IL-10;
TNF;
INF ;
GM-CSF;
NSE;
S100;
MBP
Il-6;
IL-8;
IL-10

Specimen
Source and
Collection
Times
CSF
Acute: Daily
from hospital
admission to 5
days post-injury

IL-6 and IL-10 CSF concentrations (and all
cytokines) were significantly increased
compared to controls at each day, with higher
concentrations trending during the first 24-48
hours:
IL-6,

Serum
Acute: 6 hours
post injury

Mostly (97.7%)
male, ≥ 14yrs.

Significant IL-6, IL-10, and TNF Results

IL-10, p < 0.05

Increases in Il-6 correlate with unfavorable 6month outcome (GOS):
IL-6, p=0.03

Note. Glasgow outcome score (GOS); Glasgow outcome score-extended (GOS-E); intracranial pressure (ICP): cerebral
profusion pressure (CPP): cerebral spinal fluid (CSF): Interleukin (IL); tumor-necrosis factor α (TNFα); soluble vascular
adhesion molecule-1 (sVCAM-1); soluble intracellular adhesion molecule-1 (sICAM-1); and soluble Fas (sFAS); c-reactive
protein (CRP)
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ABSTRACT
Blast exposure is common in military personnel during training and combat
operations, yet biological mechanisms reacted to cell survival and function that
coordinate recovery remain poorly understood. This study explored how moderate blast
exposure influences gene expression; specifically, gene-network changes following
moderate blast exposure. On day 1 (baseline) of a 10-day military training program,
blood samples were drawn, and health and demographic information collected. Helmets
worn throughout training measured overpressure in pounds per square inch (psi). On day
7, some participants experienced moderate blast exposure (peak pressure ≥5 psi). On day
10, 3 days post-exposure, blood was collected and compared to baseline with RNAsequencing to establish gene expression changes. Based on dysregulation data (RNAsequencing) and top gene-networks [Ingenuity® Pathway Analysis (IPA®)], a subset of
genes was validated (NanoString). Five gene-networks were dysregulated; specifically,
two highly significant networks: 1. Cell death/survival (score: 42), including 70 genes,
with 50 downregulated, and 2. Cell structure, function, and metabolism (score: 41),
including 69 genes, with 41 downregulated. Genes related to ubiquitination, including
neuronal development/repair: UPF1 (UPF1, RNA Helicase and ATPase) were
upregulated while UPF3B (UPF3 Regulator Of Nonsense Transcripts Homolog B) was
downregulated. Genes related to inflammation were upregulated, including ARRB1
(arrestin β1), implicating inflammation in recovery. AKT1, a gene coordinating cellular
recovery following TBIs, was upregulated. Moderate blast exposure induced significant
gene expression changes including gene-networks involved in cell death/survival and
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cellular development/function. The present findings may have implications for
understanding blast exposure pathology and subsequent recovery efforts.
Key words: Blast; overpressure; gene-expression; RNA-sequencing; NanoString
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CHAPTER THREE
A MODERATE BLAST EXPOSURE RESULTS IN DYSREGULATED GENE
NETWORK ACTIVITY RELATED TO CELL DEATH, SURVIVAL, STRUCTURE,
AND METABOLISM
Introduction
When an individual is in close proximity to a blast, the resulting overpressure (i.e.
shock wave) can cause injury to the brain and/or body (Jones, Fear, & Wessely, 2007).
The increased use of improvised explosives, sophisticated weaponry, and explosive entry
techniques has led to increased risk of blast exposure. Specifically, in military personnel
who deployed to recent conflicts of Operation Iraqi Freedom (OIF) and Operation
Enduring Freedom (OEF), an estimated 300,000 service members were exposed to at
least one blast from adversary attack (Tenielien & Jaycox, 2008). Blast overpressure from
firing weapons is increasing commensurate with increases in weaponry power. High
intensity blast exposure events can damage connective tissues, including the central
nervous system, resulting in cerebrovascular damage and blood brain barrier disruption.
Significant overpressure can result in tearing of the long axons of neurons (diffuse axonal
injury) leading to the associated deficits and comorbidities of a traumatic brain injury
(TBI) (Mac Donald et al., 2016; Yurgil et al., 2014). There is evidence suggesting blastinduced TBI (biTBI) has distinct features from blunt-force or penetrating TBI (Courtney
& Courtney, 2015). However, it is difficult to evaluate the consequences of blast in
isolation using human subjects, as there is often concomitant blunt force or penetrating
TBI when objects are propelled and contact the skull (e.g. shrapnel) or the individual is
thrown. These challenges contribute to the relatively poor understanding of the
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pathophysiologic responses to blast and lack of therapies to treat blast-exposed
individuals. Moreover, the response and subsequent recovery from blast exposure
represent an important line of research that remains to be further explored and may
elucidate the biological mechanisms associated with blast.
Differential gene expression is reported in a small number of clinical TBI studies
(Cho et al., 2016; Gill et al., 2016; Livingston et al., 2016; Merchant-Borna et al., 2016),
with few studies relevant to blast TBI (Carr et al., 2015; Gill, Cashion, et al., 2017;
Heinzelmann et al., 2014). Gene expression regulation is imperative to appropriate
cellular response to external mechanical, environmental, or biological stimuli, and the
nuclear factor kappa-light-chain enhancer of activated B cells (NF- B) complex is a main
transcription factor of these adaptive gene expression changes (Hayden & Ghosh, 2008).
More specifically, the NF- B complex is a transcription factor central to numerous
cellular pathways influencing cell survival and proliferation, including inflammatory and
immune responses, gene activation, and ubiquitination (Hayden & Ghosh, 2008). Animal
models demonstrate that the NF- B complex regulates the innate immune response
through upregulation of proinflammatory cytokines including tumor necrosis factor
(TNF) (Bohuslav et al., 1998), interleukin 1 (IL-1) (Lawrence, 2009), and interleukin 6
(IL-6) (Baeuerle & Baltimore, 1996). In addition, mutations and epigenetic changes
within the NF- B pathway have been linked to immune and inflammatory diseases
(Courtois & Gilmore, 2006). Cytokines are among a number of factors that may activate
NF- B. NF- B becomes activated when ubiquitin degrades its inhibitory protein, I K,
freeing NF- B to enter the nucleus and activate gene transcription (Baeuerle &

84

Baltimore, 1996; Chen, Bhoj, & Seth, 2006). Study of gene expression changes following
blast exposure may elucidate some of these complexities surrounding the roles and
relationships of ubiquitin and inflammatory cytokines following blast exposure.
Within clinical studies of TBI, changes in the NF- B network are reported in a
limited number of studies (Cho et al., 2016; Gill et al., 2016; Livingston et al., 2016;
Merchant-Borna et al., 2016), but have not yet been examined in biTBI. Preclinical
studies of blast exposures have demonstrated altered gene expression, including cognitive
impairment (Bailey, Sujith Sajja, Hubbard, & VandeVord, 2015; Tweedie et al., 2016)
and immune function (Struebing et al., 2017). Recent work in military training that
involves personnel exposure to blast has demonstrated that ubiquitin carboxy-terminal
hydrolase-1 (UCH-L1) is weakly correlated with repeated exposure to low-level blast
(Carr et al., 2015), consistent with previous work in TBI (Papa et al., 2012) and blast
exposure (Heinzelmann et al., 2014; Tate et al., 2013). In particular, Heinzelmann et al.
(2014) found protein ubiquitination genes (associated with neuronal recovery, central
regulator in IPA) to be downregulated in military personnel with chronic symptoms
following blast head injury. UCH-L1 is predominately expressed in the neurons and
neuroendocrine cells within the brain (Doran, Jackson, Kynoch, & Thompson, 1983;
Leroy, Boyer, & Polymeropoulos, 1998) and is an enzyme responsible for protein
degradation, thus providing a role in ubiquitin stability within neurons and maintaining
neuronal health (Osaka et al., 2003). In animal models, a mutation in the UCH-L1 gene
causing a truncated protein is associated with neurodegeneration, likely due to the
buildup of ubiquitin and subsequent lack of protein clearance (Saigoh et al., 1999). Given
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this limited number of clinical studies, this study sought to further examine differential
gene expression pathways in a blast exposed population. The purpose of this study was to
examine gene networks involving cell death and survival as well as cell structure,
function, and metabolism to investigate the role of these networks specific to biTBI.
Materials and Methods
To address the gaps in the knowledge surrounding the consequences of exposure
to isolated blast, a unique cohort of military personnel engaged in training on advanced
techniques for breaching buildings with controlled explosives was utilized. The breaching
activities were conducted under close supervision and with personal protective equipment
and established safety procedures, eliminating the chance of concomitant blunt-force or
penetrating TBI. Moreover, recruiting from a training environment, as opposed to realworld combat, facilitated accurate measurement of isolated blast exposures using helmets
equipped with pressure sensors (see Blast measurement). This novel sampling also
facilitated a collection of baseline data, including pre-exposure blood draws to support
assessment of gene expression changes after blast. During the two-week training
program, some participants (n = 29) experienced a moderate blast exposure with peak
pressure exceeding 5 pounds per square inch (psi), which exceeded the training range
limit of 4 psi and was more than 200% greater than typical exposures measured in such
training (e.g., Carr et al., 2015). These 29 cases were studied for gene expression changes
related to cell death and survival as well as cell structure, function, and metabolism from
training day 1 to training day 10. Unbiased RNA-sequencing (RNA-seq) was used to
detect dysregulated genes (Gill, Cashion, et al., 2017). Ingenuity pathway analysis (IPA)
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of dysregulated genes was used to identify gene networks, two of which were validated in
the present study using NanoString’s nCounter® system.
Participants.
All study protocols were reviewed and approved by the Institutional Review
Boards (IRBs) at the Naval Medical Research Center and Walter Reed Army Institute of
Research (NMRC#2011.0002; WRAIR#1796) as described in a past publication (Carr et
al., 2015). Prior to study participation, each participant provided informed consent. The
parent study from which the present study is drawn was comprised of (N = 108) male
active-duty military service members who were engaged in two-week blast training
programs, as either a student or instructor. The goal of the course was to teach advanced
techniques for explosive breaching, a tactic used to gain access into secured structures.
All participants provided demographic and health history data at baseline, as well as
blood samples. For the present study, participants (n = 29) examined were those who
experienced a moderate blast exposure (≥ 5psi). These 29 individuals provided blood
samples at the end of training (day 10) that were used in the present study to examine
gene expression changes from baseline to 3 days post-moderate blast exposure.
Self-reported data provided by participants at baseline included demographic,
health, and blast-history information. Demographic data included age, military rank, and
educational status. Health information collected included smoking status and history of
TBI (see Table 3-1). Previous blast exposure data was also obtained through self-reports
on how many blast exposures had been experienced during breaching and artillery fires
using the following ordinal scale: 0, 1-9, 10-39, 40-99, 100-199, 200-399, and 400+ blast

87

exposures. Details regarding the surveys used to collect data have been previously
described (Carr et al., 2015).
Blast measurement.
Objective blast data was collected using standard Army combat helmets equipped
with bilateral sensors capable of measuring blast parameters greater than a threshold of
0.4 psi on either sensor. Helmets were worn throughout training and the average of the
right and left sensor was used as data to approximate levels of explosive blast each
participant experienced; the sensitivity of the sensors is based on the technological
specifications of the device itself (micro Data Acquisition System, μDAS; Applied
Research Associates, Inc., Albuquerque, NM) as well as considerations for signal-tonoise ratios and effect on data interpretation.
Laboratory Methods.
Blood Sampling.
Whole blood samples were collected at baseline and at the end of 2-week training;
3 days after moderate blast. Blood was collected in PAXgene tubes and stored in a -80°C
freezer until the time of batch processing.
RNA-seq.
Random fragmentation of complementary deoxyribonucleic acid (cDNA)
followed by 5’ and 3’ adapter ligation was used to create a cDNA library. Average
fragment length was 150-170bp. RNA integrity was assessed using Agilent Technologies
2100 Bioanalyzer and the mean value was 8.9 with standard error of 0.05. Samples from
29 participants on day 1 and day 10 were sequenced for mRNA using the Illumina
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HiSeq®2500 Next Generation Sequencing system (Illumina Inc., San Diego, CA). Using
this system, we performed RNA-seq to read paired-ends; we read 101 bases per each end.
Sequencing data used in the study were deposited in the Gene Expression Omnibus
(GEO) with GEO ID GSE89866.
Ingenuity Pathway Analysis.
Dysregulated genes were further explored using IPA® software, build version
389077M, content version 27821452, released 2016-06-14, Qiagen, Redwood City, CA).
Two pathways of interest were identified (see “Results” for details and Figures 3-1 and 32).
NanoString.
A subset of genes examined in RNA-seq data were selected to validate gene
expression changes using a direct digital detection system (Nanostring Technologies,
Seattle, WA). In selecting genes to validate, the extent of dysregulation, biological
plausibility, and the position of the protein within the IPA® pathway diagrams were
considered. Two pathways were identified, one focused on cell death and survival and
another focused on basic structure, function, and development. A panel was designed for
each pathway to include 50 markers of interest, plus a total of 10 reference/housekeeping
genes for data normalization (Table 3-2 and Table 3-3). Probes for the 50 genes of
interest and the housekeeping genes were designed and manufactured by Nanostring
Technologies. NanoString was used to determine the mean copy number of each mRNA
probe of interest based on manufacturer’s protocol. The standard manufacturer protocol
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was followed for sample preparation, hybridization, and detection (see Supplement for
more detailed information regarding housekeeping genes and NanoString methods).
Statistical Analysis
Overview.
The Statistical Package for the Social Sciences (SPSS; version 22; IBM
Corporation, Armonk, NY) and Nanostring’s nSolverTM Analysis Software (version 3;
Nanostring Technologies, Seattle, WA) were used for all analyses.
RNA-seq Analysis.
The moderate blast exposed cases (n = 29) met quality control (QC) criteria based
on the RNA Integrity Number (RIN) and were subsequently sequenced. In total, between
52.5 million and 75.5 million read counts were completed for each sample; in 94.95% of
base calls, an accuracy of at least Q30 was achieved. To establish bioinformatics QC,
FastQC (version 0.11.5, Babraham Bioinformatics, Cambridgeshire, UK) was used. Data
was aligned to a reference genome (hg19) using an open-source aligner, STAR, (version
2.5) (Dobin et al., 2013). To count the number of reads mapped to genes, HTSeq software
was used (version 0.6.1p1) (Anders, Pyl, & Huber, 2015). DESeq2 (version 1.12.3)
(Love, Huber, & Anders, 2014) was used to identify differentially expressed genes, with
the Wald test used to determine statistical significance, p values adjusted for multiple
testing using the Benjamini-Hochberg procedure, and a cutoff value of false discovery
rate (FDR) of 0.05.
Nanostring Validation Analysis.
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Raw data was analyzed using nSolverTM 3.0 digital analyzer software using
standard settings and quality control parameters. It was normalized against housekeeping
genes. Fold changes and p-values were calculated using a t-test adjusted for multiple
comparisons using the Benjamini-Yekutieli false discovery rate method for samples
before and after blast exposure, with statistical significance defined at the level of p<0.05.
Results
Demographic results.
Participants in the study were male military service members with a mean age of
31.2 and a mean length of service of 11.2 years (Table 3-1). Almost half of participants
(46.3%) had a history of greater than 40 prior blast exposures. No significant differences
based on demographic information were noted among the cohort (Gill, Cashion, et al.
(2017).
RNA-seq results.
Results of the RNA-seq analysis demonstrated significant gene-activity changes
(p<0.05) following a moderate blast with multiple networks being dysregulated (Table 34). The present study reports on two of the most significant gene-network activity
changes (Figures 3-1 and 3-2) determined by Ingenuity® Pathway Analysis (IPA®)
software (IPA®, Qiagen, Redwood City, CA). In total, five pathways were identified,
including two sets of two pathways that shared overlapping functions and were
subsequently merged together to form two pathways of interest in the present study. One
merged pathway centered on cell death and survival; this pathway was comprised of
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genes implicated in apoptosis, necrosis, autophagy, mitophagy, ferroptosis, survival,
regeneration, and recovery, with a score of 42 (Figure 3-1). The second merged pathway
focused on development, metabolism and cell structure/function; this pathway consisted
of genes involved in cytoskeleton, organelles, cellular metabolism, lipid metabolism, heat
shock, cell motion, cell growth, and differentiation, with an IPA score of 41 (Figure 3-2).
NanoString was used to validate the RNA sequencing results. Nanostring
analysis showed 32 significantly differentially expressed genes in the Cell Death and
Survival network (p < 0.05) and 35 significantly differentially expressed genes in the Cell
Structure, Function, and Metabolism network (p < 0.05), validating differential
expression of these two gene networks following blast exposure.
Discussion
In this study, activity changes are reported in two gene networks after moderate
blast exposure in military personnel engaged in training. Differentially regulated
networks after blast included cell death and survival (see Figure 3-1), which is related to
nonsense mediated decay, as well as cellular structure, function, and development (see
Figure 3-2). Genes within these networks relate to ubiquitination, apoptosis, as well as
activity related to ribosomes, mitochondria, and inflammation. Findings from this study
provide novel insight for understanding the biological changes that occur following blast,
which for some individuals, may result in biological changes that increase their risk for
neurological or behavioral symptoms and deficits. These findings may ultimately
contribute to characterizing the cellular mechanisms of blast exposure to improve
diagnosis, monitoring, and prognosis of military personnel exposed to blast.
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A number of genes related to ubiquitination are increased in activity following
blast exposure, including tripartite motif containing 12 (TRIP12), a gene encoding an E3
ubiquitin-protein ligase involved in ubiquitin fusion degradation. Protein ubiquitination
initiates the removal of oxidized and misfolded proteins following injury, and its
processes can protect neurons from reactive oxidative species (ROS) which accumulate
following blast exposure in pre-clinical models (Kochanek et al., 2013). These findings
support the previous report of increased UCH-L1, the primary protein for ubiquitination,
following repeated low-level blast (Carr et al., 2015). This finding suggests that there
may also be overlap with the biological mechanisms related to recovery from TBIs in
civilians, as UCHL1 increases are one of the most often reported changes following a
TBI (Diaz-Arrastia et al., 2014; Toman, Harrisson, & Belli, 2016). In contrast, as
reported in a previous publication, the activity of genes related to ubiquitin were lower in
activity in military personnel with TBIs, with many related to blast exposures, and
chronic symptoms (Heinzelmann et al., 2014). Therefore, it may be that ubiquitin activity
is critical to acute recovery from biTBIs, and that in some individuals, there is a reduction
in activity that may place them at higher risk for chronic symptoms. In support of this,
pre-clinical studies show that reductions or inactivation of ubiquitin activity results in
poor outcomes, including behavioral deficits, possibly indicating long-term
neurodegenerative processes (Svetlov et al., 2010).
Additional genes that may relate to neuronal recovery are altered in activity
following a moderate blast in this report. Specifically, gene activity changes are observed
within the nonsense mediated decay (NMD) pathway, including UPF1 and UPF3B,
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which are responsible for neuronal specific cell development and repair through a
reciprocal pattern of activity (Kurosaki & Maquat, 2016). Previous studies show an
interaction in the activity of these two genes, such that when one gene is less active, the
other gene will compensate, preserving the activity of this network; the present findings
mirror these previous studies. The present findings show that UPF1 was increased in
activity, whereas UPF3B was downregulated. These findings suggest that in response to
the blast, injury mechanisms may have been initiated (inflammation, aberrant cellular
formation, and cell death), and this initiation may result in an upregulation of UPF1, in
an effort to preserve the activity of the NMD pathway. Subsequently, the expression of
UPF3B is suppressed, hindering possible detrimental neurological effects. These findings
suggest complex gene-activity changes following blast exposure that may be occurring to
promote recovery, implicating the need for additional studies to understand the temporal
relationship of these changes and their relation to neuronal recovery.
Another gene downregulated in military personnel following blast within the
structure, function, and development pathway was NAE1 (NEDD8 Activating Enzyme E1
Subunit 1), a protein associated with the neddylation pathway. Vogl, A.M., et al. showed
that neddylation was a critical regulator of dendritic spine development, reporting that in
NAE1 knockout mice, there were cognitive deficits as well as synaptic and
neurotransmitter impairments (Vogl et al., 2015). The down-regulation observed in the
military population could suggest similarly that exposure to blast hinders the neddylation
pathway and might suggest a marker of injury resulting directly from blast exposure.
Additionally, recent in vitro work suggests Il-1β may inhibit NEDD8 and neddylation in
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conjunction with increased ubiquitination; while activation of NEDD8 downregulates the
NF-κB pathway (Yan, Guan, Peng, & Zheng, 2017). This is of interest, as genes within
the NF-κB network also show activity changes, with most genes becoming more active.
The NF-κB network is a dominant activator of the immune system following TBI and this
activity is essential as it initiates secondary injury mechanisms required for neuronal
recovery. However, if activity of this pathway is too high, or too long-lasting, it can be
detrimental to neuronal recovery (Jassam, Izzy, Whalen, McGavern, & El Khoury, 2017).
One gene in the pathway, ARRB1(arrestin β1), is increased following blast exposure. This
gene has been reported to play a role in the beta-adrenergic receptor kinase (BARK)
mediated desensitization of beta-adrenergic receptors. In TBI patients, catecholamines
surge after injury has been linked to immunosuppression and greater mortality risk that is
reversed through β-blocker treatment (Schroeppel et al., 2010). ZBTB7B (zinc finger and
BTB domain containing 7B) is also upregulated after a blast and is linked to reductions in
CD8-cytotoxic activity (Wang et al., 2008), which could be a mechanism to prevent
further cellular damage after blast injury.
Another gene related to immune activity with increased activity is AKT1, a hub
that included approximately 14 connections in the structure, function, and development
network. AKT1 encodes for a serine-threonine protein kinase (AKT1), which is known to
regulate a vast number of cellular processes including neuronal survival, glucose uptake,
protein and fatty acid synthesis, cell proliferation, and the previously mentioned role in
apoptosis (Oeckinghaus & Ghosh, 2009; Vergadi, Ieronymaki, Lyroni, Vaporidi, &
Tsatsanis, 2017). Additionally, AKT1 may function in the inflammatory response as an
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upstream activator of the nuclear factor kappa light-chain enhancer of activated B cells
(NF- B) (Lian et al., 2015). Interestingly, in this population, significantly elevated levels
of the cytokines tumor necrosis factor alpha (TNF ) and interleukin 6 (IL-6) have been
reported during the acute period following moderate blast (Gill, Motamedi, et al., 2017).
This finding is relevant as NF- B is recognized as a master regulator of cytokines
including TNF and IL-6 (Neumann & Naumann, 2007; Oeckinghaus & Ghosh, 2009).
Studies of the NF-κB pathway have implicated the pathway in regulation of
proinflammatory cytokines during meningitis (Barichello, Generoso, Simoes, Elias, &
Quevedo, 2013) and in blood-brain barrier permeability (Merrill & Murphy, 1997).
Additionally, the NF- B pathway has been found to be dysregulated in clinical studies of
acute and subacute TBI (Cho et al., 2016; Gill et al., 2016; Livingston et al., 2016;
Merchant-Borna et al., 2016). Upregulation of AKT1 in this sample suggests activation of
the NF-κB pathway; a finding that supports these prior studies, though the specific role of
AKT1 in blast effects on the central nervous system remains to be examined.
Other genes related to NF- B pathway also show increased activity, including the
Flt3 (dimer) that encodes for a receptor tyrosine kinase. Flt3 is implicated in multiple
signaling pathways including regulation of the proliferation and survival of hematopoietic
cells, which ultimately relates to the number of intermediate monocytes (Zawada et al.,
2016). This has possible implications, as intermediate monocytes promote production of
inflammatory cytokines within the NF- b network, including TNF- and Il-1 (Wong et
al., 2012), suggesting the possibility of a pro-inflammatory response through increased
production of intermediate monocytes.
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Genes related to apoptosis are observed to change in activity following blast;
findings of interest as preclinical models show blast exposure results in astrocytic and
microglial activation, oxidative stress, axonal and vascular damage, and inflammation,
which ultimately contribute to programmed cell-death (Agoston & Elsayed, 2012;
Agoston, Gyorgy, Eidelman, & Pollard, 2009; Goodrich et al., 2016; Saljo, Mayorga,
Bolouri, Svensson, & Hamberger, 2011). Specifically, there is an activation of caspase
complexes, a family of cysteine-dependent proteases, which have been previously
associated with neuronal and oligo-dendroglial cell death in both pre-clinical and human
brain injuries (Schoch, Madathil, & Saatman, 2012). Otherwise referred to as apoptosis
executioners, caspase-3 and -7 are both indirectly activated by MBIP, a major hub of the
cell structure, function, and metabolism network. Increased expression in caspase-3 and 7 complexes have also been previously linked to TBIs in pre-clinical models (Clark et al.,
2000; Larner, McKinsey, Hayes, & KK, 2005) and to mortality in patients with severe
TBIs (Zhang et al., 2006). Increased activity in other apoptosis genes following blast
include EPB41L3, or erythrocyte membrane protein band 4.1-like 3, and EPB41L3, a
tumor suppressor gene strongly expressed in the brain that promotes apoptotic pathways
and inhibits cellular proliferation (Li et al., 2011). These findings suggest that moderate
blast results in expression of apoptosis inducing genes, and that mitigating these activities
may be protective.
Lastly, several mitochondrial genes and genes connected with the mitochondrial
gene network are dysregulated, including COA5, HIBH, RPL6, RPL35, as well as
mitochondrial ribosomal genes MRPL50, MRPL1, MRPL3, and MRPL46. Although the
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function of mitochondria is not yet well understood in blast exposures, it is worth noting
that mitochondrial dysfunction has been implicated in preclinical TBI pathology.
Previous studies have indicated that following TBI an influx of intracellular calcium
leads to disruption of the mitochondrial membrane potential, impairing ATP production
and creating ROS, activating cell death pathways and leading to neuronal damage
associated with cognitive impairments (Ohta et al., 2013; Walker & Tesco, 2013). The
biological mechanisms specific to blast effects on the central nervous system in the
context of mitochondrial genes is not yet known.
Conclusion
The findings reported here provide further characterization of gene activity that
occurs following moderate blast exposure, including changes in the activity of key
pathways for ubiquitination, NF- B, apoptosis and mitochondrial activity. This study had
a unique design, as it allowed for evaluation of changes in gene-activity following a
moderate blast exposure, by comparing gene-activity to baseline prior to blast exposure.
These findings highlight the need for future studies in larger samples that include the
collection of additional acute days of gene expression data, to complement consideration
of acute and chronic symptomology and neuronal changes. This study’s gene expression
findings related to ubiquitination and inflammatory pathways add to previous TBI
literature even though there was no acute TBI diagnosis in this cohort. Further study of
such blast-associated effects and the role of these networks and associated proteins is
warranted.
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Table 3-1.
Demographic and previous explosive exposure of participants exposed to moderate blast
Variables
Mean Age in Years

Moderate Blast (N=29)
31.2 (4.4)

(SD)
Mean Years of

11.2 (4.7)

Service (SD)
Number of Prior

Artillery Fires, % (n)

Explosive Breaches
0-9

20.7% (6)

10-39

34.8% (10)

40-99

17.2% (5)

100-199

20.6% (6)

200-399

6.9% (2)
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Figure 3-1.
Cell death and survival pathway

Note. Ingenuity® pathway analysis (IPA®) figure shows dysregulated cell death and
survival pathway following moderate blast. Genes described in the text included: UPF1,
UPF3B, ARRB1, ZBTB7B, flt3, HIBCH, RPL6, RPL35, MRPL1, MRPL3, MRPL36, and
MRPL50. See Legend for IPA networks for symbol meanings.
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Figure 3-2.
Structure, function, and development pathway

Note. Ingenuity® pathway analysis (IPA®) figure shows dysregulated structure, function,
and development pathway following moderate blast. Genes described in the text include:
TRIP12, NAE1, AKT1, MBIP, COA5, and EPB41L3. See Legend for IPA networks for
symbol meanings.

103

Note: Legend for IPA® Networks, Figures 3-1and 3-2.

Note. Legend indicates main features of the IPA® network, including molecular shapes,
targeted and non-targeted relationships between molecules, and color showing increased
or decreased measurement. Adapted from the Qiagen, Inc. IPA® legend
http://ingenuity.force.com/ipa/IPATutorials?id=kA250000000TN2wCAG
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Table 3-2.
Genes included in the cell death and survival pathway.
Gene Symbol

Gene Name

Ref Seq Accession

HKG

NM_001090.2

Yes

NM_024722.2

-

log2 Fold Change

Adjusted p-value

ATP Binding Cassette
ABCF1

Subfamily F Member 1
Acyl-CoA Binding Domain

ACBD4*

Containing 4

ALAS1

5'-Aminolevulinate Synthase 1 NM_000688.4

Yes

-0.199499195

0.020347576

0.242752898

0.028367932

Arachidonate 12ALOX12B*

Lipoxygenase, 12R Type

NM_001139.2

-

-0.346622555

0.039772707

ALOXE3*

Arachidonate Lipoxygenase 3

NM_001165960.1

-

-0.228199903

1

NM_001040118.2

-

0.269598353

0.04521624

ArfGAP With RhoGAP
Domain, Ankyrin Repeat And
ARAP1*

PH Domain 1
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ARRB1*

Arrestin Beta 1

NM_004041.3

-

0.278700332

0.006452812

BCL2L13*

BCL2 Like 13

NM_001270733.1

-

0.179780094

0.04946175

NM_182962.2

-

-0.507459422

0.00558523

Baculoviral IAP Repeat
BIRC3*

Containing 3
2,4-Dienoyl-CoA Reductase 1,

DECR1

Mitochondrial

NM_001359.1

Yes

DIDO1*

Death inducer-obliterator 1

NM_001193369.1

-

-0.09345587

0.045208841

FLT3*

Fms Related Tyrosine Kinase 3 NM_004119.2

-

0.389648012

0.018925186

Glyceraldehyde-3-Phosphate
GAPDH

Dehydrogenase

NM_002046.3

Yes

Growth Factor Receptor
GRB2*

Bound Protein 2

NM_002086.4

-

0.214453639

0.048161569

GUSB

Glucuronidase beta

NM_000181.3

Yes

0.194071193

0.03424108

HIBCH*

3-Hydroxyisobutyryl-CoA

NM_014362.3

-

-0.137136152

0.048761345
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Hydrolase
High Mobility Group
Nucleosomal Binding Domain
HMGN3*

3

NM_004242.3

-

-0.201298014

0.02317844

Hypoxanthine
HPRT1

Phosphoribosyltransferase 1

NM_000194.1

Yes

IPO8

Importin 8

NM_006390.2

Yes

Potassium Voltage-Gated
Channel Subfamily H Member
KCNH7*

7

NM_033272.2

-

0.441079018

0.038059517

MAGEH1*

MAGE Family Member H1

NM_014061.3

-

-0.294631712

0.003622067

-93 miR

MicroRNA 93

NR_029510.1

Yes

NM_004531.4

-

-0.266516936

0.049007307

Molybdenum Cofactor
MOCS2*

Synthesis 2
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Mitochondrial Ribosomal
MRPL1*

Protein L1

NM_020236.3

-

-0.62382527

0.00331706

NM_007208.2

-

-0.330469686

0.030366265

NM_022163.3

-

-0.260611172

0.010945064

NM_019051.1

-

-0.46102798

0.010773055

NM_022100.1

-

-0.277593921

0.003523616

NM_014018.2

-

-0.368377224

0.0463031

NM_021963.3

-

-0.394155658

0.040740338

Mitochondrial Ribosomal
MRPL3*

Protein L3
Mitochondrial Ribosomal

MRPL46*

Protein L46
Mitochondrial Ribosomal

MRPL50*

Protein L50
Mitochondrial Ribosomal

MRPS14*

Protein S14
Mitochondrial Ribosomal

MRPS28*

Protein S28
Nucleosome Assembly

NAP1L2*

Protein 1 Like 2
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Nucleosome Assembly
NAP1L3*

Protein 1 Like 3

NM_004538.4

-

-0.403261661

0.04324522

NM_138704.2

-

-0.138835375

0.069775418

NM_017615.2

-

-0.244479492

0.016903185

-0.462238206

0.039312303

0.19447752

0.023843395

NSE3 Homolog, SMC5-SMC6
NSMCE3*

Complex Component
NSE4 Homolog A, SMC5-SMC6

NSMCE4A*

Complex Component
Parkin RBR E3 Ubiquitin

PARK2*

Protein Ligase

NM_004562.2

-

PGK1

Phosphoglycerate Kinase 1

NM_000291.2

Yes

Proline-Serine-Threonine
Phosphatase Interacting
PSTPIP2*

Protein 2

NM_024430.3

-

0.327102801

0.029452324

RFX2*

Regulatory Factor X2

NM_000635.3

-

0.371048376

0.028931549

RNF10*

Ring Finger Protein 10

NM_014868.3

-

0.363231062

0.019697501
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RPL11*

Ribosomal Protein L11

NM_000975.2

-

-0.422877581

0.016695613

RPL15*

Ribosomal Protein L15

NM_001253379.1

-

-0.285314324

0.023453576

RPL22*

Ribosomal Protein L22

NM_000983.3

-

-0.264541621

0.021464081

RPL30*

Ribosomal Protein L30

NM_000989.2

-

-0.408465221

0.017083487

RPL35*

Ribosomal Protein L35

NM_007209.3

-

-0.43080228

0.010643658

RPL4*

Ribosomal Protein L4

NM_000968.2

-

-0.289569243

0.020267917

RPL6*

Ribosomal Protein L6

NM_000970.3

-

-0.340254818

0.018412596

RPL9*

Ribosomal Protein L9

NM_000661.4

-

-0.714413772

0.001773623

NM_001159597.1

-

-0.311600753

0.038059517

0.19259478

0.016276538

-0.261036039

0.010073305

SH3 And SYLF Domain
SH3YL1*

Containing 1
Staufen Double-Stranded RNA

STAU1*

Binding Protein 1

NM_017454.2

-

TBP

TATA-Box Binding Protein

NM_001172085.1

Yes

TESPA1*

Thymocyte Expressed,

NM_001098815.2

-
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Positive Selection Associated
1
TPM4*

Tropomyosin 4

NM_003290.2

-

0.161122161

0.016276538

TRMT10B

TRNA Methyltransferase 10B

NM_144964.3

-

-0.196738227

0.026654574

TSPYL4*

TSPY Like 4

NM_021648.4

-

-0.247290787

0.008592219

NM_002911.3

-

0.254526328

0.03643324

NM_080632.2

-

-0.2020123

0.026669595

NM_015872.2

-

0.243249222

0.025478126

UPF1, RNA Helicase And
UPF1*

ATPase
UPF3 Regulator Of Nonsense

UPF3B*

Transcripts Homolog B (Yeast)
Zinc Finger And BTB Domain

ZBTB7B*

Containing 7B
Zinc Finger CCCH-Type

ZC3H15*

Containing 15

NM_018471.2

-

-0.335063911

0.026607119

ZKSCAN3*

Zinc Finger With KRAB And

NM_001242895.1

-

-0.253800344

0.031068942
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SCAN Domains 3
ZNF106*

Zinc Finger Protein 106

NM_022473.1

-

ZNF32*

Zinc Finger Protein 32

NM_006973.2

Yes

Note. HKG=house-keeping gene. *Validated by NanoString
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0.294418924

0.015098223

-0.355641394

0.012837388

Table 3-3.
Genes included in the structure, function, and development pathway.
Gene Symbol

Gene Name

Ref Seq Accession

HKG

NR_003256.2

-

log2 Fold Change

Adjusted p-value

ATP Binding Cassette
ABCD4*

Subfamily D Member 4

-0.199499195

0.020347576

ATP Binding Cassette
ABCF1

Subfamily F Member 1

NM_001090.2

Yes

ACYP1*

Acylphosphatase 1

NM_001107.3

-

-0.329474401

0.019194616

NM_001014432.1

-

0.17005921

0.038615925

0.242752898

0.028367932

-0.235773531

0.040849382

AKT Serine/Threonine Kinase
AKT1*

1
5'-Aminolevulinate Synthase

ALAS1

1

NM_000688.4

Yes

ANKS6*

Ankyrin Repeat and Sterile

NM_173551.3

-
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Alpha Motif Domain
Containing 6
APP*

Amyloid Precursor Protein

NM_000484.3

-

0.275234781

0.033723847

ARCN1*

Archain 1

NM_001655.4

-

0.171105347

0.046801529

NM_152269.4

-

-0.204227132

0.026071674

NM_000491.3

-

0.584216904

0.011252651

NM_144697.2

-

-0.475138427

0.038059517

NM_013252.2

-

0.43694439

0.013654046

NM_001008215.2

-

-0.188436396

0.030279095

Chromosome 12 open
C12orf65*

reading frame 65
Complement Component 1, Q

C1QB*

Subcomponent, B Chain
Circadian Associated

CIART*

Repressor of Transcription
C-Type Lectin Domain Family

CLEC5A*

5 Member A
Cytochrome C Oxidase

COA5*

Assembly Factor 5
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Coatamer Protein Complex
COPA*

Subunit Alpha

NM_004371.3

-

0.2593244

0.019024708

Coatamer Protein Complex
COPB2*

Subunit Beta

NM_004766.2

-

0.192983112

0.012365191

DCLRE1B*

DNA Cross-Link Repair 1B

NM_022836.3

-

0.198400973

0.017155237

DECR1

2,4-Dienoyl-CoA Reductase 1

NM_001359.1

Yes

Erythrocyte Membrane
EPB41L3*

Protein Band 4.1 Like 3

NM_012307.2

-

0.431151189

0.006476354

FAAH2

Fatty Acid Amide Hydrolase 2

NM_174912.3

-

-0.499379188

0.005745525

NM_052966.2

-

0.40324029

0.024746754

0.194071193

0.03424108

Family with sequence
FAM129A*

similarity 129, member A
Glyceraldehyde-3-Phosphate

GAPDH

Dehydrogenase

NM_002046.3

Yes

GUSB

Glucuronidase Beta

NM_000181.3

Yes
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Hypoxanthine
HPRT1

Phosphoribosyltransferase 1

NM_000194.1

Yes

IPO8

Importin 8

NM_006390.2

Yes

KIAA0513*

KIAA0513 Ortholog

NM_014732.3

-

0.361322535

0.014586154

NM_005779.2

-

0.400554788

0.000715584

Lipoma HMGIC Fusion
LHFPL2*

Partner-Like 2
LUC7 Like 3 Pre-MRNA

LUC7L3*

Splicing Factor

NM_006107.2

-

-0.279039102

0.042125529

MAP7D1*

MAP7 Domain Containing 1

NM_018067.3

-

0.26655588

0.039772707

NM_001144891.1

-

-0.304655557

0.017155256

NR_029510.1

Yes

NM_014180.3

-

-0.361248608

0.023357416

MAP3K12 Binding Inhibitory
MBIP*

Protein 1

miR-93
Mitochondrial Ribosomal
MRPL22*

Protein L22
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Mitochondrial Ribosomal
MRPL39*

Protein L39

NM_017446.3

-

-0.30416698

0.015173431

Methylsterol Monooxygenase
MSMO1*

1

NM_001017369.1

-

-0.237679234

0.041114756

MTX2*

Metaxin2

NM_006554.4

-

-0.369413967

0.019530729

MTX3*

Metaxin3

NM_001010891.4

-

-0.370201897

0.032915527

NM_001018159.1

-

-0.324495292

0.007350252

NM_145063.2

-

-0.205410287

0.0115853

NEDD8 Activating Enzyme E1
NAE1*

Subunit 1
O-Acyl-ADP-Ribose Deacylase

OARD1*

1
Ovarian Carcinoma
Immunoreactive Antigen-Like

OCIAD2

Protein 2

NM_152398.2

-

-0.349639139

0.004637306

OXSM*

3-Oxoacyl- Acyl Carrier

NM_017897.2

-

-0.306169512

0.028418587
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Protein Synthase,
Mitochondrial
PGK1

Phosphoglycerate Kinase 1

NM_000291.2

Yes

0.19447752

0.023843395

NM_005028.3

-

0.180982773

0.033210105

NM_004162.4

-

0.18204685

0.136291748

Phosphatidylinositol-5Phosphate 4-Kinase Type 2
PIP4K2A*

Alpha
RAS-Associated Protein

RAB5A*

RAB5A
RAP1 GTPase Activating

RAP1GAP2*

Protein 2

NM_015085.4

-

0.219298444

0.011143681

RSPH3*

Radial Spoke 3 Homolog

NM_031924.4

-

0.272080541

0.032117983

Slingshot Protein
SSH1*

Phosphatase 1

NM_018984.3

-

0.269175026

0.010309573

SSH2*

Slingshot Protein

NM_033389.3

-

0.315283525

0.024375198
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Phosphatase 2
TBP

TATA-Box Binding Protein

NM_001172085.1

Yes

NM_153333.2

-

-0.242696303

0.044714506

Transcription Elongation
TCEAL8*

Factor A Like 8
Tigger Transposable Element

TIGD1*

Derived 1

NM_145702.1

-

-0.53120337

0.012433895

TMEM237*

Transmembrane Protein 237

NM_001044385.1

-

-0.394403177

0.032253724

TMEM261*

Transmembrane Protein 261

NM_001318058.1

-

-0.464675435

0.002668268

TMEM263

Transmembrane Protein 263

NM_152261.2

-

-0.34231287

0.048588716

Translocase Of Outer
TOMM5*

Mitochondrial Membrane 5

NM_001001790.2

-

-0.354166369

0.045960581

TP53RK*

TP53 Regulating Kinase

NM_033550.3

-

-0.213093565

0.017767807

TPD52*

Tumor Protein D52

NM_005079.2

-

-0.330475184

0.038005975

TPRKB*

TP53RK Binding Protein

NM_016058.2

-

-0.443196546

0.006016182
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TRIP12*

Tripartite Motif Containing 12

NM_004238.1

-

0.231188855

0.003223298

Zinc Finger CCHC-Type
ZDHHC23

Containing 23

NM_173570.3

-

-0.520810011

0.004066651

ZNF706*

Zinc finger protein 706

NM_001042510.1

-

-0.10910689

0.031066687

NM_005455.4

-

-0.40446744

0.019490303

Zinc Finger RANBP2-Type
ZRANB2*

Containing 2

Note. HKG=house-keeping gene. *NanoString validation.
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Table 3-4.
IPA® Network Scores
Network

IPA Network Score

Metabolic

45

Cell Death and Survival

42

Post-Translational
Modification

42

Cancer, Cell Death and
Survival

42

Immunological Diseases

37

Merged Networks

IPA Network Score

Cell Death and Survival

42

Cell Structure, Function, and
Metabolism

41

Note. Network scores are numerical values used to
rank fit of molecules to the network. The scores are
calculated using an algorithm based on Fisher’s Exact
Test. Eligible molecules are compared to the Ingenuity
Knowledge Base of over 1 million molecules curated
from literature findings. Highly interconnected genes
imply significant biological function.
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CHAPTER FOUR
INTERLEUKIN-6 ASSOCIATED WITH ACUTE CONCUSSION IN MILITARY
COMBAT PERSONNEL
Introduction
Concussion, or mild traumatic brain injury (mTBI), is recognized as one of the
most prevalent injuries among military members serving in Operation Iraqi Freedom
(OIF) and Operation Enduring Freedom (OEF), yet biomarkers related to these injuries
and the related recovery processes remain elusive (DePalma, 2015; Jones, Fear, &
Wessely, 2007). The most common cause of concussions sustained by deployed
personnel worldwide is blast exposures, especially by improvised explosive devices
(IEDs) (Ritenour & Baskin, 2008). A blast exposure can directly result in a concussion,
and it may also contribute to blunt force injuries if the soldier comes into contact with
objects resulting from the exposure to the blast, i.e. being thrown into objects or being hit
by objects from the blast (Champion, Holcomb, & Young, 2009; Ramasamy, Harrisson,
Clasper, & Stewart, 2008). Blast exposure effects multiple organs and tissues, including
the central nervous system, which is well documented in preclinical models (Mac Donald
et al., 2011). It is also increasingly recognized that military personnel can sustain multiple
blast exposures as well as concussions during combat deployments, and the consequences
of these injuries are just now being determined (Carr et al., 2016). Over time, blast
exposures as well as blunt force injuries are associated with neurological symptoms that
are garnering concern for the health and well-being of military personnel and veterans
(Carr et al., 2015; Mac Donald et al., 2016; Mac Donald et al., 2014). At this time,
limited objective measures exist for identification of individuals who may be at high risk
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for developing complications and poor outcomes following concussion, including those
affected by concussion and blast exposures during deployment. Thus, identifying
underlying biological changes that occur following a concussion or mTBI are crucial to
identify those military personnel who may
be at the most risk, who require increased monitoring and preventive interventions, and
for ongoing monitoring of individuals who may be at high risk for poor outcomes (Prieto,
Ye, & Veenstra, 2008).
Peripheral biomarkers show promise in distinguishing patients with traumatic
brain injuries (TBIs) who require additional monitoring and interventions, yet most
previous studies primarily include severe patients (Papa et al., 2016; Papa et al., 2012).
Thus, protein biomarkers may be useful in monitoring those at high risk for poor
outcomes, which may be especially beneficial among concussed individuals who may not
otherwise follow up on mild subjective symptoms (Menon, Schwab, Wright, & Maas,
2010). Specifically, studies of blood-based inflammatory protein biomarkers may
implicate the underlying inflammatory processes following concussions that are
important for acute recovery (Ferreira et al., 2014; Woiciechowsky et al., 2002) and may
relate to chronic symptoms (Kumar, Boles, & Wagner, 2015; Licastro et al., 2016). Not
only may inflammatory biomarkers help monitor outcomes, but they may also help
identify inflammatory pathways that may be targeted for therapies (McKee & Lukens,
2016). Of interest are pro- and anti-inflammatory cytokines, as they have been implicated
in the underlying balance of inflammatory processes which occur following a TBI
(Hinson, Rowell, & Schreiber, 2015; Woodcock & Morganti-Kossmann, 2013). For
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example, preclinical brain injury studies of interleukin (IL)-6 indicate some IL-6 activity
is beneficial for recruiting immune cells and improving outcomes, especially in the acute
phase (Penkowa et al., 2003). However, harmful outcomes may result from either IL-6
deficiency, as demonstrated in IL-6 knockout mice (Penkowa, Giralt, Carrasco, Hadberg,
& Hidalgo, 2000), or chronic IL-6 overexpression (McKee & Lukens, 2016; Penkowa et
al., 2003). Likewise, the study of IL-10 in preclinical brain injury models has shown
poor outcomes in IL-10 knockout mice, with IL-10 administration improving
neurological function and decreasing lesion volume (Kline et al., 2002). In human
studies, elevated levels of IL-6, IL-10, and TNF , among others, have been associated
with poor outcomes in severe cases of TBI (Arand, Melzner, Kinzl, Bruckner, &
Gebhard, 2001; Ferreira et al., 2014; Woiciechowsky et al., 2002). However, fewer
studies have evaluated cytokines in concussions. This lab has previously reported that
elevated levels of plasma inflammatory cytokines, IL-6 and TNF , are concurrent with
chronic neurological symptomology among military personnel who experienced blunt
force and/or blast injury (within 16 months of deployment) (Devoto et al., 2016). This lab
also reported an association between moderate blast exposure and acute increases in
levels of IL-6 and TNF within 16 months of deployment in a military training
population (Gill et al., 2017). Yet, peripheral levels of IL-6, IL-10, and TNF have not
yet been measured during the first 24 hours following concussion sustained during a
military combat deployment.
To better understand the role of inflammatory cytokines in concussions, cytokines
levels of (IL-6, IL-10, and TNF ) were measured acutely following a medically
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diagnosed concussion, during transport to a medical facility, and then again 24 hours later
to characterize the relationship between cytokines and recovery from acute brain injury.
This project is needed to expand the understanding of peripheral inflammatory biomarker
levels in a cohort of deployed military personnel who sustain concussions. Findings from
this line of research will provide the basis to identify the biological underpinnings of
inflammatory processes occurring in the acute stage of recovery from concussion
sustained in austere environments like military deployment where blast has become a
primary cause of injury, which is necessary to improve recovery trajectories.
Methods
Participants.
This study protocol was reviewed and approved by the Research Institutional
Review Boards at the US Army Medical Research and Materiel Command (M-10216)
and the Walter Reed Army Institute of Research (WRAIR #2028, #2529). Each study
participant provided informed consent prior to participation. This unique, observational
cohort study consisted of: 1) deployed military personnel who sustained a concussion,
provider diagnosed, without other major medical diagnosis and received acute medical
care (n=45) and 2) healthy control participants in the same deployment environment who
did not sustain concussion or other illness or injuries (n=49). Both groups were deployed
to units in the same region of operations in Afghanistan during 2012. Participants had
blood draws at two time points: 1) time point 1 was at the time of medical care, less than
8 hours after concussion, or at the time of initial encounter for the healthy control group
and 2) time point 2 was at 24 hours following the time of the first blood draw.
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Blood sampling.
Whole blood was drawn and processed for serum, using standard protocols,
within one hour of the blood draw. Serum was aliquoted and stored at -80 C until batch
processing and analyses.
Laboratory methods.
IL-6, IL-10, and TNF concentrations were measured using Simoa technology.
Simoa™ (Quanterix, Lexington, MA), an ultrasensitive single-molecule enzyme-linked
immunosorbent assay, as previously described (Mondello et al., 2014). The IL-6, IL-10,
and TNF assays have low limits of detections (0.006pg/mL, 0.0022pg/mL, and
0.011pg/mL, respectively). Samples were run in duplicate, and the personnel running
analyses were blinded to group. Average coefficient of variance (CV) were 4.75%,
4.43%, and 4.78% for IL-6, IL-10 and TNF , respectively. Samples with CVs > 15%
were excluded.
Statistical methods.
SPSS version 25 (IBM Corporation, Chicago, IL) was used to conduct statistical
analyses, and GraphPad Prism version 7.0d (Graph Pad Software, San Diego, CA) was
used to create figures. Baseline demographic characteristics were compared between
healthy and concussed groups using Pearson’s chi square (race and gender) and ANOVA
(age). Distributions did not require adjustment for normality. The differences in
concentrations of IL-6, IL-10, and TNF at two time points (time point 1 = <8 hours after
injury with time point 2 = 24 hours following time point 1) were compared between the
healthy and concussed groups using Mann Whitney U tests. Mean difference was
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calculated by subtracting each participant’s cytokine concentration at time point 2 from
the concentration level at time point 1, resulting in a variable that reflects the total change
in each cytokine between the groups. This calculated change resulted in the creation of a
variable that could then be compared between the groups to determine if there were
differences in the change in cytokine concentrations between these groups. A Mann
Whitney U test was conducted to evaluate if there was a significant change in the
cytokines in the concussed group compared to the healthy control group. Since groups
were similar in demographic characteristics, we did not include any covariates in these
models.
Results
Demographics.
The sample included primarily male (96.8%) participants who were active duty
service members (n=94) deployed to Afghanistan. The mean age was 26.41 years
(SD=6.364) with a range of 19 to 48 years of age. Here, military personnel who were
medically diagnosed with a concussion and received acute care (n=45) were compared to
healthy controls with no diagnosis of concussion (n=49) deployed to the same combat
station. The two groups did not differ in demographic features including sex, race, or age
(see Table 4-1). All participants within both groups had a Glasgow Coma Score (GCS) of
15. The concussed personnel were diagnosed by a healthcare provider <8 hours following
injury. Of the concussed personnel, 33 (73.3%) participants were exposed to blast during
the injury event, with the others reporting a blunt force injury (see Table 4-2).
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Table 4-1.
Demographic Data

Mean age in years
(SD)

Healthy Controls
(N=49)

Concussion
(N=45)

Significance

26.63 (6.978)

26.36 (5.747)

p=0.841a
F=0.041a

p=0.066b

Sex
Male
Female

49 (100%)
0

42 (93.3%)

(0%)

3 (6.7%)

p=0.297b

Race
White
Black
Hispanic
Pacific Islander
Asian
Middle Eastern
Other

35 (71.4%)
5 (10.2%)
6 (12.2%)
2 (4.1%)
1 (2.0%)
0 (0.0%)
0 (0.0%)

21
0
5
1
1
1
2

(67.7%)
(0.0%)
(7.5%)
(3.2%)
(3.2%)
(3.2%)
(6.5%)

Note. The percentages in each column refer to the proportion of individuals in each sex
and race category. aAnova bPearson’s chi square *p value significant at the p<0.05 level.
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Table 4-2.
Clinical Data
Reason for visit

Concussion (N=45)

Blast exposure

n=33 (73.3%)

Blunt force injury, only

n=12 (26.7%)

Note. The percentages in each column refer to the proportion of individuals with each
reason for visit.
Inflammatory protein changes following mild concussion.
Comparisons at time point 1 and time point 2. Differences in IL-6, IL-10, and
TNF between healthy and concussed groups were evaluated at each time point (time
point 1 = <8 hours after injury; time point 2 = 24 hours following time point 1). At timepoint 1, IL-6 concentrations were significantly greater in the concussed group (M=3.92,
SD=9.30) compared to the healthy control group (M=1.48, SD=0.50; U = 420.00, z= 5.12, p<0.001) (see Figure 1a). Compared to healthy controls, the concussed group did
not significantly differ at time point 1 in concentrations of IL-10 (p=0.358) or TNF
(p=0.382) (see Figure 4-1,b-c). At time point 2, no significant differences were detected
between concussed and healthy controls for IL-6 (p=0.075), IL-10 (p=0.937), or TNF
(p=0.390) concentrations (see Figure 4-1,a-c).
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Figure 4-1 a-c
Comparison of Cytokines between Concussed and Healthy Controls at Two Time Points
a
.
.

b.

136

c.

Note. Time point 1 is <8 hours after injury. Time point 2 is 24 hours after time point 1.
Mann Whitney U tests were conducted to compare each cytokine’s concentration
between the healthy and concussed groups at each time point for a. IL-6, b. IL-10, and c.
TNF . IL-6 concentration was significantly higher in the concussed group at time point 1
at p<0.0001.
Mean Change Across Time. The mean difference between time point 1 and time
point 2 was compared between the concussed and healthy control groups for IL-6, IL-10,
and TNF . A Mann Whitney U test was conducted to determine that the mean difference
in IL-6 was significantly different in the concussed group as compared to the healthy
control (M= -1.94, SD=7.91; U = 315.00, z= -5.96, p<0.001) (see Figure 4-2a). However,
there was no difference between groups in the change of IL-10 (p=0.158) or TNF
(p=0.777) (See Figure 2b-c). The percentage change in IL-6 was -67.7% in the concussed
group compared to 33.5% in the healthy controls.
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Figure 4-2 a-c
Mean Difference in Each Cytokine Over Time from Time Point 1 to Time Point 2
a
.

b
.
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c.
.

Note. Time point 1 is <8 hours after injury. Time point 2 is 24 hours after time point 1.
Mean difference = (each participant’s cytokine concentration at time point 2) -( each
participant’s concentration level at time point 1). Mann Whitney U tests were conducted
to determine if there were differences in the mean change variable between these groups.
a. IL-6, b. IL-10, and c. TNF . IL-6 was significantly different in the concussed group as
compared to the healthy control at p<0.0001.
Discussion
The findings of higher IL-6 within 8 hours of a medically diagnosed concussion
sustained during combat deployment is consistent with previous studies that report
acutely elevated levels of IL-6 in severe TBI patients (Arand et al., 2001; Ferreira et al.,
2014; Woiciechowsky et al., 2002). In fact, this study is the only one known that reports
acute biomarker findings in a deployed cohort of military personnel with concussion.
There are a variety of factors that make a deployed population unique, and for this study,
paramount is the high rate of blast exposure. This finding is in line with this lab’s
previous report that linked IL-6 elevations to a moderate blast exposure sustained during
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training by an undiagnosed population which did not include blunt force. That elevation
was then followed by a decrease in IL-6 in sampling on subsequent days to below
baseline levels (Gill et al., 2017). Therefore, the present findings indicate that
concussions sustained during deployment, highly comorbid with blast, result in elevations
of IL-6, following by a decrease in concentrations within 24 hours. This finding suggests
that IL-6 is coordinating recovery from concussions, as well as blast exposures, and that
understanding these complex relationships may be important to improving care provided
to military personnel with complex, and often overlapping injuries sustained in combat
stations.
IL-6 is involved in the modulation of pro- and anti-inflammatory activity
following a TBI, with evidence pointing to the importance of the balance of IL-6 levels in
the promotion of recovery following TBIs and concussions (McKee & Lukens, 2016).
Cytokines, such as IL-6, orchestrate the acute inflammatory response to brain injury
(Helmy, Carpenter, Menon, Pickard, & Hutchinson, 2011; Hinson et al., 2015). In
support of this, preclinical models that knock out IL-6 activity result in poor behavioral
performance following a TBI (Ley, Clond, Singer, Shouhed, & Salim, 2011) as well as
increased apoptosis and delayed neuronal regeneration (Penkowa et al., 2000).
Detrimental outcomes also occur with elevated IL-6 activity following a TBI, including
delays in motor coordination and neuronal tissue repair in preclinical models (Penkowa et
al., 2003; Yang, Gangidine, Pritts, Goodman, & Lentsch, 2013). There is also evidence of
increased IL-6 concentration in human post-mortem brain tissue obtained following a
severe TBI that resulted in mortality, compared to patients who died from non-central

140

nervous system causes (Frugier, Morganti-Kossmann, O'Reilly, & McLean, 2010). There
may be long-term health consequences that result if IL-6 remains imbalanced, as findings
of elevated IL-6 may be indicative of chronic neurological symptoms or deficits (Devoto
et al., 2016).Therefore, findings from the current study showing that an IL-6 elevation
occurs within hours of a concussion, and are then similar to healthy controls at 24 hours
later, suggests that IL-6 is playing a role in recovery from these mild injuries.
Considering these early findings in concussion, additional studies with longer follow up
are warranted to understand the role of IL-6 in recovery and links to long-term
consequences.
Conversely, here is reported that IL-10 and TNF were not significantly different
between the concussed and healthy military cohorts. This differs from a previous report
of elevated levels of TNF in military personnel following blast exposure, along with
elevated IL-6 levels (Gill et al., 2017). One explanation may be differences between the
samples in the two studies. Gill et al. (2017) studied military personnel in a wellcontrolled training environment, with no reported incidences of blunt injuries and no
medical diagnosis, while the present cohort included military personnel diagnosed with a
concussion. These reported differences in injury event characteristics may account for a
lack of TNF differences between the concussed and healthy military personnel.
Likewise, IL-10 was not significantly different between the groups in the present study, a
finding that replicated Gill et al. (2017). As would be expected from non-significant
findings of IL-10 and TNF cohort differences at time point 1, mean change over time
was also not significant between the healthy and concussed cohorts. The absence of an
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upregulation of IL-10 concurrently with the IL-6 elevation is suggestive of possible
immune dysregulation. Both pro- and anti-inflammatory cytokines are produced by
microglia following insult to the brain, and the two types work in concert to determine
the fate of affected neurons, with anti-inflammatory cytokines shifting the balance toward
neuroregenerative and neuroprotective biological pathways, and pro-inflammatory
cytokines shifting the balance toward apoptosis and cell death (Hernandez-Ontiveros et
al., 2013). Specifically, elevations concurrently in IL-6 and IL-10 have been observed in
studies of severe TBI (Ferreira et al., 2014) and, increases in serum IL-10 seem positively
correlated with more severe TBI (Di Battista et al., 2016; Schneider Soares et al., 2012).
Thus, in the current study, the lack of an increase of IL-10 is not surprising based on the
previous literature, and the mild injury in these cases suggests a state of immune
dysregulation that may have consequences that require larger sampling and more in-depth
clinical measures. IL-10 is traditionally classified as exerting anti-inflammatory effects,
while IL-6 is traditionally defined as pro-inflammatory characteristics (Brandt &
Pedersen, 2010; Hernandez-Ontiveros et al., 2013; McKee & Lukens, 2016), with
increasing evidence for IL-6 anti-inflammatory characteristics (Brandt & Pedersen,
2010). IL-10 may confer neuroprotective effects in animal models (Barrett et al., 2017;
Chen et al., 2014; Zou et al., 2017). Thus a lack of increase in IL-10 suggests that there
may be immune dysregulation that may relate to clinically relevant implications that
should be determined in future studies.
There are a number of factors in the current study that limit interpretations of
these findings, including a relatively small sample size, yet this is the first study to report
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acute biomarkers obtained from active duty military personnel who sustained concussions
during a military deployment. Additional limitations in the scope of this study include a
lack of neuroimaging, such as computerized tomography (CT) scans, as well evaluation
of long-term outcomes. The nature of the combat environment may limit specificity in the
current study, as blast exposure and blunt injuries often occur concurrently in the same
injury event. Differences between injury types may account for discrepancies with the
literature, though it is outside the scope of this study to delineate effects of blast from
blunt force injury causes.
In conclusion, reported here is a significant elevation of IL-6 levels in concussed
military personnel less than 8 hours following injury. This is the first reported
observation of peripheral levels IL-6, -10, and TNF in a combat environment to
determine biomarkers of concussions sustained during combat station deployments, in a
cohort that had high rates of comorbid blast exposure. The present finding of IL-6
elevation warrants further exploration of inflammatory cytokines in combat injuries
involving concussion and blast, especially in future studies designed to account for the
aforementioned limitations. Future studies may examine acute and chronic neurological
symptomology associated with inflammatory cytokine levels, distinguish individuals at
high risk for developing neurological complications, and identify underlying biological
pathways to mitigate inflammation and improve outcomes. The present findings of
elevated IL-6 may be further explored in larger cohorts, as well as to determine
inflammatory pathways that may be targeted for therapies.
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CHAPTER FIVE
DISCUSSION
Concussions are a significant health concern worldwide, especially among
military personnel (Defense and Veterans Brain Injury Center, 2017; Taylor, 2017).
Given the limited FDA-approved interventions, substantial societal economic burden, and
risk of long-term neuronal health consequences, it is essential that new therapeutic
approaches are explored and developed (Carroll et al., 2004; Cassidy et al., 2014; Ma,
Chan, & Carruthers, 2014; Maas, Stocchetti, & Bullock, 2008). This research aimed to
build on the biological foundation necessary for future developments in treatment,
monitoring, and prognosis by investigating underlying inflammatory processes, through
gene expression and protein analysis, immediately following concussions with blast
exposures. As a result, this research has contributed to emerging knowledge of
inflammatory response in military personnel experiencing acute concussion.
Summary of Key Outcomes
The purpose of the dissertation research was to examine alterations in
inflammatory processes following traumatic brain injury. During the course of this
research, gaps were identified in current literature specific to gene expression and
inflammatory cytokines following concussion in military personnel. Additionally, we
were presented with the unique opportunity to analyze samples collected both in a
military training environment, as well as overseas during combat in Afghanistan. Each
factor is discussed below, as well as the response in the research program, and a brief
overview of key outcomes resulting from each study.
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1. Gap Identified: While a literature review of multiple clinical studies
examined the significance of the inflammatory response in persons with TBI,
there are few research publications which describe inflammatory-related gene
expression and proteins in clinical populations with mild TBI or concussion.
Response: The research results in Chapter 2 addressed Gap 1 by examining
the current state of the literature over the last 10 years in two ways: 1) gene
expression studies in mild TBI and, 2) inflammatory protein markers in mild
TBI.
Key Outcomes: In Chapter 2, a review of the current literature demonstrated
that inflammatory cytokines, including IL-6, IL-10, and TNF , may be
elevated in the acute time period following mild TBI or concussion and that
chronically elevated levels are associated with poor outcomes. In addition,
gene expression studies showed that alterations do occur following mild brain
injury, including inflammatory pathways. One of these inflammatory
pathways is NF- B, which is considered a master regulator of inflammatory
cytokines. However, studies in inflammatory cytokines, and especially gene
expression, are limited in number at this time, with findings requiring
validation in additional studies. Further, most studies are limited to the
civilian population, and they do not consistently delineate between different
subtypes of injury including blast exposure. Thus, examination of cytokines
and gene expression in military personnel with concussion from blast
exposure is needed to continue to build on this knowledge.
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2. Gap Identified: Although concussion is recognized as the signature injury in
military personnel serving in recent conflicts, gene expression data related to
recovery processes remain poorly studied, especially in the most common
cause of injury—blast exposure.
Response: Chapter 3 explored gene expression alterations following moderate
blast exposure in a military training population.
Key Outcomes: Chapter 3 describes the contribution to existing literature
which demonstrates that gene expression is altered following brain injury.
This dissertation study showed two differentially regulated gene networks
following moderate blast exposure: 1) cell death and survival, and 2) cellular
structure, function, and development. These gene networks included
alterations in key biological pathways related to ubiquitination, neuronal
recovery, and immune and inflammatory pathways. Specifically, gene
expression changes were observed that activate immune and inflammatory
pathways involving the NF- B pathway and the AKT1 gene. These findings
build on previous work in the same population of moderate blast exposure
showing increased concentrations of inflammatory cytokines IL-6 and TNF
(Gill et al., 2017).
3. Gap Identified: Inflammatory cytokines (IL-6, IL-10, and TNF ) in the acute
stage following concussion have not been examined in deployed military
personnel who experienced concussion and blast exposures.
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Response: In Chapter 4, measured IL-6, IL-10, and TNF concentrations
were described at two acute time points following provider-diagnosed
concussion in military combat personnel.
Key Outcomes: Results identified in Chapter 4 contributed to existing work
demonstrating acute elevations of IL-6 following concussion. Specifically, the
findings showed significantly increased concentrations in IL-6 less than 8
hours following concussion, which were highly comorbid with blast (>70% of
concussed individuals reporting blast). This increased IL-6 concentration was
followed by a decrease in IL-6 concentration within 24 hours. IL-6, in balance
with other cytokines, is known to modulate the inflammatory process
following brain injury; this is also supported in preclinical models (Ley,
Clond, Singer, Shouhed, & Salim, 2011; McKee & Lukens, 2016; Penkowa,
Giralt, Carrasco, Hadberg, & Hidalgo, 2000; Penkowa et al., 2003). Thus,
findings from this study suggest that IL-6 is coordinating recovery from
concussions, including those caused by blast exposures. Further research
could contribute to the understanding of the cytokine balance, important to
improving care of the complex, and often interrelating, concussion and blast
injuries sustained by military personnel in combat stations. Importantly, this
study is unique in that it is the only one at this time to measure cytokines in
deployed military personnel with concussion.
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Significance of Key Outcomes
The research outcomes within this dissertation provide several key contributions
to knowledge about inflammatory responses following concussion, including:
1. The first review of gene expression and inflammatory cytokines in mild traumatic
brain injury clinical populations;
2. Contribution to the growing body of research demonstrating altered gene
expression networks following blast exposure in human populations;
3. Evidence of altered inflammatory gene pathways, including the regulator of
cytokines NF- B, following blast exposure in a military training population;
4. The only study to date that measures inflammatory cytokines in military
personnel deployed to combat stations who experienced concussion highly
comorbid with blast; and,
5. Evidence of increased IL-6 concentrations in the acute period following
concussion comorbid with blast exposure.
Strengths and Limitations of the Research
The strengths and limitations of each chapter has been discussed previously but
the cumulated strengths and limitations of the overall research program are discussed
here.
The research program has multiple strengths. First, the research papers have
addressed complex questions using different study designs and research methodologies.
During the course of this study, this lab was presented with the unique opportunity to
analyze samples collected both from military training personnel as well as combat

152

personnel overseas in Afghanistan. Thus, questions regarding activation of the
inflammatory response following blast exposure and concussion were able to be
addressed in two cohorts of military personnel: 1) A well-controlled training environment
with only blast exposures; and, 2) A real-world combat setting with concussions and blast
exposures representing the experience of deployed military personnel. Second, the
controlled training environment represents a unique opportunity to explore the impact of
blast alone, as there were no other known blunt force injuries observed. In the training
environment, samples obtained in PAXgene DNA tubes were collected pre and post
moderate blast exposure, which allowed for the analysis of gene expression changes
before and after the moderate blast exposure. Previous reports in the same population that
indicate an increase in inflammatory cytokines (IL-6 and TNF ), together with the
present study findings of activation of inflammatory pathway genes, strengthened the
evidence for altered inflammatory systems following blast exposure in human
populations. Third, the combat setting, to date, is the only deployed military population in
which blood has been collected for the purpose of measuring biomarkers following
concussion. Importantly, inflammatory cytokines (IL-6, IL-10, and TNF ) were able to
be examined in a real-world combat environment, with concussions often occurring
simultaneously with other sources of injury and involving blast exposures. Data from this
dissertation study aligned with previous reports of acute increases in IL-6, suggesting that
further exploration of IL-6 is relevant to future research in concussions and blast
exposure.
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There are several limitations in this program of research. In addition to the
strengths described above, the use of two cohorts presented challenges. First, there are
differences in the descriptions of the injuries between the two cohorts. While the combat
population had provider-diagnosed concussions, largely comorbid with blast exposure,
there was a lack of concussion diagnosis in the military training population exposed to
moderate blast. Despite these differences, it is important to note that both cohorts
experienced blast exposures. Second, the nature of the combat environment creates
unavoidable differences from a controlled training environment. For example, the force
of the blast exposure was not able to be measured in the combat environment as it is in a
training setting. Additionally, blunt force injury is difficult to delineate from blast
exposures in a combat setting. Though the nature of this sample presented some
limitations, the majority of combat personnel experienced blast exposure as the cause of
concussion so met eligibility for inclusion in this research study. Rarely does the
opportunity arise to study the effects of blast in human populations. Thus, despite the
differences between the cohorts, these researchers believe that both the training and
combat populations have made significant contributions to understanding inflammatory
processes following blast, and that knowledge gained from each study will help guide
future studies moving forward.
Implications for Healthcare Genetics and Future Directions for Study
This research program has presented a number of novel findings in the context of
understanding activation of the inflammatory response following concussion and blast
exposure in the military. Namely, knowledge gained from these studies to be considered
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in moving the research forward include activation of inflammatory gene networks and
changes in IL-6 over time. However, there is a pressing need to investigate the
relationship between inflammatory processes to recovery from concussion and blast
exposures. Specifically, the research methodology of examining gene expression and
protein products has application to the field of Healthcare Genetics in its potential for
translation from bench to bedside care.
Research agenda.
The literature review in Chapter 2 looked at clinical traumatic brain injury studies
of gene expression and related proteomic pathways. Those results identified a continued
need to conduct additional research studies in both gene expression and cytokine activity
following concussions in human populations. This dissertation research contributed to
that need through two studies in the military population described in Chapter 3 and 4.
However, as identified in Chapter 2, additional studies, both in civilian and military
populations, with standardized identification of various brain injury subtypes and
severities, are recommended. Additionally, there is a need to map outcomes with gene
expression and cytokines over time, a need which is reflected in Chapters 3 and 4 of this
research program.
Results in Chapter 3, which identified differentially regulated gene networks
following blast exposure in a military training environment, suggested a need for further
evaluation of gene expression in larger cohorts, with additional acute days of blood
sample collection. Collection of data over time would allow for a more in-depth analysis
of gene expression changes over time. With collection of the participants’ symptoms
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using objective and measureable tools, the gene changes could be mapped to poor
outcomes. Finally, exploration in gene network changes would give indications of the
underlying biological processes. Similar to cytokines and the changes related to the NFB network in the Chapter 3, protein products of those gene changes could be
measured—a technique which would have clinical utility for healthcare personnel caring
for patients at the bedside. Specifically, in application to the field of Healthcare Genetics,
a future study could be designed to capture gene expression data and cytokines at the
same time points within the same cohort.
Per results in Chapter 4, it is recommended that inflammatory cytokines in
military personnel with concussion and blast exposures be further explored in larger
cohorts. Future studies should be designed to account for the limitations mentioned
above, including delineating blast from other subtypes of concussion. Acute and chronic
neurological symptoms may be collected and associated with inflammatory cytokine
levels over time. This information may help to characterize individuals at risk for
developing neurological complications, as well as further elucidate the underlying
inflammatory pathways that may be targeted for therapies in order to improve outcomes.
Finally, as referred to in Chapter 3 above, the measure of protein biomarkers may have
potential clinical utility for identification and/or monitoring of inflammatory processes
over time. The elevated IL-6 concentration in this study is interesting given the similar
increase in IL-6 seen in a previous report by Gill et al. (2017), as well as the increased
expression of inflammatory-related genes in Chapter 3 of this work. Thus, there may be
reason to further explore the question of cytokines informing concussions.
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Conclusion
Concussion and blast exposure in the military remains an important concern for
military personnel, as well as civilians, around the world. The acute period following
injury is crucial for appropriate activation of the inflammatory response, with prolonged
imbalances in the inflammatory response likely leading to poor outcomes. This research
program resulted in 3 papers, each of which focused on the essential need to further
elucidate inflammatory gene expression and cytokine responses to acute concussion.
With research from Chapters 2 and 3, Chapters 3 and 4 respectively, indicating
significantly altered gene expression networks and increased IL-6 during the acute time
period, this research contributes to the existing literature and provides direction for
continued exploration. The research findings and potential future directions will have
application to the field of Healthcare Genetics for researchers and health care
professionals seeking to develop, and eventually implement, therapeutics to improve
patient outcomes following concussion.
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Appendix A
Abbreviations
BBB: blood brain barrier
CNS: central nervous system
GCS: Glasgow Coma Scale
GOS: Glasgow Outcome Scale
ICP: intracranial pressure
IL-6: interleukin 6
IL-10: interleukin 10
IPA: ingenuity pathway analysis
ISF: interstitial fluid
TBI: traumatic brain injury
mRNA: messenger ribonucleic acid
mTBI: mild traumatic brain injury
NF- B: nuclear factor kappa light-chain enhancer of activated B cells
OEF: Operation Enduring Freedom
OIF: Operation Iraqi Freedom
ROS: reactive oxygen species
TNF : tumor necrosis factor
Tregs: Regulatory T cells
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DEPARTMENT OF THE ARMY
WALTER REED ARMY INSTITUTE OF RESEARCH
503 ROBERT GRANT AVENUE
SILVER SPRING, MD 20910-7500
REPLY TO
ATTENTION OF

MCMR-UWZ-C

13 February 2018

MEMORANDUM FOR Walter Carr, MAJ, MS, Chief, Military Psychiatry, Center for Military
Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), 503 Robert
Grant Ave., Silver Spring, MD 20910-7500
SUBJECT: Project Qualifies as Research Not Involving Human Subjects, WRAIR #2529.
1. A determination was made that the project WRAIR #2529 entitled, “Analysis for a
Comparative Evaluation of Blood Biomarkers and Automated QEEC from Concussed and NonConcussed Cohorts in a Combat Zone (version 1.2, dated 09 February 2018), does not require
review by the WRAIR Institutional Review Board (IRB) in accordance with WRAIR Policy
Letter #12-09, as the project involves analysis of pre-existing de-identified data and specimens
where the investigator and study team do not have access to any identifiable information;
therefore, this research activity does not meet the definition of research involving human
subjects and 32 CFR 219 does not apply.
2. The primary objectives of this project are to complete final analysis and documentation of
assay results for specimens collected under U.S. Army Medical Research and Materiel
Command (USAMRMC) protocol M-10216 (WRAIR #2028), entitled “A Comparative Evaluation
of Blood Biomarkers and Automated QEEC from Concussed and Non-Concussed Cohorts in a
Combat Zone ”. Per the existing Department of Defense Institutional Agreement for IRB Review
(IAIR) between WRAIR and USAMRMC, WRAIR relied on the Headquarters USAMRMC
Institutional Review Board (IRB) for the ethical review of that protocol. The Headquarters,
USAMRMC IRB closed protocol M-10216 (WRAIR #2028) on 18 September 2017. The study
data and specimens collected under protocol M-10216 (WRAIR #2028) have been de-identified
by removing and destroying the link between subject identity and subject data and serum
samples. De-identified specimens collected under protocol M-10216 (WRAIR #2028) were
provided for biomarker analyses to the National Institute of Health/National Institute of Nursing
Research (NIH/NINR) Laboratory for Tissue Injury, as described in the protocol. The NIH Office
of Human Subjects Research (OHSR) determined the work conducted at the NINH NINR to be
not human subjects research in a memorandum dated 17 February 2015. The work to be
completed in this project will consist of quantitative comparison of NINR assay results and
complementary de-identified data previously collected.
3. This project is funded through institutional resources at NINR and WRAIR; there is no transfer
of funds between institutions and no costs to itemize.
4. This project was found to be scientifically feasible and valid, militarily relevant, and
appropriately resourced by Jeffrey L. Thomas, COL, MS, Director, Center for Military Psychiatry
and Neuroscience, on 31 January 2018.
5. No additional information is needed at this time. However, should the study team gain access
to any personal identifiers or codes linking the participants with their specimens, the submitted
project would need an independent determination by either the WRAIR Institutional Review

MCMR-UWZ-C
SUBJECT: Project Qualifies as Research Not Involving Human Subjects, WRAIR #2529
Board Chair or the Director, Human Subjects Protection Branch (HSPB), as to whether or not
the investigator is engaged in human subjects research, and whether or not the WRAIR IRB
review and approval are required. The HSPB reserves the right to review the project records to
re-assess the determination of research not involving human subjects. The WRAIR HSPB also
reserves the right to review the project records and re-assess the NHSR determination as part
of post approval compliance monitoring. The PI is responsible for maintaining records that
confirm that the executed activities match the project that was evaluated and found to be
research not involving human subjects.
6. The point of contact for this action is Anna Sanner, M.D., M.P.H, at 301-319-9866 and
Anna.V.Sanner.ctr@mail.mil.

TIBOR TUZSON, MD
Exemption Determination Official
Human Subjects Protection Branch
Walter Reed Army Institute of Research
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Eiserman, Julie (NIH/OD) [C]
From:
Sent:
To:
Subject:

Gill, Jessica (NIH/NINR) [E]
Wednesday, February 18, 2015 7:41 AM
Eiserman, Julie (NIH/OD) [C]
RE: Follow Up re: Request for Determination for OHSRP #12767

Julie‐ No, he has de‐identified the samples so that there are not longer any identifiers for the subjects.
Thanks
‐Jessica
From: Eiserman, Julie (NIH/OD) [C]
Sent: Wednesday, February 18, 2015 7:40 AM
To: Gill, Jessica (NIH/NINR) [E]
Subject: RE: Follow Up re: Request for Determination for OHSRP #12767

Your collaborator won't have access to the code key as the PI of the other study?

Sent with Good (www.good.com)
From: Gill, Jessica (NIH/NINR) [E]
Sent: Wednesday, February 18, 2015 7:20:05 AM
To: Eiserman, Julie (NIH/OD) [C]
Subject: RE: Follow Up re: Request for Determination for OHSRP #12767

Julie‐ Yes, they will be coded, so the correct answer is b. I apologize for this error, please let me know how I may be of
help in correcting it.
Thank you
‐Jessica
From: Eiserman, Julie (NIH/OD) [C]
Sent: Tuesday, February 17, 2015 10:05 PM
To: Gill, Jessica (NIH/NINR) [E]; Olivera, Anlys (NIH/NINR) [F]; Livingston, Whitney (NIH/NINR) [F]; Martin, Christiana
(NIH/NINR) [F]
Subject: Follow Up re: Request for Determination for OHSRP #12767

Hello,
I am reviewing your request for determination and I just want to confirm something about this request related to your
answer (below).
9. Select the best description that applies to the specimens or data:
(a) X_ Specimens, data or information will not contain any identifiable information,
and cannot be linked to individual subjects by you or your collaborators.
(b) ___ Specimens, data or information will be coded, however that code cannot be
used by either the provider or the receiver to identify specific individuals.
(c) ___ Specimens, data or information will be coded so that the provider of the
samples/data can link them to specific individuals but the receiver will not be able
1

to do so.
I just want to confirm that the specimens and data will be coming to you completely anonymous rather than coded since
your collaborator is the PI of the project and would likely have access to identifiers. In addition, because you will be
receiving data and specimen, you would likely need to receive everything coded rather than anonymous so you can link
the specimens and data to each other. If I am misunderstanding something, please let me know.
Julie M. Eiserman, MA, CCRP [C]
Health Science Policy Analyst
Office of Human Subjects Research Protections
10 Center Drive, Bldg. 10, Suite 2C146
Bethesda, MD 20892‐1154
Office Phone: 301‐402‐3444
Fax: 301‐402‐3443
OHSRP website: https://federation.nih.gov/ohsr/nih/index.php (NIH login required)
Public site: http://ohsr.od.nih.gov/
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OHSRP #12767
REQUEST FORM: OHSRP DETERMINATION FOR
RESEARCH USE OF DE IDENTIFIED SPECIMENS OR DATA
Date of Request: 1‐26‐2015
Requestor’s name: Jessica Gill

e‐mail: gillj@mail.nih.gov

Role: X Investigator __Administrative support __Other, explain: ________
Name of NIH Senior Investigator: Jessica Gill
(The investigator must be an NIH employee)
IC: NINR

Laboratory/Branch: Tissue Injury Branch

Building & Room No.: 60, 254

Tel. No.: 451‐8452 FAX No.: 301‐451‐1678

Is the NIH Senior Investigator an NIH employee (FTE)?

X Yes _______No

Senior Investigator Signature:
(Signature of Investigator who will conduct research, Dr.
Jessica Gill)
Supervisor Signature:
____

______________________________________________
(Signature of official for IC, e.g., Lab/Branch Chief, Dr. Ann

Cashion)
Name of NIH investigator conducting research if not the NIH Senior Investigator: (i.e,
junior investigator, contractor investigator, fellow, student)
Anlys Olivera, Ph.D, IRTA Postdoctoral Fellow, Whitney Livingston, post‐bac IRTA, and
Christiana Martin, post‐bac IRTA
Please provide the name and e mail of any others who should receive a copy of the
OHSR determination: Hyung‐Suk Kim, kimy@mail.nih.gov
1. What role will the NIH investigator(s) have in this research project? (check all that
apply)
__x_ Analyze samples/data
___ Consultant/advisor to collaborator(s)
__x_ Author on publication(s)/manuscript(s) pertaining to this research
___ Investigator or the NIH holds an IND/IDE for this research
___ Other, please describe: ______________________________________________
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REQUEST FORM: OHSRP DETERMINATION FOR
RESEARCH-USE OF DE-IDENTIFIED SPECIMENS OR DATA
2. Title: An Examination of Neurological Proteins Related to Traumatic Brain
Injuries in Military Personnel Deployed in Afghanistan
3. Describe in lay terms the research activity that will be performed:
The overall objective of this project is to examine concentrations of proteins including
tau and GFAP following acute traumatic brain injuries (TBls) in military personnel who
were deployed to Afghanistan. Subjects had 2 blood samples, with the first occurring
within 12 hours of the TBI, and the second 24 hours following the TBI. These samples
were collected during deployment to Afghanistan under a protocol with the primary
investigator of Dr. Walter Carr “A Comparative Evaluation of Blood Biomarkers and
Automated QEEG from Concussed and Non‐Concussed Cohorts in a Combat Zone,
Walter Reed Army Institute of Research Protocol #2028.”
4. Proposed start date: 2/20/15

Proposed completion date: 2/09/16

5. Specify the nature of the specimens or data: (select all that apply)
___ iPSC lines
___ hESC
___ Fetal Tissue
___ WES/WGS
___ GWAS
X Other human specimens (e.g. tissue, blood, derivatives), describe: Blood
X Data (e.g. clinical or research information or laboratory results) describe:
De-identified data, including demographics (age, sex, race), and traumatic brain
injury-related information

Other, describe:
6. Will specimens or data be? (select all that apply)
Collected Yes__ No
Received
Yes X No__
Sent
Yes No__
7. If receiving or sending, list the collaborating investigator(s):
Name
Institution/IC
Address/e‐mail
FWA number*
Walter Carr Walter Reed Army Institute of Research walter.s.carr.mil@mail.mil,
FWA= 00000152
8. Do the specimens, data or information:
Already exist?
Yes X
No__
If “no”, explain:_________________________________________________
9. Select the best description that applies to the specimens or data:
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REQUEST FORM: OHSRP DETERMINATION FOR
RESEARCH-USE OF DE-IDENTIFIED SPECIMENS OR DATA
(a) 
X Specimens, data or information will not contain any identifiable information,
and cannot be linked to individual subjects by you or your collaborators.
9 Specimens, data or information will be coded, however that code cannot be
(b) ___
used by either the provider or the receiver to identify specific individuals.
(c) ___ Specimens, data or information will be coded so that the provider of the
samples/data can link them to specific individuals but the receiver will not be able
to do so.
10. If c is selected above, please follow the instructions below:
Projects involving coded research specimens obtained from a non‐NIH collaborator
will require a de‐identification agreement. Please e‐mail your collaborator(s) the
following agreement language modified to reflect the nature of your collaboration.
Attach the completed agreement to this submission.
De identification Agreement:
Provider of coded specimens or data:
I, [Name] of [Institution], holder of the code‐key or cipher for the coded
[specimens, data (specify)], promise not to release the identity of the subjects
from whom the coded [specimens, data (specify)] originated, until the subjects
decease to [Recipient Name] at [Recipient Institution].
Recipient of coded specimens or data:
I, [Name] of [Institution], recipient of the coded [specimens, data (specify)],
promise not to request the identity of the subjects from whom the coded
[specimens, data (specify)] originated, until the subjects decease from [Sender
Name] at [Sending Institution].
11. If data are being extracted from existing records, who will extract the data? (if
applicable)
(a) ___ NIH Investigator
(b) _x__ non‐NIH Collaborator
(c) ___ NIH Contractor
(d) Other, specify:
If a or c, will an Honest Broker or data use agreement be used? Yes__ No__
If yes, complete and attach the Honest Broker Assurance or Data Use Agreement to
this submission; e‐mail ohsr_nih_ddir@od.nih.gov to request the form.
12. Where are the subjects of this research activity located? Subjects were recruited
Page 3 of 5

REQUEST FORM: OHSRP DETERMINATION FOR
RESEARCH-USE OF DE-IDENTIFIED SPECIMENS OR DATA
while deployed as active duty military personnel deployed in Afghanistan.
13. If human subjects are located elsewhere (not at NIH), will you have direct contact
or intervention with them? (For example, as subject's physician, obtaining specimens
directly from the subject?) Yes__ No X
14. Do the specimens, data or information come from:
___ NIH BTRIS
___ NIH Medical Records
X Repository
If an NIH Repository, specify: ________________________________________
___ Pathological waste
___ Autopsy material
___ Publicly available source
___ Originate from an IRB‐approved protocol?
___ Other_____________________________________________________________
15. Will the results of the research be returned to the provider(s) of the specimens or
data?
(a) ___ No, results will not be returned to the provider(s)
(b) X Yes, aggregated results will be returned to the provider(s)
(c) ___ Yes, results that are linked to identifiable individuals, will be returned to
provider(s)
(d) ___Yes, the results of this project will be returned to an active NIH IRB‐approved
protocol? If yes, protocol ID: ____________
If b or c, is the NIH project consistent with the IRB/EC‐approved protocol at the
collaborating institution? Yes_x_ No__
16. Per NIH guidance, are all conflicts of interest by NIH employees, if any, resolved?
X Yes _____No**
*A Federalwide Assurance (FWA) is issued by the U.S. Department of Health and Human
Services (DHHS)/ Office of Human Research Protections (OHRP) to institutions which
receive Federal funds/support to conduct human subjects research. To search for the
FWA# for domestic or international institutions go to
http://ohrp.cit.nih.gov/search/fwasearch.aspx?styp=bsc
**If the answer is “No”, note that OHSRP will be unable to make a determination and
research may not proceed until all conflicts are resolved. For more information, see the
October 2011, A Guide to Preventing Financial and Non‐Financial Conflict of Interest in
Human Subjects Research at NIH. For assistance review the list of Ethics Coordinators
and find the contact for your IC: http://ethics.od.nih.gov/coord.pdf

Page 4 of 5

OHSR (NIH/DDIR)
From:
Sent:
To:
Subject:
Attachments:

Gill, Jessica (NIH/NINR) [E]
Monday, January 26, 2015 4:47 PM
OHSR (NIH/DDIR)
review of possible exempt protocol
gill_CARR_OHSRP.doc

Hello‐ I am attaching an application for the review of a possibly exempt protocol . Please let me know if any questions
arise or if other information would be of help. Thank you.
‐Jessica
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OHSR (NIH/DDIR)
From:
Sent:
To:
Subject:

OHSR (NIH/DDIR)
Friday, January 30, 2015 12:34 PM
Gill, Jessica (NIH/NINR) [E]
Req for Determination Rec'd_OHSRP 12767

Good afternoon Dr. Gill,
This email is to verify that OHSR has received your Request for Determination and it is currently being processed as
OHSRP #12767. Please use this number in any future correspondence regarding this study.
Protocol Title: An Examination of Neurological Proteins Related to Traumatic Brain Injuries in Military Personnel
Deployed in Afghanistan
Thank you.
Sincerely,
Chris Brentin
OHSRP ‐ National Institutes of Health
Bldg 10, Suite 2C146
Bethesda, MD 20892
Office Telephone: 301‐402‐3444
Office Fax: 301‐402‐3443
The NIH is committed to maintaining the highest standards for the protection of human
subjects.
Please consider the environment before printing this e-mail
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Original Submission Date: 11/10/2010
Version # 14.0 & Date: 01/23/2017
MEMORANDUM FOR OFFICE OF RESEARCH ADMINISTRATION, NAVAL MEDICAL
RESEARCH CENTER
SUBJECT: Application and Request for Approval of Human Subjects Research
STUDY SITE(s): X NMRC, X WRAIR, X NIH/NINDS
Protocol Number: NMRC.2011.0002 (WRAIR #1796; NINDS #12-N-0065)
Protocol Title: Experienced Breacher Injury Study: Evaluation of the Bio-Effects from Chronic
Exposure to Low-Level Blast
Principal Investigators
LCDR Peter B Walker PhD MSC USN
Naval Medical Research Center (NMRC)
503 Robert Grant Ave. 1E06
Silver Spring, MD 20910-7500
301-319-9995
peter.b.walker@navy.mil
CITI: 29 April 2015
MAJ Angela M. Yarnell, MSC, USA
Research Psychologist
Department of Behavioral Biology
Walter Reed Army Institute of Research
503 Robert Grant Ave.
Silver Spring, MD 20910
(301) 319-9679
angela.m.yarnell.mil@mail.mil
CITI: 08 October 2013
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2. ABSTRACT
2.1 Purpose
The purpose of this study is to evaluate the cognitive and neurophysiological effects of chronic exposure
to repeated low-level blast overpressure. The results of previous studies (NMRC.2007.0006;
NMRC.2009.0011; NMRC Project #60) show converging evidence for a neurophysiological effect from
cumulative exposure to blast that is consistent with anecdotal reports of cognitive impairments by
members of the professional community known as “Breachers”. These studies were undertaken as a
result of a request by the Breacher instructors who had subjective complaints of memory impairment and
on occasion, balance and sleep difficulties. However, the number of instructors was small and a larger
group evaluation is needed at this time to verify whether breaching activities may result in increased risk
for cognitive impairment. The proposed study will expand on these findings by examining a larger cohort
of experienced Breachers who may be incurring a cumulative effect of low-level blast exposure over the
course of several years in the profession. Analysis of this unique population will yield a greater effect
size than previous studies of Breacher instructors with the goal of identifying the mechanisms underlying
cognitive deficits specifically related to repeated low-level blast exposure and identify the most
efficacious means of detecting mild traumatic brain injury (mTBI) in soldiers.
2.2 Research Design
Volunteers will be recruited from the military and civilian law enforcement Breacher communities for a
multi-phase, cross-sectional study of chronic exposure to low-level blast overpressure (“breaching blast”).
Experienced Breachers are those with at least 4 years of experience with exposure to low-level blast from
breaching either in the field or as instructors for explosive entry training courses. Phase A of the study
will include field assessments of Breachers during explosive entry training to measure breaching
environments and blast exposure and evaluate the acute effects of low-level blast exposure. Phase B will
involve subjects travelling to the National Institute of Neurological Disorders and Stroke (NINDS) of the
National Institutes of Health (NIH) in Bethesda, MD for neuropsychological testing, neuroimaging, blood
components analysis, vestibular and auditory testing, and a sleep assessment. Subjects will also be
invited back to NINDS for a 1-year follow-up assessment to look at the progression of the effects.
2.3 Methodology / Technical Approach
We will evaluate individuals from the military and civilian law enforcement Breaching communities with
extensive breaching experience and compare their cognitive performance with that of age, gender, and
service length matched individuals with exposure to non-blast related overpressure (e.g. artillery units)
and those with no prior exposure to overpressure. For Phase A, we will evaluate between 100 to 150
breachers and between 25 and 50 artillery personnel during breacher and artillery training. In addition,
we will evaluate between 25 and 50 unexposed individuals for a total of up to 250 subjects. For Phase B,
we will evaluate a minimum of 15 subjects from each of the three groups (breachers, artillery personnel,
and unexposed individuals) for a total of at least 45 subjects, with an upper limit of 60 subjects (20 per
group). Subjects for Phase B may come from the subject pool for Phase A, however, subjects are not
required to participate in Phase A in order to be eligible for Phase B. In addition, subjects from all 3
groups will be asked to bring a companion to NIH for an interview to capture changes in daily functioning
that subjects may not be able to self-assess, which could yield an additional 60 subjects. However,
subjects are not required to bring a companion to participate in the Phase B; therefore, the actual number
of companions that will be evaluated is unknown. Companions can also participate in the study remotely.
The sum of the maximum number of possible subjects over all groups in both phases is 370.
During Phase A of the study, staff from the Naval Medical Research Center (NMRC) and the Walter
Reed Army Institute of Research (WRAIR) will conduct daily field assessments during explosive entry
training to evaluate the acute effects of breaching in an experienced population. These assessments will
include neuropsychological tests of cognitive and emotional functioning, symptomology, vestibular
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system assessments, eye-tracking, analysis of sleep patterns, and blood components sample analysis for
biomarkers of brain injury. In addition, blast measurement experts from Applied Research Associates,
Inc. (ARA) will accompany the research team to gather data on blast pressure using pressure sensors on
the subject and in the environment to estimate the magnitude and frequency of the overpressure energy
transmitted to the head.
In Phase B, subjects will travel to NINDS in Bethesda, MD for a multi-day visit for a series of evaluations
to measure cognitive and neurophysiological changes related to exposure. These procedures are
described in detail in Appendix A and will include neuropsychological testing, blood components
analysis for biomarkers, vestibular and auditory testing, a sleep assessment (polysomnography), and
neuroimaging studies using diffusion tensor imaging (DTI), susceptibility weighted imaging (SWI),
perfusion imaging, imaging with Gadolinium contrast, and functional magnetic resonance imaging
(fMRI). To participate in this study, volunteers will be required to consent to both DOD and NINDS
protocols; however, they can opt out of individual procedures for any reason.
All procedures outlined in this protocol are subject to modification or replacement with methods that are
similar in time commitment and method of administration to tasks contained in the current version of the
protocol. We will not substitute tasks that introduce additional risks beyond that of the approved tasks
without explicitly requesting their use via an amendment to this protocol.
3. OBJECTIVES AND SPECIFIC AIMS
The objective of this study is to determine the cognitive and neurophysiological effects of chronic
exposure to low-level blast overpressure in the professional community of “Breachers” (explosive entry
personnel). The primary goal is to detect differences in cognitive performance and neurological
functioning between experienced Breachers and well-matched control groups to substantiate and guide
surveillance.
The specific aims of the study are as follows:
Phase A
Specific Aim #1: Replicate and augment NMRC.2007.0006, by examining the acute effects of breaching
on cognitive and emotional functioning in individuals with chronic exposure to low-level blast
overpressure using blast exposure characterization in conjunction with neuropsychological testing,
vestibular system assessments, eye-tracking, and sleep pattern analysis.
Specific Aim #2: Characterize multiple breaching blast environments, as well as a non-blast generated
overpressure environment, and measure variations in individual exposure levels due to tactical and
environmental factors.
Specific Aim #3: Develop acute time-courses of blood biomarker levels that are associated with brain
injury by collecting blood samples from subjects before, during, and after breaching blast exposure.
Phase B
Specific Aim #4: Examine long-term effects of chronic exposure to breaching blast on neurophysiological
and cognitive functioning using neuropsychological testing, structural and functional neuroimaging,
blood components sample analysis, vestibular and auditory testing, and a sleep assessment.
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Specific Aim #5: Determine the most effective techniques for detecting neurophysiological and cognitive
changes specific to breaching blast exposure by contrasting the experimental population with a wellmatched control group consisting of individuals with extensive exposure to overpressure not related to
blast (e.g. artillery units), as well as a control group with no history of overpressure exposure.
Specific Aim #6: Capture changes in daily functioning that the subjects may not be able to self-assess by
conducting interviews with a close companion using questionnaires that target the companion’s
perception of the primary subject’s daily function and by comparing responses to questionnaires that both
the companion and subject answer.
Specific Aim #7: Examine the progression of long-term neurophysiological and cognitive changes in
experienced Breachers by conducting a 1-year follow-up assessment.
4. MEDICAL APPLICATION / MILITARY RELEVANCE
In both training and operations, Warfighters are repeatedly exposed to blast events in the course of
carrying out their duties. Very little data exists on the effect of this exposure on the physiological
function of the human body, and none of the available data addresses the risk of cognitive impairment as
a result of chronic repeated blast exposures. In 2005 and 2006, Breachers from both military and civilian
law enforcement units began expressing some sensitivity to the risk of injury as a result of multiple blast
exposures. Because Breachers apply explosives as a means of gaining access to barricaded or hardened
structures, these specialists can be exposed to as many as a dozen 0.3 to 10 pound charges per day during
training exercises and even larger numbers during night time operations. Although the Breachers’
concerns are based upon anecdotal data and self-diagnosis, the symptoms they report, including sleep
pattern disruption and short term memory loss, are similar to those reported by the Defense and Veterans
Brain Injury Center (DVBIC) and others in the military community in regard to veterans returning from
the recent and ongoing conflicts in Afghanistan and Iraq.
To address the profound issues related to the diagnosis and treatment of TBI, the United States Congress,
through Public Law 110-252, established the Center for Neuroscience and Regenerative Medicine
(CNRM) as a collaborative intramural program in May 2008. The CNRM is a contributing program
resources for the execution of this study to include use of the CNRM funded MRI scanner, personnel and
data sharing; however, no CNRM funds are being utilized in the performance of this study. Imaging data
will be processed and stored by the CNRM at the NIH Clinical Center.
The concerns raised by Breachers present a unique opportunity for the blast injury research and medical
communities to gather blast injury data on human subjects in a fully characterized blast environment.
Analysis of this blast injury data will serve to answer the Breachers’ question, “Are we being injured in
our breaching maneuvers?” and will provide some characterization of the blast effects. This information
can then be applied to improve our understanding of non-penetrating, non-impact neurological injuries
occurring in the combat environment and develop appropriate mitigation strategies.
5. BACKGROUND AND SIGNIFICANCE
Significance of breacher research
There is limited published literature on the neurophysiological effects of blast exposure in humans and
none of that literature represents repeated exposure to low-level blast. Breachers, more formally known
as explosive entry personnel, are a unique population who are by occupational definition exposed to
controlled blast. Instructors who train new breachers, by virtue of their job description, are routinely
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exposed to low-level blast. Although this blast exposure does not result in clinical injury, the cadre of
breacher instructors at USMC Weapons Training Battalion reported concerns with potential for injury
from this repeated blast exposure. It is on the basis of these anecdotal reports that the original study of
bio-effects from repeated exposure to blast was conducted. Those anecdotal reports included memory
difficulty, sleep disturbance, and characteristics similar to those reported by the Defense and Veterans
Brain Injury Center (DVBIC) for patients with traumatic brain injury returning from OEF/OIF. The
primary objective of that study was to collect data during USMC breacher training to support the
evaluation of potential for injury, with particular attention to breacher instructors. A multi-disciplinary
collaboration was employed to meet this objective, including investigative teams for blast environment
characterization, neurocognitive assessment, auditory/vestibular assessment, toxicological evaluation, and
neuroimaging evaluation.
Reports from this ongoing study and others conducted by NMRC and WRAIR are currently in
preparation for submission as publications. The results of these studies are largely a function of
converging evidence, that is, complimentary observations across measures and across modalities. This
converging evidence points to a previously undocumented phenomenon in this professional community.
It also illustrates that further exploration of this issue is warranted. There are many benefits to studying
this further including: risk management, the preservation of health and safety for members of this
professional community, and the potential to generalize findings to blast-related post-concussion disorder
and mild traumatic brain injury. Obtaining a larger sample of control subjects, which is also a part of this
proposed protocol, is necessary to improve the quality of analyses of these data sets and assist in
identifying subtle changes in central nervous system function.
Primary injury from blast
Primary injury from exposure to blast is not well understood and remains controversial, especially in
respect to injury to the brain (Warden, 2006). Primary injury from blast is only beginning to be
documented with neuroimaging techniques (Warden et al., 2009) and animal models are in development
(Ahlers et al., 2008). The principal means to characterize this injury for clinical and research purposes is
through behavioral evidence. The study proposed here will address primary blast injury as specific to the
breacher training environment. Results of this study may be generalizeable to primary blast injury from
other settings, an ancillary objective of this research. The importance of this ancillary objective is
underlined in the documented blast exposures among U.S. service personnel deployed to operations in
Afghanistan and Iraq (OEF/OIF).
A potential injury resulting from repeated exposure to low-level blast in the breacher training
environment should be expected to be a relatively small effect. A large effect, a noticeable injury or
impact on behavior, that occurred in any repeated fashion would be expected to have been recorded by
training command personnel and appropriately prevented through revision in procedures. Regular
operations yielding noticeable injuries would not be sustainable and, through logical consideration alone,
should not be expected. A small injury or effect, developing slowly over time and exposure and to
differing degrees across individuals, might be expected to escape notice. A slow to develop small effect to
which some individuals are resilient might be detectable only with targeted objective measurement.
The type of insidious injury potentially at issue here may be present in breacher instructors, as a function
of their routine exposure to low-level blast. Instructors for breacher training activities are exposed to
repeated controlled low-level blast with each training session, for each group of new breacher trainees.
Also, for breacher instructors, such repeated exposure to blast in a training setting can be expected to
occur following a successful career of blast exposure as a breacher in operational settings. Those
operational exposures would be less controlled than in the training environment. The breacher trainees
cycling through this training environment would not have the same history of blast exposure or frequency
of exposure. The trainees are much greater in number than the instructors and their absence of any small
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injury might further mask the detection of an effect among the instructors from an occupational exposure
to blast.
Relevance of sports concussion studies
The sports concussion literature can guide our understanding of blast injury hypothesized in the original
study of breacher bio-effects. The research literature on closed head injury includes multiple terms of
concussion, post-concussion syndrome, and mild traumatic brain injury (mTBI). These diagnostic labels
have significant overlap in meaning, associated symptoms, and assessment methods, so such research is
relevant to the present study, even though the injury mechanisms differ. (The breacher training
environment presents potential for primary blast injury but not secondary, tertiary, or quaternary injury.)
It is useful to point out now that there is also overlap in symptomology between post-concussion
syndrome and post traumatic stress disorder (PTSD) but that the subject population of primary focus in
this research, breacher instructors, is exposed to blast in the controlled settings of a training environment
so the contributions of PTSD to the present study will be minimized.
In a specific study from the sports concussion literature McCrea’s (McCrea et al., 2003) NCAA
concussion study tracked 1631 collegiate football players from baseline on assessments of memory,
cognitive processing, mental flexibility, verbal fluency as well as balance and other symptoms. These data
showed not only changes in these assessments as a function of concussion but also showed a time course
of recovery, using a daily testing schedule not dissimilar to that proposed in the present study. Also
relevant to the proposed effort, two studies of military populations susceptible to sports concussion
(Bleiberg et al., 2004; Warden et al., 2001) showed decrement in cognitive function association with
concussion. Bleiberg (Bleiberg et al., 2004) administered preseason baseline testing with the Automated
Neuropsychological Assessment Metrics (ANAM) to 729 athletes who were members of the United
States Military Academy (USMA). ANAM is a computer-based behavioral assessment of neurocognitive
performance, reflecting brain function. Following baseline, those who sustained head injury and those
who were not injured (control group) were subsequently administered ANAM at regular intervals. In this
repeated testing, cognitive impairment was present in the injured group on the day of injury and 1-2 days
post-injury (Bleiberg et al., 2004). The injured subjects recovered from their cognitive impairment 3-7
days post-injury. In this study of USMA head injury using ANAM, concussion was demonstrated not
only by a decrease in performance on the ANAM, but also by a lack of practice effects.
A meta-analysis of sports concussion literature Broglio (Broglio & Puetz, 2008) showed that the
demonstration of effects of concussion on neurocognitive status were moderated by several factors: the
inclusion of control groups, time from baseline testing to date of injury, and method of neurocognitive
testing administration. A separate meta-analysis of the neuropsychological effects of sports concussion
Belanger (Belanger & Vanderploeg, 2005) showed that there are impairments across several different
neuropsychological domains, with the largest deficits in the following areas: global functioning, memory
acquisition, and delayed memory. Also, concussed athletes were found to fully recover
neuropsychologically within 7-10 days following injury. The effect sizes of concussion on
neuropsychological performance for single assessments were double that of serial assessments; this
finding is likely due to the practice effects from repeated administration of the neuropsychological tests.
The studies that included subjects with previous head injuries had larger effect sizes than those that did
not include such subjects; it was concluded by the authors that this finding indicates that prior head injury
is associated with poorer cognitive performance (Belanger & Vanderploeg, 2005). These meta-analysis
findings – ability-specific impairment, recovery from injury, practice effects in serial assessments, testing
modality and individual differences in impairment as a function of previous injury – all have direct
bearing on the present study.
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Justification for proposed experimental procedures
Blast characterization (Phase A)
The purpose of the environment instrumentation is to characterize the blast environment to which the
breachers are exposed, thus supporting the first aim of the study: examining the acute effects of
breaching. The addition of the environmental characterization data addresses the primary shortfall
associated with pure clinical blast injury studies, which is the ambiguity of the blast conditions associated
with the observed neurophysiological changes. At this time, we do not know which components of the
blast are dominant causal factors in the onset of mild TBI from blast, but based upon the physics of blast
and research by the Naval Medical Research Center using a porcine model, blast overpressure is believed
to be the most likely component. We will measure individual blast exposure levels while subjects are
performing breaching techniques and correlate these levels with symptom reports and neuropsychological
data collected before, during, and after breacher training.
Neuropsychological Tests (Phase A & B)
The neuropsychological tests for this protocol include the Automated Neuropsychological Assessment
Metrics (ANAM4) TBI Battery and the Immediate Post-concussion Assessment and Cognitive Test
(ImPACT 2.0). We selected the ANAM4 TBI Battery as a central tool in this protocol given the 20+ year
history of ANAM development in DOD medical research activities, National Rehabilitation Hospital’s
specific efforts in ANAM4 validation for TBI, and DVBIC’s extensive use (N>8,000) of ANAM4 TBI
Battery with paratroopers in ongoing evaluations at Ft. Bragg. Key references for the type of cognitivebehavioral symptoms associated with TBI and mild TBI come from research and clinical observation in
sports medicine described above. It must be noted that the two studies with military populations and
ANAM reported above both suffer from methodological weaknesses and also that there are still
unresolved issues in the use of computerized test batteries for clinical assessment of cognitive function.
A thorough review of ANAM, its use, and approaches to analyses is available in a special issue of
Archives of Clinical Neuropsychology (Kane, 2007). This ANAM-dedicated supplement includes 11
papers that provide a comprehensive review of ANAM, including a review paper focusing on the use of
ANAM with concussion (Cernich et al., 2007). From consideration of this literature, key
recommendations in the use of ANAM4 are captured in the proposed research.
In addition to the ANAM4 TBI Battery, we are also proposing to include the Immediate Post-Concussion
Assessment and Cognitive Testing (ImPACT 2.0) (Lovell, 2006) and the Defense Automated
Neurobehavioral Assessment (DANA). ImPACT is a computerized neuropsychological test battery
developed in the early 1990’s by the University of Pittsburg Medical Center that was specifically
designed for the evaluation of sports concussion. This battery has recently been adapted for the military
for the assessment of mTBI and is currently in use as part of a baseline neurocognitive testing program by
the United States Army Special Operations Command (USASOC). ImPACT has been shown to be
sensitive to the acute effects of concussion and has been validated as a reliable measure of neurocognitive
performance related to concussion (Iverson et al., 2004; Iverson et al., 2005; Lovell et al., 2006).
Furthermore, studies using reliable change indices demonstrated that repeated administrations over a 2week period revealed no practice effects (Iverson et al., 2002). From consideration of this literature, we
are proposing to use ImPACT as part of the neuropsychological tests included in this protocol. DANA is
a behavioral assessment tool developed for DOD use in field settings to reflect personnel impairment and
level of functioning. DANA's development leverages what the DOD has learned through the employment
of ANAM and other neurocognitive assessment tools (NCATs) for the evaluation of head injury. DANA
is a flexible platform and can accommodate many uses, including a 40-minute exhaustive assessment and
as a 5-minute surveillance assessment. The 40-minute DANA augments what will be learned from the
ANAM and ImPACT; however, the ANAM and ImPACT are principal measures in this protocol and the
40-minute DANA is a supporting measure. If there are operational requirements limits in personnel
availability in the before and after training paradigm, ANAM and ImPACT would be used preferentially;

17

the 5-minute DANA is relatively brief and non-intrusive and is expected to be used without operational
requirements limits in personnel availability.
In addition to cognitive impairment following mild traumatic brain injury, mood disturbances may occur
as well. Moore (Moore et al., 2006) found in their review of the literature on mTBI and anxiety that the
prevalence of anxiety among those with mTBI was 23%, higher than an estimated rate for a non-injured
population. The authors also found that PTSD, the re-experiencing of traumatic events, ranges in
frequency from 20-84% among mTBI patients (Moore et al., 2006). The authors point out that the comorbidity rate of depression and anxiety ranges 33-65% and that the majority of studies of mTBI focus on
depression and anxiety separately. In one of the few studies that focused on both of these disorders
within TBI, Jorge (Jorge et al., 2004) found that all subjects who met the criteria for generalized anxiety
disorder (GAD), defined as excessive worry over issues in everyday life, also met criteria for depression.
From consideration of this literature, a series of questionnaires and cognitive/emotional test batteries will
be used to capture mood and other behavioral disturbances.
Biomarkers (Phase A & B)
Evidence is accumulating that TBI initiates a physiologic cascade that can be detected in blood
components. Initial findings of research with this professional community have shown evidence for a
positive relationship between blast exposure, elevated symptomology, performance deficits, and elevation
of specific biomarkers in blood serum (including UCH-L1, SBDP150, SBDP120, MAP-2, EMAP-11,
GFAP, and VCAM). This research has been conducted by WRAIR in partnership with Banyan
Biomarkers (Alachua, FL, USA) and was most recently presented at the Advance Technology
Applications for Combat Casualty Care 2010 Conference (St. Pete’s Beach, FL). More recent pilot studies
with mTBI patients and also with rodent models have indicated mTBI-related changes in other
biomarkers (S100 beta, neuron specific enolase, brain derived neurotrophic factor, monocyte chemotactic
protein, and peroxiredoxin 6) and in epigenetic and gene expression (using genes identified from separate
studies with rodents exposed to repeated blast), and methylation analysis (which allows identification
potential epigenetic changes that might be specific to human blast-related TBI). These results suggest
that blood components biomarkers could serve as field-able diagnostic tools for mild traumatic brain
injury that could augment non-field-able conventional diagnostic tools, such as CT and MRI, which may
not be sensitive to mild and diffuse brain injury. Therefore, we will analyze blood components samples
for a panel of biomarkers that will provide extensive information on blast-induced brain injury and
potential mechanisms of injury.
Neuroimaging (Phase B)
To achieve maximal sensitivity and specificity for the detection of TBI, the current study incorporates
multiple magnetic resonance imaging (MRI) neuroimaging endpoints, including diffusion tensor imaging
(DTI), perfusion imaging, susceptibility weighted imaging (SWI), imaging with Gadolinium contrast, and
functional magnetic resonance imaging (fMRI). These endpoints have been efficacious in demonstrating
changes in mild TBI that are otherwise occult using routine anatomical computerized tomography (CT)
and MRI approaches (Arfanakis et al., 2002; Inglese et al., 2005; McAllister et al., 1999; McAllister et al.,
2001; Sigmund et al., 2007).
DTI is a recently developed MRI-based quantitative technique that can measure macroscopic axonal
organization in nervous system tissues. Diffusion is the random microscopic translational motion of
molecules (in MRI, usually water) in a fluid system and in the biological tissues. The DTI sequence is
particularly effective in the detection of microstructural disruption of white matter (Arfanakis et al.,
2002). Choice of this sequence is based upon recent data generated in a porcine model of mild blastinduced TBI clearly demonstrating traumatic axonal injury occurs following experimental low-level blast
exposure. This sequence relies upon the normal anisotropic movement of water within brain white matter
tracts. While water normally moves longitudinally down the length of white matter tracts, microstructural

18

disruption of white matter tracts will cause a reduction in this normal anisotropic movement of water.
This loss of normal anisotropy may be quantified through the DTI approach. DTI has proven effective in
detecting changes across the spectrum of TBI, from moderate to severe, which are occult on standard T1
and T2 MRI sequences.
Perfusion imaging techniques are sensitive to microscopic levels of blood flow (Hoeffner, 2005). Arterial
spin labeling as a recently developed perfusion MRI technique measures perfusion without the need for
an exogenous tracer by labeling the water in the arterial blood entering the brain, to provide an
endogenous tracer of perfusion (Keston et al., 2003). Perfusion imaging can provide insights into the
relationship between cognitive function and blood flow in the brain (Hillis, 2007). It has long been
recognized that reduction in regional cerebral blood flow (rCBF) is associated with impairment of neural
function in that area of brain. The reduced rCBF (hypoperfusion) can be secondary to dysfunction, as
exemplified by the temporal and parietal hypoperfusion, for example, seen in studies of patients with
Alzheimer’s disease (Grossman et al., 2001). Adequate blood flow is necessary for both neural function
and neural viability. Tissue receiving blood flow that is between 10 and 30% of the normal blood flow
rate is getting just enough to survive, but not enough to function (Astrup et al., 1977). Therefore, imaging
of blood flow can reveal areas of dysfunctional tissue that may be responsible for cognitive deficits after
blast injury.
The SWI sequence is particularly effective in the detection of microhemorrhage within the brain
(Sigmund et al., 2007). Microhemorrhage is a known feature of diffuse brain injury. This sequence
capitalizes upon differences in magnetic susceptibility between deoxyhemaglobin and the surrounding
neurological tissues. The SWI approach combines magnitude and phase information from a highresolution, 3D T2 weighted gradient echo sequence to dramatically increased contrast of magnetically
susceptible tissues.
Gadolinium-based contrast agents are used during MRI to increase the sensitivity for detecting
differences between tissues and are used by radiologists to look at changes in blood vessels in the brain.
Using this contrast agent can enhance the image in the area near a leak or proliferation of blood vessels,
indicating a disruption of the blood-brain barrier (Giesel et al., 2010). Blast injury has been shown to
causes increased permeability of the blood-brain barrier (Hicks et al., 2010). However, the duration of
this effect and its association with clinical and other markers of injury are not understood. Therefore, we
propose to administer Gadolinium contrast during structural MRI scanning to explore the hypothesis that
cumulative exposure to low-level blast causes chronic increased permeability in the blood-brain barrier.
While the previous sequences provide exquisite sensitivity in detecting microstructural changes in brain
tissues, fMRI is highly sensitive at detecting changes in neurological activity within the brain. The
principle of fMRI is similar to SWI in that it detects susceptibility differences associated with
deoxyhemaglobin within the brain. However, in contrast to increases in deoxyhemaglobin at sites of
hemorrhage, fMRI detects decreases in deoxyhemaglobin that accompany the increased delivery of
oxygenated blood to areas of high neurological activity. fMRI is typically performed during and
following the performance of specific tasks. These tasks are designed to test particular neurological
function which may relate to motor function, sensation, or cognition. In the current investigation, tasks
will be employed which assess working memory, executive functioning, and social functioning given the
recommendation of clinicians experienced with current military TBI patient populations and anecdotal
evidence of symptoms reported by experienced Breachers. Previous use of fMRI in the study of brain
function has shown that fMRI is a technique useful for identifying prefrontal dysfunction related to
executive cognitive abilities in TBI patients without structural lesions on MRI (Fontaine et al., 1999;
McAllister et al., 1999; McAllister et al., 2001), whereas CT scans and conventional MRI are only weakly
related to executive function deficit in TBI patients (Fontaine et al., 1999; Vilkki, 1992).
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Sleep (Phase A & B)
Sleep disturbances are observed in 50% of the TBI population (Castriotta et al., 2007), however, the sleep
architecture that characterizes specific degrees of TBI (mild, moderate, and severe) has been addressed by
few studies. A recent meta-analysis concerning sleep disturbances and TBI suggested that mild TBI
correlates more strongly with sleep disruption than severe forms of TBI (Orff et al., 2009), giving
credence to anecdotal accounts of sleep disturbances reported by Breacher Instructors and revealing a
further need to dissect the sleep architecture of TBI subpopulations to determine a acute and long term
treatment strategies. We will study acute effects of blast exposure on sleep-wake patterns and circadian
rhythms during breacher training by assessing movement using wrist-worn actigraphy devices.
Actigraphy is the use of a portable device that records movement over extended periods of time to give an
accurate measure of sleep patterns and circadian rhythms (Morgenthaler et al., 2007) and has been
validated against the gold-standard polysomnography for recording sleep/wake under field conditions
(Signal et al., 2005). In addition, subjects who participate in Phase B who have a significant sleep
disturbance as indicated by actigraphy data collected during Phase A or self-report, will undergo a sleep
assessment using a one night polysomnographic recording to rule out the presence of overt sleep disorders
(e.g., obstructive sleep apnea, periodic leg movements during sleep, etc.).
Vestibular and Auditory Assessments (Phase A & B)
Breachers wear hearing protection during all breaching maneuvers however, exposure to blast presents an
inherent risk to the auditory and vestibular systems. Both military and law enforcement Breachers report
incidents of transient post-blast auditory and balance problems (observation and USMC Dynamic Entry
School verbal report, June 6, 2007) and recent studies have demonstrated a link between blast exposure
and vestibular disorders (Hoffer et al., 2010; Scherer & Schubert, 2009; Sylvia et al., 2001). Furthermore,
research shows that athletes demonstrate decreased stability up to three to five days post injury, which
may be the result of ineffective use of one or more of their sensory systems (Guskiewicz et al., 1997).
There is strong evidence demonstrating the impact of balance deficits on functional performance and
increased risk of re-injury (Goldie et al., 1994; Lehmann et al., 1990). Therefore, to evaluate potential
effects from this exposure, the auditory and vestibular systems will be assessed in this protocol using a
sensory integration of balance test using the Portable BioSway Device, as well as self reports as part of a
daily symptom questionnaire (e.g. dizziness, tinnitus, noise sensitivity). In addition, subjects who
participate in Phase B will be assessed using computerized dynamic posturography as well as clinical
tests of balance function and a self-reported questionnaire to evaluate the impact of symptoms on quality
of life. Similar assessments have been shown to be successful in characterizing sequelae with TBI
(Basford et al., 2003; Jury & Flynn, 2001; Newton, 1995; Wober et al., 1993) and vestibular disorders
(El-Kashlan et al., 1998; Furman, 1995; Yardley et al., 1998). Additional tests will also be employed to
assess peripheral vestibular and auditory functioning and to distinguish disorders of the peripheral and
central vestibular systems.
Eye-Tracking Test (Phase A)
TBI has been shown to increase performance variability in visuomotor tasks that require sustained and
focused attention (Robertson et al., 1997; Stuss et al., 1989). Because predictive visual tracking requires
both intact attention and working memory (Barnes, 2008), it has been suggested that visual tracking
performance can be used to supplement conventional evaluations of mTBI (Heitger et al., 2009). In
addition, increased performance variability during predictive visual tracking has been demonstrated in
individuals with mTBI and correlated with white matter track vulnerability (Maruta et al., 2010).
Therefore, we will use a portable eye-tracking system that uses a highly predictable circular pursuit
paradigm to evaluate anticipatory eye-tracking. This paradigm involves the anticipation of target motion,
which requires higher cognitive input than visual-feedback controlled smooth pursuit eye movements.
This test will provide additional insight into the link between blast exposure and higher cognitive
processes known to be mediated by the prefrontal cortex.
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Justification for the use of human subjects
Human subjects are required for this protocol to understand the impact of years of cumulative exposure to
low-level blast generated overpressure that service members and law enforcement personnel experience.
While animal experimentation with artificially generated overpressure can provide dose-response curves
that exceed safety thresholds for humans, it is critical to compliment this research with human subjects
that have cumulative exposure over several years.
Potential Benefits
There is no direct benefit to subjects for participating in this study. The documentation of neurocognitive
change or other injury in this study that can be reasonably associated with exposure to blast would be an
important first step in a means to mitigate risks in future training and in breaching operations.
Enhancement of protection from blast exposure would be a benefit for military members and civilian law
enforcement personnel assigned to Breacher duty and for all exposed to operational blasts. Payment to
subjects is not considered a benefit because it is a fair compensation for time and inconvenience
associated with participating in this research.
6. PLAN
6.1 New Investigational Drugs / Investigational Devices Exemption Status
N/A
6.2 Selection of Subjects
6.2.1 Type of the Subject Population
The target population for this study consists of individuals from military and civilian law enforcement
Breacher communities with at least 4 years of experience in the breaching profession and extensive
exposure to breaching blast. Breachers with less experience will also be included in Phase A of the
study. In addition, the study will include a control group consisting of experienced active duty or
prior active duty military personnel with extensive exposure to non-blast generated overpressure (e.g.
artillery units) and a second control group consisting of experienced active duty or prior active duty
military personnel with no prior exposure to overpressure. We will also include companions of the
primary subjects.
6.2.2 Inclusion and Exclusion Criteria (see Eligibility Checklist, Appendix B)
a. Inclusion Criteria
Experimental Group: Breachers
To be included in the experienced Breacher Group, individuals must be active duty or prior active
duty military personnel or civilian law enforcement personnel, between the ages of 18 and 60, with at
least 4 years of experience in the breaching profession and actively involved in breacher training
and/or operations (minimum of annual exposure). An alternate criterion to years of breacher
experience is exposure to a significant number of breaching blasts, specifically, exposure to 400
breaching blasts or more within a career, will be considered “experienced” by the investigators.
Individuals who are eligible to participate in breacher training will be allowed to participate in Phase
A regardless of inclusion/exclusion criteria in order to preserve training group integrity, unless they
decline to provide informed consent.
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Control Group 1: Artillery
To be included in Control Group 1, individuals must be active duty or prior active duty military
personnel that are demographically similar to the Breacher Group in terms of age, gender, service
length, and operational and/or deployment experience, and have at least 4 years experience with
exposure to concussive environments not related to blast (e.g. artillery units) (minimum of annual
exposure). An alternate criterion to years of experience is exposure to a significant number of
concussive evolutions, specifically, exposure to 400 or more within a career, will be considered
“experienced” by the investigators. Individuals who are eligible to participate in artillery training will
be allowed to participate in Phase A regardless of inclusion/exclusion criteria in order to preserve
training group integrity, unless they decline to provide informed consent.
Control Group 2: Unexposed
To be included in Control Group 2, individuals must be active duty or prior active duty military
personnel or law enforcement personnel that are demographically similar to the Breacher Group in
terms of age, gender, service length, and operational and/or deployment experience. Operational
experience is defined as years of experience actively involved in military or law enforcement
operations and/or number of operations with the condition that operations include direct mission
engagement roles rather than support roles. Military deployment or law enforcement patrol are
examples of direct mission engagement roles and shore logistics or office based call center are
examples of support roles.
Companion Group (Phase B)
To be included in the companion group, individuals must be considered a close companion of an
experimental or control group subject over the age of 18 with knowledge of the subject’s daily
functioning (e.g. spouses, family members, domestic partners, close friends, etc.).
b. Exclusion Criteria
In order to preserve training group integrity, all individuals participating in breacher or artillery training
will be invited to participate in Phase A of the study. The following exclusion criteria are applicable only
to Phase B.
Experimental/Control Groups
Children will be excluded from this study
History of moderate or more severe brain injury with loss of consciousness greater than 5 minutes
Current diagnosis of other CNS disorder (e.g. epilepsy)
A medical condition that would make participation detrimental to the subject (e.g. severe clinical
depression, unstable heart disease)
MRI contraindications (see MRI Safety Questionnaire, Appendix B; includes pregnancy, screening
test will be performed prior to MRI)
Control Group 1
Previous experience with explosive entry training
Exposure to blast from Breaching (greater than 40 individual blasts)
Control Group 2
Previous experience with explosive entry training
Exposure to blast or overpressure of any kind (greater than 40 individual blasts)
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Companion Group (Phase B)
None
6.2.3 Recruitment
a. Equitable Selection of Subjects
Children will be excluded from this study as a consequence of not being eligible to participate in
explosive entry training. Women who meet eligibility criteria will be included as primary subjects and
will also be included in the companion group. There is no exclusion of any minority from
participation in this protocol.
b. Recruitment Procedures
This collaborative research team is already in contact with individuals who will be eligible to
participate in this protocol, by virtue of blast-related engineering programs (ARA), active research
protocols, and interaction at annual breacher meetings. Investigators and other personnel named on
this protocol will advertise this study by word of mouth and approved advertisements (e.g.,
information sheet). Individuals who believe they are eligible and are interested in this research would
contact the research team and would be invited to participate.
Phase A will differ from Phase B in that environmental characterization will include coordination
with a breaching site and chain of command or supervisory support in addition to individual consent.
For Phase A, an in-person meeting will be arranged between members of the research team and the
representatives from the unit conducting breacher training. In that meeting, copies of this protocol
and informed consent forms will be provided and the protocol procedures will be discussed. The
discussion will resolve the feasibility of the protocol for that site and logistics required to support the
study. The unit representatives will also be briefed on the possibility of individual subjects being
invited to travel to NIH to participate in Phase B. Providing that protocol criteria are met and
procedures are feasible and accepted, Informed Consent will be reviewed. If consent is granted by
unit representatives, scheduling and other arrangements will be made. Informed Consent and
eligibility criteria will then be reviewed for each individual participating in the training before any
research participation. Any individual not consenting to participate will not be affected by this
research, in terms of either the conduct of research procedures or participation in training activities.
In order to avoid influence from senior leadership, officers and senior non-commissioned officers
from the subjects’ units and/or the training group will not be present during the consent process. In
addition, officers, non-commissioned officers, and training supervisors who are participating in the
study will be consented separately and will not be present during the consenting of subordinates.
Recruitment of the control groups will be conducted in a similar fashion by coordinating with units
that conduct artillery training as well as a unit at one of the performance sites that can provide
personnel who would be eligible to participate as unexposed control subjects. Initial contact with
these units will be conducted via informal word of mouth advertizing. Interested parties can follow
up with the research team via coordination with unit commanders as described above.
For Phase B, interested persons will be recruited as individuals. Interested individuals will be
contacted by the Research Contact and eligibility criteria and Informed Consent will be reviewed.
Additional information about the study can be provided to the individual over the phone or via e-mail
if requested. One additional criterion for this DOD protocol is MRI compatibility. The items on a
standard of care MRI Safety Questionnaire (Appendix B) will be reviewed and the questionnaire will
be provided to the individual. Similarly, persons for the Companion group will also be contacted by
the Research Contact and invited to participate as individuals. The initial contact to the Companion
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will, of course, be made by the subject who has already agreed to participate. Companions who are
unable to travel to NIH may participate in the study remotely. “Off-site” companions will be
screened over the phone and will exchange study documents with the investigators via mail. For any
individual agreeing to participate in Phase B, scheduling, travel arrangements, and question and
answer will be completed over the telephone by the Research Contact.
Recruitment may be by advertisement in multiple media formats including Facebook, Twitter,
newspapers, newsletters, and radio. Recruitment may also include word of mouth, oral presentations
and/or distribution of approved recruiting materials at events, meetings, and briefings wherein the
desired recruit population might reasonably be expected to attend. In accordance with DoD
Instruction 3216.02, an ombudsman will be present for the recruitment of Service members in a group
setting. All advertisements, both general and specific to this study, will have been reviewed and
approved by the IRB prior to their use.
Additionally, the approved flyers and written advertisements will be used in color as submitted, or
may be printed in black and white. The color of the ads may vary. Color changes will not be used to
change the emphasis of an ad. The size of the ads may vary, but all parts of the ads, including fonts
and pictures, will be changed proportionately to the rest of that ad. Disproportionate changes in size
will not be used to change the emphasis of an ad. The flyer and the IRB approved written ads may be
placed in print publications of recruitment venues such as authorized military bases, base newspapers
or magazines, as well as on the US military (.mil) domain websites for the military bases, their
newspapers, magazines, or Facebook pages. It is recognized that posting recruitment notices must be
in accord with the recruitment venue’s policies and may require specific approval before proceeding.
c. Compensation
Military service members may not be compensated for their participation in research while “on duty”
with the exception of compensation for blood draws. During Phase A of the study subjects will be
compensated $25 per blood draw. Military service members must be on official leave status during
their participation in Phase B of the study, and they must have their supervisor’s and Unit
Commander’s written approval. For participation in Phase B, compensation for primary research
subjects will be provided in accordance with NIH and DOD guidelines, and will include $70 per day
of participation. Total possible compensation ($70.00/day up to 5 days, plus an additional $50 for
completion of the sleep study) = $400.00. Individuals who participate in the 1-year follow-up visit
will be compensated according to the same guidelines described above. This visit is expected to last
3 days for a total possible compensation of $210.Companions of primary subjects will not be
compensated for participating in the companion group interviews.
Study related expenses for primary subjects and companions participating in Phase B will be paid for
by NIH, including travel to and from NIH, hotel fees, and the NINDS standard per diem
reimbursement for 3 meals per day.
6.2.4 Consent Process
Information about this protocol, including purpose, risk, benefit, eligibility criteria, contact points,
and volunteers’ right to decline participation or withdraw at any time with no consequence, will be
provided to prospective subjects either in person or through an initial email to interested subjects.
During the consent process, the Consent Form describing in detail the study procedures and risks is
given to the subject and written documentation of informed consent and HIPAA authorization are
required prior to enrolling in the study. A copy of the informed consent document will be given to
the subjects for their records. Separate Consent Forms will be used for participation in each Phase of
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the study, as individuals may only be eligible or available to participate in specific portions of the
study. The consent procedures will be the same for the experimental and control groups.
For Phase A, arrangements to obtain Informed Consent from individual volunteers will first be made
with the Commanding Officer of the training site after obtaining permission for protocol activity.
Informed Consent will be obtained at the training site by a member of the research team listed as a
“Consenter” (see Section 9. Roles and Responsibilities). Subjects will be assigned a random study
number at the time of consent. This procedure prevents coercion as the Consenter is not in the
volunteers' chain of command or connected to any medical treatment to which they are entitled.
Subjects may be asked to participate in multiple evolutions of Phase A (e.g. if the research team
revisits a field site for additional data collection) and can do so under the original consent form as
long as it is valid. As there is no training site for the unexposed control group, consent for these
subjects will be conducted in a suitable location, such as the unit’s headquarters facility.
For Phase B, volunteers will be asked to sign both the DOD consent form for this protocol and the
NINDS consent form (NINDS consent forms are included in Appendix A). The consent process for
Phase B is described in detail in the NINDS protocol. Interested individuals will be contacted by the
Research Contact and questions about research participation, if any, will be addressed and
arrangements for travel to NIH will be made. Informed Consent will be obtained when the individual
is on site at NIH in Bethesda. “Off-Site” companions will be consented over the phone.
6.3 Study Design and Methodology
6.3.1 Study Design
This is an observational study that will evaluate neurophysiological and cognitive changes related to
chronic exposure to low-level blast overpressure by comparing experienced Breachers to a wellmatched control group using a battery of neuropsychological assessments, physiological markers, and
experimental procedures.
6.3.2 Study Methodology/Procedures
Subject Participation
This protocol consists of 2 phases. Subjects may participate in the entire study as per their
availability and eligibility, or may elect to only participate in one portion of the study. Subjects are
not required to participate in Phase A in order to enroll in Phase B, and vice versa. Subjects may
participate in Phase A first and then choose to enroll in Phase B, or vice versa, depending on their
availability and the training schedule of their operational group. Furthermore, subjects may be asked
to participate in multiple data collection evolutions (e.g. multiple visits to field sites by the research
team for Phase A; 1-year follow-up visit to NIH by the subject for Phase B).
A goal of Phase A is to evaluate up to 150 breachers, 50 artillery personnel, and 50 unexposed
controls using neuropsychological measures and blood components analysis in order to develop a
time-course of biomarker levels that are associated with brain injury. In order to achieve this goal,
and to maximize the efficient use of resources during site visits to training facilities, we will also
include individuals who do not meet criteria for experienced operators with extensive exposure. In
order to preserve training group integrity, all individuals participating in breacher or artillery training
will be invited to participate in Phase A of the study. From this pool of subjects, operators and
instructors with at least 4 years of experience and who meet eligibility criteria may be invited to travel
to NINDS to participate in Phase B. Recruitment for Phase A will continue after the enrollment goals
for Phase B have been met.
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Demographics Form and Head Injury Questionnaire
After Informed Consent has been obtained, subjects will be asked to complete a Demographics Form
and Head Injury Questionnaire (Appendix B) that will ask them to provide information about their
breaching history, other blast exposure, operational and deployment history, history of major medical
issues, history of sleep patterns, and history of head injury (dates and duration will be recorded when
is present). In addition, the questionnaire will include items related to cognitive and psychological
health, including elements of the Post Traumatic Stress Disorder scale (Bombardier et al., 2006) and
the Beck Depression Inventory (Beck et al., 1996). Subjects will also be asked to complete the
Combat Exposure Checklist, which measures the frequency of stressful events experienced during
deployments. If possible, scores from the Armed Services Vocational Aptitude Battery (ASVAB) ,
standard predeployment baseline assessments, or an equivalent law enforcement aptitude test will be
recorded for pre-exposure baseline functioning. These data are collected in support of interpretation
of primary research data.
Phase A: Field Assessments
In Phase A, a research team consisting of staff from NMRC, WRAIR, and ARA will travel to various
breacher training facilities (for example: Ft. Benning, GA; Marine Corps Base Quantico, VA; Fort
Bragg, NC; Montgomery County Police Department, MD) to conduct daily field assessments before,
during, and after explosive entry training and concomitant blast exposure. Individual sites will be
added to the protocol as each collaboration is formalized. Our research team is currently in the
process of establishing a formal partnership with the United States Army Special Operations
Command (USASOC), which will provide access to various sites where breacher training is
conducted. The field assessments will include symptomology, neuropsychological tests, vestibular
system assessments, eye-tracking, sleep pattern analysis, and blood components analysis for
biomarkers. These procedures are described in the following subsections of this document.
Additionally, during the training period, the research team will instrument the training environment to
measure blast exposure. An important principle guiding this research protocol is to make no changes
to the standard protocols for explosive entry training and to minimize additional burdens (e.g., 1-hour
end-of-the-day test session) on the volunteers participating in this research. Parallel data collection
using all of the above mentioned procedures will occur daily for 5 days prior to the start of breacher
training, on breaching days, and for up to 7 days after training is complete in order to establish a
baseline and observe the time-course of signal changes. A typical breacher training evolution
involves a 2-week course with approximately 5 days of exposure to breaching blast (see section 6.3.5
Study Time Line), however, training schedules and amount of exposure varies between training
groups. Participation in any of the data collection sessions or individual procedures will be subject to
the requirements of the operational community and may be refused without consequence by any
individual subject or for all subjects at a particular site by the training group commander.
Subjects from control group 1 will be assessed during artillery training with the same procedures as
the Breacher subjects. Control group 2 will be assessed according to the same methods and
scheduling, albeit absent any connection to blast or other exposure to overpressure. Arrangements for
an appropriate location for data collection for control group 2 will be made with the participating unit.
As there will no blast measurements taking place for this group, a classroom would be sufficient for
the 1-hour of daily testing.
Phase B: Hospital Assessments
In Phase B, subjects will travel to NINDS in Bethesda, MD to undergo 5 days of neurophysiological
and cognitive assessments including neuropsychological tests, blood components analysis for
biomarkers, vestibular and auditory testing, a sleep assessment, and neuroimaging studies using DTI,
SWI, perfusion imaging, imaging with Gadolinium contrast, and fMRI. The details of these
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procedures are described in the NINDS protocol attached as Appendix A. A companion will be
invited to accompany each subject to NINDS and asked to complete questionnaires that may capture
changes daily functioning that subjects are not able to self-assess. Subjects will be invited back to
NINDS 1 year following their initial visit for follow-up testing. As with Phase A, participation in any
of the procedures may be refused without consequence.
6.3.3 Collection of the Human Biological Specimens
For Phase A, no greater than 10ml of blood per collection will be acquired once a day from subjects
via venipuncture to the volunteer’s extremity (e.g., antecubital vein) by a military phlebotomist or
other individual certified to draw blood, with the exception of an additional 10 ml drawn on the first
and the last days of sample collection (i.e., an additional 20 ml). For a typical 2-week training
evolution, with maximum daily participation before, during, and after blast exposure, approximately
19 blood draws would take place, for a total of 210ml of blood. However, the specific number of
blood draws will vary between training groups depending on the length of the training course, subject
availability, and feasibility as determined by the researchers and training directors. These samples
will be sent to the following laboratories where they will be assayed to look for internal indicators for
changes after neurological insult at a molecular and cellular level: Banyan Biomarkers in Alachua,
Florida; James J. Peters VA Medical Center/Mount Sinai School of Medicine in Bronx, NY; National
Institute of Nursing Research, National Institutes of Health, Bethesda, MD. The samples will also be
used to quantify biomarkers in blood from subjects to see how they correlate to measures of injury
severity, progression, and outcome. The samples will be stored by study identification code, but the
key that links the specimen by code to the individual’s information will also be stored (separately) at
NMRC/WRAIR so data will be identifiable for the duration of their storage. For Phase B, a single
20ml sample will be collected using the same procedures and will be sent to the collaborating
laboratories described above to be assayed in the same way as described for Phase A. All samples
will be destroyed once assayed.
See Appendix B for details of the Banyan Biomarkers standard operation procedures for serum
collection and storage. Once analyzed, the blood samples will be destroyed. Note that collection of
cerebrospinal fluid (CSF) is described in this appendix but will not be executed in this protocol.
Collection and storage of other blood components (peripheral blood mononucleated cells) will be by
parallel methods but with difference in collection container (e.g., green top vacutainer v red top or
tiger top vacutainer).
6.3.4 Data Collection
Phase A: Field Assessments
Physical Characteristics of Exposure
This protocol for the environmental characterization will use two pressure sensors per individual. The
pressure transducers sensing the exposure will be mounted to the left and right exterior surface of the
helmet. Since the entire system is located on the exterior of the helmet, the drilling of holes that could
potentially compromise the ballistic performance of the shell will not be necessary. Also, because the
entire system is located on the exterior of the helmet, there is no risk of the system causing discomfort
to the wearer. The output from the transducer will be recorded and digitized by a miniature data
acquisition system (uDAS) mounted to the rear surface of the helmet. The sampling rate of the uDAS
system is 1 million samples per second. Each unit is self triggered so a trigger cable, which is a
tripping hazard, is not required. The uDAS system and sample output from the unit are shown in the
Figure below. Each pressure gage weighs approximately 0.0025 ounces (0.08 grams) and has
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diameter of 6.6 millimeters and a thickness of 0.84 millimeters. The entire uDAS system, including
the power supply and automatic trigger, weighs 0.40 kilograms (15 oz).
The proposed sensor system was designed for, approved in the associated protocol for, and used in
the Congressionally Directed Medical Research Programs (CDMRP) sponsored program, Brain
Injury Biomarkers and Behavioral Characterization on mTBI in Soldiers Following Repeated, LowLevel Blast Exposure (WRAIR #1635).
Data down-loads from each helmet system will occur at the end of every test day when the batteries
in the units are recharged. The charging and download will occur through a common USB download
port which mates with a docking station that has enough ports to automatically charge and download
data from all of the helmets at one location. The docking station will have an automated link to a
secure server at ARA’s office in Denver, Colorado. This system allows the coded laboratory-quality
pressure data to be recorded on breachers and transmitted without having any of the research team
permanently located at the test site for the duration of the study. Data in this study will be stored in
Denver, CO by the individual’s study identification code and processed by trained personnel.

Figure 1: uDAS System and sample pressure output
The data from the systems will be used to estimate the magnitude, energy, and frequency content of
the shock wave transmitted to the head region from each exposure. The results from each exposure
will be tabulated and time stamped so that the cumulative exposure for each individual will be
calculated.
To augment the pressure measurements recorded on each individual, the research team will make a
site visit to each test location to deploy additional instrumentation to aid in the interpretation of each
individual’s pressure data. During these visits the research team will use additional pressure gauges
positioned inside the structure while the breaching exercises are being conducted. These additional
gauges will be used to assist in the explanation of any pressure anomalies observed in the individual’s
pressure data.
Supporting all of the electronic data collected, video recording of field exercises will be made using
wireless camera systems in and around the breaching area to enhance the precision in determining
physical relations between study subjects, features in the environment, and distance from blast.
Videos collected for data analysis purposes will be used in briefings to training group commanders to
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demonstrate the relationship between the characteristics of the exposure event and the exposure
levels. Videos will be used only if individuals in the video are “blurred” or otherwise de-identified.
Symptomology
Subjects will complete a Symptom Questionnaire (Appendix B) daily at multiple time points before,
during, and after training, as per subject availability. This questionnaire will be used to assess the
presence of symptoms consistent with brain injury (e.g. headaches, ringing in ears, forgetfulness,
etc.). It includes 32 items rated by the subject on a 5-point Likert Scale (0-4; 0 = not experienced at
all; 4 = a severe problem) and a constant vs. intermittent choice. The questionnaire also includes
space for the subject to report other symptoms they are experiencing.
Neuropsychological Measures
Subjects will perform the ANAM4 TBI Battery daily at multiple time points before, during, and after
training, as per subject availability. The ANAM4 TBI battery is specifically designed, based on
empirical data and experience, to be sensitive to TBI and to be administrable within approximately 20
minutes. This test battery is administered on computer, which allows it to be administered to large
groups with multiple workstations, and it is designed to easily accommodate repeated administration,
by sampling from a large pool of items for each administration. The ANAM4 TBI Battery includes
the following 8 tests, with the neuropsychological qualities assessed listed in brackets:
Stanford Sleepiness Scale [Self-Assessment Fatigue (state/trait)]
Mood Affect Score [Vigor (high energy level), Happiness (positive disposition), Depression
(dysphoria), Anger (negative disposition), Fatigue (low energy level), Anxiety (anxiety level),
Restlessness (motor agitation)]
Simple Reaction Time [Basic Neural Processing (speed/efficiency)]
Code Substitution [Associative Learning (speed/efficiency), Visual Search, Sustained Attention,
Working Memory]
Procedural Reaction Time [Processing Speed (Choice RT/Rule Adherence)];
Mathematical Processing [Working Memory]
Matching to Sample [Visual Spatial Memory]
Code Substitution (Delayed) [Retention]
In addition to the ANAM, subjects will also perform the ImPACT Version 2.0 and the Defense
Automated Neurobehavioral Assessment (DANA). ImPACT will be conducted before and after
training, as per subject availability. Version 2.0 of ImPACT is a computer administered
neuropsychological test battery that has been shown to be sensitive to the acute effects of concussion
and can be administrable within approximately 25 minutes. It consists of six individual test modules
that measure aspects of cognitive functioning including attention, memory, reaction time, and
processing speed. This test can also accommodate multiple administrations, albeit separated by
several days to avoid interference, by sampling from additional versions of the individual modules.
The ImPACT 2.0 includes the following 6 modules, with the neuropsychological qualities assessed
listed in brackets:
Word Memory [Immediate and delayed memory for words]
Design Memory [Immediate and delayed memory for designs]
X’s and O’s [Attention, concentration, working memory, reaction time]
Symbol Match [Visual processing speed, learning and memory]
Color Match [Focused attention, response inhibition, reaction time]
Three Letters [Attention, concentration, working memory, visual-motor speed]
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DANA will be conducted before and after training as well as periodically during training, as per
subject availability. DANA is a behavioral assessment tool developed for DOD use in field settings to
reflect personnel impairment and level of functioning. In the current study, its 2 principal uses will be
a 40-minute exhaustive assessment and as a 5-minute surveillance assessment. The 40-minute
assessment includes the following 16 tests (in order of execution): Simple Reaction Time, Verbal
Learning Test (Learning), Code Substitution (Learning), Verbal Learning Test (Recall, short delay),
Procedural Reaction Time, Spatial Processing, Code Substitution (Recall), Choice Reaction,
Sternberg Memory Search, Verbal Learning Test (Recall, long delay), Simple Reaction Time,
Combat Exposure Scale, Patient Health Questionnaire-9, Pittsburgh Sleep Quality Index, PTSD
CheckList-Military, and Deployment Stress Inventory. The 5-minute assessment includes the
following 3 tests (in order of execution): Simple Reaction Time, Procedural Reaction Time, and
Choice Reaction. The 40-minute assessment can be used twice and would be used in a before and
after training paradigm in the proposed work. The 5-minute assessment can be used repeatedly, in
rapid succession, without limit on number of administrations; the 5-minute assessment would be used
in a daily paradigm in the proposed work.
See Appendix B for examples and additional descriptions of the ANAM4 TBI Battery, ImPACT
Version 2.0, and DANA.
mTBI Biomarker Analysis
Blood samples will be collected daily at multiple time points before, during, and after training, as per
subject availability. No greater than 10ml of blood per collection will be collected via venipuncture
to the volunteer’s extremity (e.g., antecubital vein) by a military phlebotomist or other individual
certified to draw blood, with the exception of an additional 10 ml drawn on the first and the last days
of sample collection (i.e., an additional 20 ml). Samples will be separated into aliquots and frozen.
Each aliquot will be labeled with the volunteer’s unique identifier (no identifiable information will be
recorded on the sample labels). The samples will be stored temporarily at the study site before
transport to the following laboratories to be assayed: Banyan Biomarkers in Alachua, Florida; James
J. Peters VA Medical Center/Mount Sinai School of Medicine in Bronx, NY; National Institute of
Nursing Research, National Institutes of Health, Bethesda, MD. Banyan Biomarkers is the
established leader in discovery of innovative brain injury biomarkers, and will analyze serum samples
for a panel of biomarkers that may include:
UCH-L1: A biomarker of cell body injury
SBDP150: Biomarker of axonal injury and cellular necrosis
SBDP120: Biomarker of axonal injury and cellular apoptosis
MAP-2: A persistent biomarker of dendritic injury
GFAP: A biomarker of glial injury
sICAM-1: A biomarker of vascular damage, and
s100β: A well-established benchmark biomarker for brain injury
Biomarker levels in serum samples obtained from study subjects will be determined by standard 96well microtiter plate based Enzyme-Linked Immunosorbent Assay (ELISA) technology. This ELISA
format employs a biomarker-specific capture antibody attached to the surface of the microtiter plate
well. An aliquot of the serum sample is mixed with buffer and applied to the microtiter well for 60-90
minutes to allow for binding of the biomarker to the capture antibody. After washing of the plate to
remove all unbound material a secondary antibody is added, which is also specific for the biomarker,
but typically which binds to a different portion (epitope) of the biomarker molecule. The resulting trimolecular complexes or sandwiches are then detected via an enzymatic reaction that involves horse
radish peroxidase (HRP). This enzyme may be directly attached to the detection antibody through
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conjugation, or indirectly via a biotin-streptavidin bridge, or through attachment of a tertiary antibody
that carries this enzyme. The enzymatic reaction involves the turn-over of a substrate that results in
formation of a color, fluorescence, or chemiluminescence, whereby the amount of substrate turn-over
is directly proportional to the number of biomarker molecules trapped in the sandwich. Measurement
of the amount of color, fluorescence or luminescence that is generated and comparison to a
calibration curve allows accurate quantization of the biomarker with a lower level of detection that
varies between 0.1 and 1.0ng/ml in serum. The precision (intra- and inter-assay coefficients of
variation) may vary between 10% and 25%, which then determines the lower limit of quantization.
In addition to serum-based biomarkers assessed by Banyan, serum and other blood components will
be assayed by other collaborators listed above. Epigenetic analyses will be performed for modulation
of gene expression mediated by DNA methylation in response to neurological insult and analysis of
autoimmune- or inflammation-based responses and broad mircoRNA arrays will be assessed as
markers of neurological insult.
See Appendix B for details of the Banyan Biomarkers standard operation procedure for serum
collection and storage. Once analyzed, the blood samples will be destroyed. Note that collection of
cerebrospinal fluid (CSF) is described in this appendix but will not be executed in this protocol.
Collection and storage of other blood components (peripheral blood mononucleated cells) will be by
parallel methods but with difference in collection container (e.g., green top vacutainer v red top or
tiger top vacutainer). Analysis of serum and other blood components will also be open to other
collaborating laboratories, based on new collaborator findings and pilot data.
Vestibular System Assessment
Subjects will undergo vestibular testing using the Portable BioSway Device (Biodex Medical Systems
Inc., Shirley NY) daily at multiple time points before, during, and after training, as per subject
availability. The Clinical Test for Sensory Integration of Balance (CTSIB) helps to determine which
sensory system (visual, vestibular, or somatosensory) a person relies on to maintain balance. It
provides a generalized assessment of how well a patient can integrate various senses with respect to
balance and compensate when one or more of those senses are compromised. It is administered by:
1) manipulating the support surface (firm vs. foam); 2) visual conditions (eyes open vs. eyes closed);
and 3) vestibular system sway reference by using the computerized sway platform, while an
individual is asked to maintain their standing balance. A 3" Airex® Indexed Foam Pad is used as the
compliant surface for the unstable support surface. The CTSIB requires subjects to complete four 30
sec tests.
Condition 1 – Eyes open firm surface: Baseline: Incorporates visual, vestibular and
somatosensory inputs
Condition 2 – Eyes closed firm surface: Eliminate visual input to evaluate vestibular and
somatosensory inputs.
Condition 3 – Eyes open on a dynamic surface used to evaluate somatosensory interaction with
visually input.
Condition 4 – Eyes closed on dynamic surface: used to evaluate somatosensory interaction with
vestibular input
See Appendix B for a detailed description of the Portable BioSway Device and standard operating
procedure for its use.
Eye-Tracking Test
Subjects will perform a Smooth Pursuit Eye Movement (SPEM) task using the head mounted,
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Portable Eye-Tracking Device (Brain Trauma Foundation) daily at multiple time points before,
during, and after training, as per subject availability. The SPEM task requires the subject to visually
track a target stimulus, a red circle of 0.2 º diameters, which follows a circular clockwise trajectory
with a radius of 7º and at a speed of 0.4 Hz. The red circle takes exactly 2.5 seconds to complete a
revolution, or cycle. A circular pursuit task was chosen because it allows for the recording of both
horizontal and vertical components concurrently, enabling a greater amount of data to be acquired in
a shorter amount of time. The signals representing eye and target movements will be simultaneously
processed during the testing trials by a proprietary “attention-detection algorithm” to produce the
“attention score”, which will represent the subject’s eye movement variability on a 1-100 scale, with
100 representing near-to-zero variability (a perfect score) and 1 representing very high variability.
The attention score, subject identifier, testing date/time and other inputted information will be saved
automatically on an irremovable storage card in a handheld control tablet for future recall.
See Appendix B for a detailed description of the Portable Eye-Tracking Device and standard
operating procedure for its use.
Sleep/Wake Actigraphy
Subjects will wear a wrist-worn device called an actigraph (ReadiBand, Fatigue Science, Honolulu,
HI, or comparable alternate product) throughout the course of data collection before, during, and after
training, as per subject availability. The actigraph records wrist movements, which are subsequently
processed through a sleep-scoring algorithm to determine sleep/wake amounts. Alternate devices
(e.g., Actiheart, CamNtech, Boerne, TX) can supplement the movement record with a heart rate
monitor record, improving sleep/wake assessments by calculating activity energy expenditure in freeliving conditions. In an example, low level exercise may yield a motion record similar to sitting in a
rocking chair or riding in an automobile but the types of activities here can be expected to have
bearing on derived sleep/wake measures.
See Appendix B for a detailed description of the ReadiBand Actigraph Device and standard operating
procedure for its use.
Phase B: Hospital Assessments
Detailed descriptions of the procedures to be conducted during Phase B appear in the NINDS protocol
attached as Appendix A.
Neuropsychological Measures
Subjects will perform a series of neuropsychological tests as well as paper-and-pencil and computer
tests of executive function, emotional function, language, memory, intelligence and other cognitive
abilities (e.g. California Verbal Learning Test, Delis-Kaplan Executive Function System Sorting Test,
and Booklet Category Test).
Note: Questionnaires or interviews related to history of abuse, sexual behaviors, or drug/alcohol
abuse will not be included as part of this study.
Blood Components Analysis
Subjects will be asked to provide a single 20ml blood sample to be sent to the following laboratories
where they will be assayed in the same way as described for Phase A: Banyan Biomarkers in
Alachua, Florida; James J. Peters VA Medical Center/Mount Sinai School of Medicine in Bronx, NY;
National Institute of Nursing Research, National Institutes of Health, Bethesda, MD.
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Neuroimaging
Subjects will undergo multiple neuroimaging sessions during their visit at NINDS using routine,
microstructural, and functional imaging techniques to achieve maximal sensitivity and specificity for
the detection of TBI. Structural imaging procedures will include magnetic resonance imaging (MRI)
to look for possible brain lesions, diffusion tensor imaging (DTI) to evaluate microstructural
disruption of white matter, perfusion imaging to look at microscopic levels of cerebral blood flow,
and susceptibility weighted imaging (SWI) to detect microhemorrhages within the brain.
Subjects will also be asked to participate in an imaging procedure that involves the use of
Gadolinium, which is a contrast agent that enhances blood vessels in MRI for detecting disruptions of
the blood-brain barrier. Only subjects that meet specific screening criteria for safe use of this
compound will be eligible for this procedure (see Potential Risks section below). Subjects will be
specifically screened for prior allergic reactions and for risk of decreased renal function according to
NIH policies. Eligible subjects who agree to participate in this procedure will have an angiocatheter
placed by an intravenous (IV) nurse in the NIH radiology department. The angiocatheter will be
placed in the upper extremity, and be of a sufficient size to accommodate power injection. Following
contrast administration, dynamic susceptibility contrast (DSC) imaging and standard structural
imaging will be performed.
Functional magnetic resonance imaging (fMRI) will be used to measure changes hemodynamic
signals related to neural activity in response to cognitive and emotional stimulation using
experimental paradigms such as the N-Back and Task Switching tasks.
Vestibular and Auditory Assessments
Subjects will undergo balance testing using computerized dynamic posturography (CDP) with a
SMART EquiTest System (NeuroCom International, Inc.). The CDP allows for the objective
quantification and differentiation among the wide variety of possible sensory, motor, and central
adaptive impairments to balance control. Tests may include the Sensory Organization Test (SOT),
which is used to identify which sensory system (vestibular, visual, or somatosensory) is abnormally
used to control balance; the Limits of Stability test (LOS), which is used to identify problems with
voluntary motor control of balance; and Dual Tasking Posturography (DTP), which is used to assess
the interaction between cognition and the control of balance. Subjects will also undergo balance
testing using the Five Times Sit to Stand test (FTSST) and the Dynamic Gait Index (DGI), and the
self-reported Dizziness Handicap Inventory (DHI).
In addition, subjects will undergo three tests of specifically designed to identify vestibular
dysfunction and distinguish disorders of the peripheral and central vestibular systems. These tests
include Sinusoidal Harmonic Acceleration (SHA), which examines the vestibulo-ocular reflex and its
response to rotations at a variety of stimulus frequencies; the caloric irrigation subtest of
videonystagmography (VNG), which examines horizontal semicircular canal function; and Vestibular
Evoked Myogenic Potentials (VEMP), which is used to evaluate the vestibulo-colic response. They
represent a diagnostic extension of the functional assessments conducted during posturography.
Finally, subjects will undergo tests of auditory functioning including pure-tone threshold assessment
and tympanometry.
Polysomnography
Subjects that have a significant sleep disturbance as indicated by self-report or actigraphy data
collected during Phase A (average total sleep time and/or sleep continuity are two standard deviations
from age-appropriate norms), will undergo a sleep assessment using one night of polysomnographic
(EEG) recording to rule out the presence of overt sleep disorders (e.g., obstructive sleep apnea,
periodic leg movements during sleep, etc.). Electrodes will be applied over the head for the EEG
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recording, around both eyes to monitor eye movements, around the chest and abdomen to monitor
respiration, and on both legs to monitor leg movement. Analyses of polysomnographic recording
includes total sleep time, sleep efficiency, latency to sleep onset and REM (rapid eye movement)
sleep, and sleep architecture with ratios of various sleep stages (stages 1, 2, 3, and REM sleep).
Companion Interview
The companion interview will consist of surveys which include demographic information,
measurements for companions’ stress, and self-rated health, as well as questionnaires that ask about
the subject including the presence of symptoms, depressed mood, physical function, and self-care.
Furthermore we will ask caregivers to complete some of the same questionnaires as the subject in
order to compare responses. For “Off-site” companions, once informed consent has been obtained,
study personnel will mail the Companion Questionnaire Battery for completion. Companions will be
instructed to contact study personnel with any questions or concerns regarding the questionnaires or if
they chose to withdraw their consent to participate in the project.
6.3.5 Study Time Line
Phase A
This diagram illustrates a hypothetical schedule of data collection adapted to a typical evolution of an
explosive entry course.
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6.4 Statistical Consideration
6.4.1 Primary Endpoints
The primary endpoints of this study will be the data collected from the neuropsychological tests, blood
components analysis, neuroimaging sessions, vestibular assessments, and sleep analysis. These measures
were selected based on their known sensitivity to brain injury and are expected to demonstrate significant
differences when comparing the experimental groups. The outcome of this research effort will be
documentation of findings and recommendation to mitigate operational risk. Results will be presented to
military commands engaged in breaching as well as prepared as manuscripts for publication.
6.4.2 Data Analysis
Data will be analyzed by repeated measures ANOVA with both within-subject factors (degree of
exposure) and between-subjects factors (Breachers vs. Artillery Controls vs. Unexposed Controls)
followed by a priori planned post-hoc tests. Post-hoc tests will use a standard correction for number of
comparisons within an analysis (e.g. Bonferonni or Geiser-Greenhouse procedures). Note that if the
distribution of data within a group on any single variable is skewed or non-normal, either non-parametric
tests will be used to analyze the data or the data will be normalized using a standard transformation such
as a log-normal transformation. Any subjects from Phase A data collection who endorse exclusion
criteria for Phase B will be considered separately in analysis.
6.4.3 Safety Monitoring
Safety monitoring will be in place primarily due to the use Gadolinium as a MRI enhancing contrast agent
during Phase B of the study. Gadolinium contrast imaging presents some moderate risks (see Potential
Risks section below for complete list). The primary risk is to people with kidney disease as they may
have a serious reaction to gadolinium contrast called “nephrogenic systemic fibrosis” which has resulted
in a very small number of deaths. Careful screening of subjects for abnormal kidney function will be the
primary process for mitigating this risk. Subjects that have diabetes, kidney disease or liver disease will
undergo a blood test to assess kidney function within 4 weeks before any MRI scan with gadolinium
contrast and those whose kidney function is not normal will not receive gadolinium for a research MRI
scan.
6.4.4 Sample Size Estimation
The goal for Phase A of this protocol is to recruit up to 250 subjects (150 breachers, 50 artillery controls,
and 50 unexposed controls). Multiple training sites will need to be visited to meet the primary goal of
this study, which is the collection of data from a significant number of individuals with chronic exposure
to blast in order to develop a time-course of acute signal changes during breacher training. In order to
maximize the efficient use of resources during visits to training facilities, we will also collect data from
individuals who do not meet criteria for experienced individuals. Therefore, the number above was
estimated based on the expected ratio of experienced individuals (operators and instructors) to
inexperienced trainees that typically appear in breacher training courses.
The goal for Phase B of this protocol is to recruit a minimum of 60 subjects (20 breachers, 20 artillery
controls, and 20 unexposed controls) to travel to NIH for the hospital based assessments. The number of
subjects to be included in this protocol was determined from consideration of the main objective of
detecting a chronic exposure effect, typically reported as an effect on cognitive ability (esp., "memory
difficulty"), and the previously observed effect size among the cohort of interest (Carr et al., unpublished
manuscript). The use of the same computer-based testing paradigm in both the completed study and the
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proposed study affords a straightforward estimation of sample size. In the more difficult and more
sensitive of the 2 computer-based tests involving demand of memory, Code Substitution Delayed, the
mean difference in accuracy (percent correct) at baseline between the experienced group and members of
the more naïve group matched according to IQ, age, and blast history, was 6.6%. With a standard
deviation of 8.46 and 6.26 for each of these 2 groups and an intergroup correlation of .33, the resultant
large effect size (.76) yields an estimate of 16 subjects needed per group to re-detect this difference at
baseline (Erdfelder et al., 1996). This effect size is consistent with related literature on concussion and
military populations (Warden et al., 2001). In the protocol proposed, considerable effort will be expended
to carefully select and support research volunteers so attrition is not expected. However, to accommodate
some attrition, error, and data loss, the requested sample size for this protocol will be 25% above the
minimum required, so 20 subjects per group are requested.
6.5 Reporting Adverse Events
6.5.1 Expected Adverse Events from Research Risks and Reporting
Potential Risks
Risks associated with the testing procedures are mitigated by having qualified medical personnel on the
team to supervise safety procedures. A risk of loss of anonymity due to data being linked to the subject’s
identity applies to both phases of the study, however, this risk is mitigated by the confidentiality
procedures (subject coding) described below. The confidentiality of active duty military service members
may not be able to be maintained as their chain of command may request information obtained during our
study (e.g. copies of consent forms, copies of questionnaires, raw or processed data). In addition, there
may be circumstances where reporting to the chain of command may be required (e.g. violations of
UCMJ, abuse, etc.). As with all research subjects, active duty service members can choose not to answer
sensitive questions.
Phase A
The significant risk of being exposed to explosives and repeated blasts that will occur during the
field assessment phase of this protocol is not different than the subjects’ level of risk during
routine explosive entry training. This protocol will have a minimal effect on their training
regimen and will be conducted during previously scheduled training events.
There is minimal risk due to the addition of sensors to subjects’ helmets, but the light weight of
this equipment (15 oz.) is not a significant burden.
During blood draw, the subject may experience some discomfort at the site of needle entry and
there is a risk of bruising. There is a remote risk of fainting or local infection. These risks are
mitigated by having trained military and civilian medical personnel conduct the blood draws.
There is a small risk of falling off of the BioSway apparatus. This will be mitigated by having a
member of the research team supervising vestibular tests.
The neuropsychological tests, eye-tracking, and sleep/wake actigraphy are not expected to pose
any risk to the subjects.
Phase B
Risks associated with the hospital phase of this protocol are described in detail in the NINDS protocol
(Appendix A). The following is a summary of these risks:
There is some risk in the transport of volunteers to Bethesda, MD, but this risk is not greater than
that most people encounter every day.
During blood draw, the subject may experience some discomfort at the site of needle entry and
there is a risk of bruising. There is a remote risk of fainting or local infection. These risks are
mitigated by having trained military and civilian medical personnel conduct the blood draws.

36

The neuropsychological tests and questionnaires may be frustrating or stressful. Subjects may
refuse to answer any question or stop a test at any time and for any reason.
All vestibular and auditory tests are standard clinical practices and present only minimal risk to
the subject including some sensation of dizziness or nausea.
During the sleep assessment, there is a risk of discomfort during the application and removal of
the EEG electrodes.
There is a small risk of emotional discomfort from performance of the functional neuroimaging
tasks; however, this risk is mitigated by explaining the nature of these tasks to the subject and
giving them the option of stopping a test at any time.
The MRI scanning procedures in this protocol present some risk to volunteers in the case of any
unsecured metal in the strong magnetic field, of unprotected exposure to the MRI noise
environment, and of potential discomfort from lying supine for an hour in a movement-restricted
environment. These risks, however, are present for any MRI procedure and are well demonstrated
to be successfully mitigated by standard protections offered in metal safety, hearing conservation,
patient screening, and patient monitoring. If participants have a question about any metal objects
being present in their body, they should inform the staff. If there is uncertainty about the
presence of metal, we will obtain plain radiographs before performing MRI. These studies are
considered part of standard care before MRI. There is a risk to operational readiness from
incidental clinical findings; however, subjects are informed beforehand of this possibility.
Gadolinium contrast imaging presents some moderate risks. The risks of the IV catheter
placement include bleeding, infection, or inflammation of the skin and vein with pain and
swelling. Symptoms from the contrast infusion are usually mild and may include coldness in the
arm during the injection, a metallic taste, headache, and nausea. In an extremely small number of
patients, more severe symptoms have been reported including shortness of breath, wheezing,
hives, and lowering of blood pressure. Subjects will not receive gadolinium-based contrast
agents if they previously had an allergic reaction to them. Subjects will be asked about such
allergic reactions before a contrast agent is administered. People with kidney disease are at risk
for a serious reaction to gadolinium contrast called “nephrogenic systemic fibrosis” which has
resulted in a very small number of deaths. Subjects that have diabetes, kidney disease or liver
disease will undergo a blood test to assess kidney function within 4 weeks before any MRI scan
with gadolinium contrast. Subjects will not receive gadolinium for a research MRI scan if their
kidney function is not normal.
6.5.2 Reporting Serious and Unexpected Adverse Events to the IRB
Serious Adverse Events: The PI will report all serious adverse events (SAE) and unanticipated problems
involving risk occurring in subjects enrolled in this DOD protocol to the NMRC Office of Research
Administration (ORA) within 24 hours. Formal reporting of all adverse events and unanticipated
problems will be completed within 5 days using the NMRC ORA IRB Form 3. Serious adverse events
will be reported even if the PI believes that the adverse events are unrelated to the protocol.
The WRAIR Division of Human Subjects Protection (DHSP) will be copied on all such reports for
acknowledgment. A summary of all serious or unexpected side effects also must be included in the
Annual Progress Report.
6.5.3 Medical Care for Research-Related Injury
No compensation will be provided for injuries that are a direct result of being in this study. It will be
explained to subjects in the consent forms that this is not a waiver or release of their legal rights and that
they should discuss this issue thoroughly with the principal investigator before they enroll in this study.
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For Phase A, military service members as well as civilians will be treated at a Military Treatment Facility
in accordance with MRMC Command Policy Memorandum 2010-10, Medical Care for Research-Related
Injury. DOD healthcare beneficiaries (e.g. active duty military, military spouse or dependent), are
entitled to medical care for injuries within the DOD healthcare system, as long as they remain a DOD
healthcare beneficiary. This care includes but is not limited to free medical care at a military treatment
facility. Non-DOD healthcare beneficiaries are also entitled to free medical care for their injury at a
military treatment facility. It cannot be determined in advance which military treatment facility will
provide care. If non-DOD healthcare beneficiaries get care for research-related injuries outside of a
military treatment facility, the subject or their insurance will be responsible for medical expenses.
For Phase B, the NIH Clinical Center will provide short-term medical care for any injury resulting from
participation in research at that site. In general, no long-term medical care or financial compensation for
research-related injuries will be provided by the National Institutes of Health, the Clinical Center, or the
Federal Government. However, subjects have the right to pursue legal remedy if they believe that their
injury justifies such action.
6.5.4 Subject Withdrawal from Participation
Subjects may withdraw from participating in the study at any time with no consequences. If a subject
withdraws during Phase A, the research team will stop data collection from that subject immediately and
it will not affect their ability to complete the training program. If a subject withdraws during Phase B, the
research team will stop data collection from that subject immediately and arrangements will be made for
their return home. Subjects who withdraw early from either Phase will be asked if we are permitted to
retain data collected up to that point. Should the subject request, their individual data will be excluded.
Subjects will be compensated for the time and/or procedures they completed as outlined in the
compensation section above.
The principal investigators may terminate participation in this study if continued participation is
considered to be detrimental to the subject’s health, if the subject fails to cooperate with the study, or if
the military mission requires it. The same rights and procedures described above apply when the
investigators terminate participation.
6.6 Human Biological Specimens/Tissue
Procedures for the collection and use of blood samples are described in this protocol. Blood samples will
be sent to collaborating laboratories and destroyed once analyzed. Details of procedures used for samples
can be reviewed in Appendix B. Collection of blood samples will be highlighted in the Informed Consent
form and described to the subject before consent is obtained.
6.7 Subject Confidentiality Protection
All subjects will be assigned a 4-digit identifier (e.g. subject #7264) generated from a random number
generator during the informed consent process. This ID# will be stored with the subject’s name and
research group assignment (i.e., breacher, control 1, or control 2) in a password protected record at
NMRC. All other data records will be labeled only with the subject ID#, vice identifying information.
The coded data from this project will be stored in locked and password-protected facilities. All data from
this project will be subject to review by blinded external reviewers. With appropriate authorization to
release, all aspects of this study and the de-individualized data may appear in open publication.
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NINDS and CNRM follow similar subject confidentiality procedures, which are described in detail in
Appendix A.
Auditing authorities for the Navy and Army, CNRM, Uniformed Services University, Henry M Jackson
Foundation, and NIH may request to review study documents, which could affect the confidentiality of
subjects’ identity and research records. Specifically, the Department of the Navy Human Research
Protections Program (DON HRPP) and the United States Army Medical Research and Materiel
Command (USAMRMC) Human Research Protection Office could perform an audit of the files, which
could include the consent forms.
6.7.1 Certificate of Confidentiality
This study does not include a Certificate of Confidentiality. Subject confidentiality will be secured using
the procedures described in this protocol. As described in the section above on potential risks, the
confidentiality of active duty military service members may not be able to be maintained as their chain of
command may request information obtained during our study (e.g. copies of consent forms, copies of
questionnaires, raw or processed data). In addition, there may be circumstances where reporting to the
chain of command may be required (e.g. violations of UCMJ, abuse, etc.). As with all research subjects,
active duty service members can choose not to answer sensitive questions.
6.7.2 HIPAA Authorization
This study will include the collection of “Identifiable Protected Health Information” as well as the
following personal identifiers: name, address, age, telephone number, e-mail address, social security
number. Therefore, in accordance with the requirements of the Health Insurance Portability and
Accountability Act (HIPAA) and DOD HIPAA regulations 6025.LL-R, subjects will need to sign a
HIPAA Authorization form (see Appendix F).
a. Confidentiality of research source documents
Data in this study will be stored by study identification code, vice other identifying information. The
key that links data code to the individual’s information will be stored separately from the data,
according to the description in the paragraph below. This stored key will be the only means to
identify subjects' data for the duration of storage and will be accessible only by the principal
investigators.
Coded hardcopies of data will be stored in locked cabinets in a locked office at NMRC/WRAIR
(Building 503, room 2W109) and at ARA’s facility in Littleton, CO (10720 Bradford Rd., Suite 102).
Data will be accessible only by study lead investigators. Electronic data will be kept in 2 forms. 1)
PC-compatible files in various software formats (e.g. MS Excel, E-Prime, Presentation, ASCII text,
MS Word; 2) neuroimaging files will be kept in the following Unix/Linux-compatible software
formats: AFNI, ANALYZE, DICOM, NIFTI. The PC-compatible files will be stored on a computer
at NMRC/WRAIR (Building 503; room 2W109) with access limited to study personnel via DOD
Common Access Card-enabled logon policy and user account privilege. NMRC/WRAIR computer
data are backed up per DOD requirements. Neuroimaging files will be kept on a non-networked
computer with Linux operating system at NMRC/WRAIR (Building 503; room 2W109), with access
limited to study personnel via physical access to the room and username/password logon
requirements.
Details for the protection of coded data stored at NINDS and CNRM are described in Appendix A.
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b. Storage and destruction of the research source documents
Upon completion of the study, data will be archived but available for future study. Data in this study
will be stored by study identification code, vice other identifying information, but the key that links
data by code to the individual’s information will also be stored (separately) so data will be
identifiable for the duration of their storage. The rationale for retaining subject identity to data is
because these data may be used in a future investigation, and that investigation could include
individuals from this protocol, for examination of longitudinal effect of exposure to blast, an
important research question for this protocol. That investigation could not be performed without
retaining data identity.
c. Sharing of research data
Data exchange with study partners will be with de-identified data and in a sample of at least 5
subjects rather than on an individual basis. The primary institutions for execution of work in this
protocol and the storage of protocol data are NMRC, WRAIR, NINDS, and ARA. NMRC holds
United States Department of Health and Human Services (DHHS) FWA Number FWA00000152;
WRAIR holds DHHS FWA Number FWA00000015; NINDS holds DHHS FWA Number
FWA00005897; and ARA holds DHHS FWA Number FWA00014065.
6.8 Reporting Protocol Deviations, Amendments, and Continuing Reviews
Any protocol deviations during the course of the study will be promptly reported to the NMRC IRB and
sponsor, as well as the WRAIR DHSP for acknowledgment.
All amendments to research documents (protocol, consent forms, etc.) will be submitted for approval to
the NMRC IRB and WRAIR DHSP. Amendments will include a memorandum outlining the changes,
clean copies of the changed research documents, as well as copies with the changes marked. Annual
continuing review reports outlining study progress and a study closeout report upon completion of the
research will also be provided to the NMRC IRB and WRAIR DHSP.
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9. ROLES AND RESPONSIBILITIES OF EACH INVESTIGATOR AND COLLABORATOR
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LEAD INVESTIGATOR,
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Neurocognitive Investigator
LEAD INVESTIGATOR,
Neurocognitive Investigator,
Consenter
LEAD INVESTIGATOR,
Engineer
Neurocognitive Investigator,
Neuroimaging
Neurocognitive Investigator,
Consenter
Neurocognitive Investigator,
Consenter
Neurocognitive Investigator,
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Neurocognitive Investigator,
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Neuroimaging
Engineer
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NIH

24

Christiane Zampieri-Gallagher

MD,
MPH
PhD

NIH

Neuroradiologist,
Neuroimaging
Neurocognitive Investigator,
Vestibular Testing
Vestibular Testing

25

Carmen Brewer

PhD

NIH

Vestibular and Auditory Testing

26

John Dsurney

PhD

NIH

Neurocognitive Investigator

27

MAJ Jeffrey Lewis

MD, PhD

NINDS

28

Michael Tierney

MA

NINDS

29

Kristine Knutson

MA

NINDS

Neurocognitive Investigator,
Consenter
Neurocognitive Investigator,
Consenter
Neuroimaging

30

CPT Aaron M. Smith

Psy.D

WRNMMC

31

CDR John Hughes

MD

NMRC

Neurocognitive Investigator,
Consenter
Research Monitor

32

Richard McCarron

PhD

NMRC

Neurocognitive Investigator

33

Thomas Balkin

PhD

WRAIR

Neurocognitive Investigator

34

Laura Coombs

PhD

ACR

Neuroimaging
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Data Analysis of Non-human
Subjects Data

----------------------------------------------ROLE DEFINITIONS-----------------------------------------------------LEAD INVESTIGATOR ................Primary responsibility for IRB compliance, documentation,
reporting, data storage
Consenter ........................................Administration of informed consent
Site Coordinator …………………..Primary responsibility for coordinating data collection at
performance sites for Phase A (identified in Delegation Log for each site)
Engineer ..........................................Design, measurement, and analysis of blast
Neurocognitive Investigator ...........Administration and analysis of neurocognitive testing
Neuroimaging .................................Design, execution, and analysis of neuroimaging data, subject
screening/MRI safety
Neuroradiologist .............................Interpretation of neuroimaging results
Vestibular and Auditory testing…...Administration and analysis of vestibular and auditory tests
Research Assistant………………...Assist with data collection and analysis
Research Contact.............................Primary contact for Phase B subjects
Research Monitor ............................Primary responsibility for overseeing safety of subjects
10. TIME REQUIRED TO COMPLETE THE RESEARCH (INCLUDING DATA ANALYSIS)
Study Duration = 5 years
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Supplement:
NanoString Methods
A subset of genes examined in RNAseq data were selected to validate gene
expression changes by assaying 50 ng of mRNA using a direct digital detection system
(Nanostring Technologies, Seattle, WA). A panel was designed for each pathway to
include 50 markers of interest, plus a total of 10 reference/housekeeping genes for data
normalization, including ABCF1, ALAS1, DECR1, GAPDH, GUSB, HPRT1, IPO8,
PGK1, and TBP (these genes are also noted in Table 3-2 and 3-3 of the dissertation
manuscript). Care was taken to ensure that reference genes selected met the following
criteria: 1) not dysregulated in the RNA-seq data for the same samples; 2) not clearly
implicated in traumatic brain injury, blast exposure, or a similar condition; and 3) no
published evidence that this is an unstable reference gene in human blood. Probes for the
50 genes of interest and the housekeeping genes were designed and manufactured by
Nanostring Technologies. Briefly, probes for marker and reference RNAs were
multiplexed and assayed using the nCounter Digital Analyzer. Samples were randomly
assigned to plates to avoid run-order bias. In an effort to control for plate-to-plate
variations and drift, one sample was used as an internal control. We also validated the
result with 50 genes from each network (100 genes total) using NanoString technology,
which showed congruent finding with RNA sequencing data.
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